id	sid	tid	token	lemma	pos
dpc-3114	1	1	dermatology	dermatology	NOUN
dpc-3114	1	2	:	:	PUNCT
dpc-3114	1	3	practical	practical	ADJ
dpc-3114	1	4	and	and	CCONJ
dpc-3114	1	5	conceptual	conceptual	ADJ
dpc-3114	1	6	original	original	ADJ
dpc-3114	1	7	article	article	NOUN
dpc-3114	1	8	|	|	ADV
dpc-3114	1	9	dermatol	dermatol	ADJ
dpc-3114	1	10	pract	pract	NOUN
dpc-3114	1	11	concept	concept	NOUN
dpc-3114	1	12	.	.	PUNCT
dpc-3114	2	1	2023;13(4):e2023215	2023;13(4):e2023215	NUM
dpc-3114	2	2	1	1	NUM
dpc-3114	2	3	effectiveness	effectiveness	NOUN
dpc-3114	2	4	and	and	CCONJ
dpc-3114	2	5	safety	safety	NOUN
dpc-3114	2	6	after	after	ADP
dpc-3114	2	7	a	a	DET
dpc-3114	2	8	switch	switch	NOUN
dpc-3114	2	9	to	to	ADP
dpc-3114	2	10	 	 	SPACE
dpc-3114	2	11	tildrakizumab	tildrakizumab	VERB
dpc-3114	2	12	:	:	PUNCT
dpc-3114	2	13	a	a	DET
dpc-3114	2	14	real	real	ADJ
dpc-3114	2	15	world	world	NOUN
dpc-3114	2	16	multicenter	multicenter	NOUN
dpc-3114	2	17	italian	italian	ADJ
dpc-3114	2	18	study	study	NOUN
dpc-3114	2	19	in	in	ADP
dpc-3114	2	20	psoriasis	psoriasis	NOUN
dpc-3114	2	21	eugenia	eugenia	NOUN
dpc-3114	2	22	veronica	veronica	PROPN
dpc-3114	2	23	di	di	PROPN
dpc-3114	2	24	brizzi1	brizzi1	PROPN
dpc-3114	2	25	,	,	PUNCT
dpc-3114	2	26	dario	dario	PROPN
dpc-3114	2	27	buononato1	buononato1	PROPN
dpc-3114	2	28	,	,	PUNCT
dpc-3114	2	29	pierfrancesco	pierfrancesco	PROPN
dpc-3114	2	30	benvenuto1	benvenuto1	PROPN
dpc-3114	2	31	,	,	PUNCT
dpc-3114	2	32	giuseppe	giuseppe	PROPN
dpc-3114	2	33	 	 	SPACE
dpc-3114	2	34	argenziano1	argenziano1	PROPN
dpc-3114	2	35	,	,	PUNCT
dpc-3114	2	36	rocco	rocco	X
dpc-3114	2	37	de	de	X
dpc-3114	2	38	pasquale2	pasquale2	NOUN
dpc-3114	2	39	,	,	PUNCT
dpc-3114	2	40	carmen	carmen	PROPN
dpc-3114	2	41	silvia	silvia	PROPN
dpc-3114	2	42	fiorella3	fiorella3	PROPN
dpc-3114	2	43	,	,	PUNCT
dpc-3114	2	44	claudia	claudia	PROPN
dpc-3114	2	45	giofrè4	giofrè4	PROPN
dpc-3114	2	46	,	,	PUNCT
dpc-3114	2	47	maria	maria	PROPN
dpc-3114	2	48	 	 	SPACE
dpc-3114	2	49	letizia	letizia	PROPN
dpc-3114	2	50	musumeci2	musumeci2	PROPN
dpc-3114	2	51	,	,	PUNCT
dpc-3114	2	52	giovanni	giovanni	PROPN
dpc-3114	2	53	palazzo5	palazzo5	PROPN
dpc-3114	2	54	,	,	PUNCT
dpc-3114	2	55	leonardo	leonardo	PROPN
dpc-3114	2	56	zichichi6	zichichi6	PROPN
dpc-3114	2	57	,	,	PUNCT
dpc-3114	2	58	anna	anna	PROPN
dpc-3114	2	59	balato1	balato1	NOUN
dpc-3114	2	60	1	1	NUM
dpc-3114	2	61	dermatology	dermatology	NOUN
dpc-3114	2	62	unit	unit	NOUN
dpc-3114	2	63	,	,	PUNCT
dpc-3114	2	64	university	university	PROPN
dpc-3114	2	65	of	of	ADP
dpc-3114	2	66	campania	campania	PROPN
dpc-3114	2	67	“	"	PUNCT
dpc-3114	2	68	luigi	luigi	PROPN
dpc-3114	2	69	vanvitelli	vanvitelli	PROPN
dpc-3114	2	70	”	"	PUNCT
dpc-3114	2	71	,	,	PUNCT
dpc-3114	2	72	naples	naples	PROPN
dpc-3114	2	73	,	,	PUNCT
dpc-3114	2	74	italy	italy	PROPN
dpc-3114	2	75	2	2	NUM
dpc-3114	2	76	u.o.c	u.o.c	NOUN
dpc-3114	2	77	.	.	PROPN
dpc-3114	2	78	dermatology	dermatology	NOUN
dpc-3114	2	79	unit	unit	NOUN
dpc-3114	2	80	,	,	PUNCT
dpc-3114	2	81	“	"	PUNCT
dpc-3114	2	82	g.	g.	PROPN
dpc-3114	2	83	rodolico	rodolico	PROPN
dpc-3114	2	84	-	-	PUNCT
dpc-3114	2	85	s.	s.	PROPN
dpc-3114	2	86	marco	marco	PROPN
dpc-3114	2	87	”	"	PUNCT
dpc-3114	2	88	hospital	hospital	PROPN
dpc-3114	2	89	,	,	PUNCT
dpc-3114	2	90	catania	catania	PROPN
dpc-3114	2	91	,	,	PUNCT
dpc-3114	2	92	italy	italy	PROPN
dpc-3114	2	93	3	3	NUM
dpc-3114	2	94	dermatology	dermatology	NOUN
dpc-3114	2	95	unit	unit	NOUN
dpc-3114	2	96	,	,	PUNCT
dpc-3114	2	97	“	"	PUNCT
dpc-3114	2	98	monsignor	monsignor	NOUN
dpc-3114	2	99	raffaele	raffaele	PROPN
dpc-3114	2	100	dimiccoli	dimiccoli	PROPN
dpc-3114	2	101	”	"	PUNCT
dpc-3114	2	102	hospital	hospital	NOUN
dpc-3114	2	103	,	,	PUNCT
dpc-3114	2	104	barletta	barletta	PROPN
dpc-3114	2	105	,	,	PUNCT
dpc-3114	2	106	italy	italy	PROPN
dpc-3114	2	107	4	4	NUM
dpc-3114	2	108	u.o.c	u.o.c	NOUN
dpc-3114	2	109	.	.	PUNCT
dpc-3114	2	110	dermatology	dermatology	NOUN
dpc-3114	2	111	unit	unit	NOUN
dpc-3114	2	112	,	,	PUNCT
dpc-3114	2	113	“	"	PUNCT
dpc-3114	2	114	papardo	papardo	ADJ
dpc-3114	2	115	”	"	PUNCT
dpc-3114	2	116	hospital	hospital	NOUN
dpc-3114	2	117	,	,	PUNCT
dpc-3114	2	118	messina	messina	PROPN
dpc-3114	2	119	,	,	PUNCT
dpc-3114	2	120	italy	italy	PROPN
dpc-3114	2	121	5	5	NUM
dpc-3114	2	122	dermatology	dermatology	NOUN
dpc-3114	2	123	unit	unit	NOUN
dpc-3114	2	124	,	,	PUNCT
dpc-3114	2	125	hospital	hospital	NOUN
dpc-3114	2	126	of	of	ADP
dpc-3114	2	127	tinchi	tinchi	NOUN
dpc-3114	2	128	pisticci	pisticci	PROPN
dpc-3114	2	129	,	,	PUNCT
dpc-3114	2	130	italy	italy	PROPN
dpc-3114	2	131	6	6	NUM
dpc-3114	2	132	u.o.c	u.o.c	NOUN
dpc-3114	2	133	.	.	PUNCT
dpc-3114	2	134	dermatology	dermatology	NOUN
dpc-3114	2	135	unit	unit	NOUN
dpc-3114	2	136	,	,	PUNCT
dpc-3114	2	137	“	"	PUNCT
dpc-3114	2	138	s.	s.	PROPN
dpc-3114	2	139	antonio	antonio	PROPN
dpc-3114	2	140	abate	abate	VERB
dpc-3114	2	141	”	"	PUNCT
dpc-3114	2	142	hospital	hospital	NOUN
dpc-3114	2	143	,	,	PUNCT
dpc-3114	2	144	trapani	trapani	X
dpc-3114	2	145	,	,	PUNCT
dpc-3114	2	146	italy	italy	PROPN
dpc-3114	2	147	key	key	ADJ
dpc-3114	2	148	words	word	NOUN
dpc-3114	2	149	:	:	PUNCT
dpc-3114	2	150	psoriasis	psoriasis	NOUN
dpc-3114	2	151	,	,	PUNCT
dpc-3114	2	152	tildrakizumab	tildrakizumab	NOUN
dpc-3114	2	153	,	,	PUNCT
dpc-3114	2	154	biologic	biologic	NOUN
dpc-3114	2	155	drug	drug	NOUN
dpc-3114	2	156	,	,	PUNCT
dpc-3114	2	157	anti	anti	X
dpc-3114	2	158	il-23	il-23	NOUN
dpc-3114	2	159	monoclonal	monoclonal	NOUN
dpc-3114	2	160	antibody	antibody	NOUN
dpc-3114	2	161	citation	citation	NOUN
dpc-3114	2	162	:	:	PUNCT
dpc-3114	2	163	di	di	NOUN
dpc-3114	2	164	brizzi	brizzi	PROPN
dpc-3114	2	165	ev	ev	PROPN
dpc-3114	2	166	,	,	PUNCT
dpc-3114	2	167	buononato	buononato	PROPN
dpc-3114	2	168	d	d	PROPN
dpc-3114	2	169	,	,	PUNCT
dpc-3114	2	170	benvenuto	benvenuto	NOUN
dpc-3114	2	171	p	p	PROPN
dpc-3114	2	172	,	,	PUNCT
dpc-3114	2	173	et	et	PROPN
dpc-3114	2	174	al	al	PROPN
dpc-3114	2	175	.	.	PROPN
dpc-3114	2	176	effectiveness	effectiveness	NOUN
dpc-3114	2	177	and	and	CCONJ
dpc-3114	2	178	safety	safety	NOUN
dpc-3114	2	179	after	after	ADP
dpc-3114	2	180	a	a	DET
dpc-3114	2	181	switch	switch	NOUN
dpc-3114	2	182	to	to	PART
dpc-3114	2	183	tildrakizumab	tildrakizumab	VERB
dpc-3114	2	184	:	:	PUNCT
dpc-3114	2	185	a	a	DET
dpc-3114	2	186	real	real	ADJ
dpc-3114	2	187	world	world	NOUN
dpc-3114	2	188	multicenter	multicenter	NOUN
dpc-3114	2	189	italian	italian	ADJ
dpc-3114	2	190	study	study	NOUN
dpc-3114	2	191	in	in	ADP
dpc-3114	2	192	psoriasis	psoriasis	NOUN
dpc-3114	2	193	.	.	PUNCT
dpc-3114	3	1	dermatol	dermatol	NOUN
dpc-3114	3	2	pract	pract	PROPN
dpc-3114	3	3	concept	concept	NOUN
dpc-3114	3	4	.	.	PUNCT
dpc-3114	4	1	2023;13(4):e2023215	2023;13(4):e2023215	X
dpc-3114	4	2	.	.	PUNCT
dpc-3114	4	3	doi	doi	PROPN
dpc-3114	4	4	:	:	PUNCT
dpc-3114	4	5	https://doi.org/10.5826/dpc.1304a215	https://doi.org/10.5826/dpc.1304a215	NOUN
dpc-3114	4	6	accepted	accept	VERB
dpc-3114	4	7	:	:	PUNCT
dpc-3114	4	8	april	april	PROPN
dpc-3114	4	9	21	21	NUM
dpc-3114	4	10	,	,	PUNCT
dpc-3114	4	11	2023	2023	NUM
dpc-3114	4	12	;	;	PUNCT
dpc-3114	4	13	published	publish	VERB
dpc-3114	4	14	:	:	PUNCT
dpc-3114	5	1	october	october	PROPN
dpc-3114	5	2	2023	2023	NUM
dpc-3114	5	3	copyright	copyright	NOUN
dpc-3114	5	4	:	:	PUNCT
dpc-3114	5	5	©	©	PROPN
dpc-3114	5	6	2023	2023	NUM
dpc-3114	5	7	di	di	NOUN
dpc-3114	5	8	brizzi	brizzi	NOUN
dpc-3114	5	9	et	et	PROPN
dpc-3114	5	10	al	al	PROPN
dpc-3114	5	11	.	.	PUNCT
dpc-3114	6	1	this	this	PRON
dpc-3114	6	2	is	be	AUX
dpc-3114	6	3	an	an	DET
dpc-3114	6	4	open	open	ADJ
dpc-3114	6	5	-	-	PUNCT
dpc-3114	6	6	access	access	NOUN
dpc-3114	6	7	article	article	NOUN
dpc-3114	6	8	distributed	distribute	VERB
dpc-3114	6	9	under	under	ADP
dpc-3114	6	10	the	the	DET
dpc-3114	6	11	terms	term	NOUN
dpc-3114	6	12	of	of	ADP
dpc-3114	6	13	the	the	DET
dpc-3114	6	14	creative	creative	ADJ
dpc-3114	6	15	commons	common	NOUN
dpc-3114	6	16	attribution	attribution	NOUN
dpc-3114	6	17	-	-	PUNCT
dpc-3114	6	18	noncommercial	noncommercial	ADJ
dpc-3114	6	19	license	license	NOUN
dpc-3114	6	20	(	(	PUNCT
dpc-3114	6	21	by	by	ADP
dpc-3114	6	22	-	-	PUNCT
dpc-3114	6	23	nc-4.0	nc-4.0	NOUN
dpc-3114	6	24	)	)	PUNCT
dpc-3114	6	25	,	,	PUNCT
dpc-3114	6	26	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-3114	6	27	,	,	PUNCT
dpc-3114	6	28	which	which	PRON
dpc-3114	6	29	permits	permit	VERB
dpc-3114	6	30	unrestricted	unrestricted	ADJ
dpc-3114	6	31	noncommercial	noncommercial	ADJ
dpc-3114	6	32	use	use	NOUN
dpc-3114	6	33	,	,	PUNCT
dpc-3114	6	34	distribution	distribution	NOUN
dpc-3114	6	35	,	,	PUNCT
dpc-3114	6	36	and	and	CCONJ
dpc-3114	6	37	reproduction	reproduction	NOUN
dpc-3114	6	38	in	in	ADP
dpc-3114	6	39	any	any	DET
dpc-3114	6	40	medium	medium	NOUN
dpc-3114	6	41	,	,	PUNCT
dpc-3114	6	42	provided	provide	VERB
dpc-3114	6	43	the	the	DET
dpc-3114	6	44	original	original	ADJ
dpc-3114	6	45	authors	author	NOUN
dpc-3114	6	46	and	and	CCONJ
dpc-3114	6	47	source	source	NOUN
dpc-3114	6	48	are	be	AUX
dpc-3114	6	49	credited	credit	VERB
dpc-3114	6	50	.	.	PUNCT
dpc-3114	7	1	funding	funding	NOUN
dpc-3114	7	2	:	:	PUNCT
dpc-3114	7	3	none	none	NOUN
dpc-3114	7	4	.	.	PUNCT
dpc-3114	8	1	competing	compete	VERB
dpc-3114	8	2	interests	interest	NOUN
dpc-3114	8	3	:	:	PUNCT
dpc-3114	8	4	none	none	NOUN
dpc-3114	8	5	.	.	PUNCT
dpc-3114	9	1	authorship	authorship	NOUN
dpc-3114	9	2	:	:	PUNCT
dpc-3114	9	3	all	all	DET
dpc-3114	9	4	authors	author	NOUN
dpc-3114	9	5	have	have	AUX
dpc-3114	9	6	contributed	contribute	VERB
dpc-3114	9	7	significantly	significantly	ADV
dpc-3114	9	8	to	to	ADP
dpc-3114	9	9	this	this	DET
dpc-3114	9	10	publication	publication	NOUN
dpc-3114	9	11	.	.	PUNCT
dpc-3114	10	1	corresponding	correspond	VERB
dpc-3114	10	2	author	author	NOUN
dpc-3114	10	3	:	:	PUNCT
dpc-3114	10	4	eugenia	eugenia	PROPN
dpc-3114	10	5	veronica	veronica	PROPN
dpc-3114	10	6	di	di	PROPN
dpc-3114	10	7	brizzi	brizzi	PROPN
dpc-3114	10	8	,	,	PUNCT
dpc-3114	10	9	md	md	PROPN
dpc-3114	10	10	,	,	PUNCT
dpc-3114	10	11	;	;	PUNCT
dpc-3114	10	12	dermatology	dermatology	NOUN
dpc-3114	10	13	unit	unit	NOUN
dpc-3114	10	14	,	,	PUNCT
dpc-3114	10	15	university	university	PROPN
dpc-3114	10	16	of	of	ADP
dpc-3114	10	17	campania	campania	PROPN
dpc-3114	10	18	luigi	luigi	PROPN
dpc-3114	10	19	vanvitelli	vanvitelli	PROPN
dpc-3114	10	20	,	,	PUNCT
dpc-3114	10	21	nuovo	nuovo	PROPN
dpc-3114	10	22	policlinico	policlinico	PROPN
dpc-3114	10	23	(	(	PUNCT
dpc-3114	10	24	edificio	edificio	PROPN
dpc-3114	10	25	9c	9c	NUM
dpc-3114	10	26	)	)	PUNCT
dpc-3114	10	27	,	,	PUNCT
dpc-3114	10	28	via	via	ADP
dpc-3114	10	29	pansini	pansini	NOUN
dpc-3114	10	30	5	5	NUM
dpc-3114	10	31	,	,	PUNCT
dpc-3114	10	32	80131	80131	NUM
dpc-3114	10	33	naples	naples	PROPN
dpc-3114	10	34	italy	italy	PROPN
dpc-3114	10	35	.	.	PUNCT
dpc-3114	11	1	e	e	X
dpc-3114	11	2	-	-	NOUN
dpc-3114	11	3	mail	mail	NOUN
dpc-3114	11	4	:	:	PUNCT
dpc-3114	11	5	eugeniaveronica.dibrizzi@gmail.com	eugeniaveronica.dibrizzi@gmail.com	X
dpc-3114	11	6	introduction	introduction	NOUN
dpc-3114	11	7	:	:	PUNCT
dpc-3114	11	8	tildrakizumab	tildrakizumab	NOUN
dpc-3114	11	9	is	be	AUX
dpc-3114	11	10	a	a	DET
dpc-3114	11	11	humanized	humanize	VERB
dpc-3114	11	12	igg1κ	igg1κ	PRON
dpc-3114	11	13	monoclonal	monoclonal	NOUN
dpc-3114	11	14	antibody	antibody	NOUN
dpc-3114	11	15	targeting	target	VERB
dpc-3114	11	16	the	the	DET
dpc-3114	11	17	p19	p19	ADJ
dpc-3114	11	18	subunit	subunit	NOUN
dpc-3114	11	19	of	of	ADP
dpc-3114	11	20	interleukin	interleukin	NOUN
dpc-3114	11	21	(	(	PUNCT
dpc-3114	11	22	il)-23	il)-23	PROPN
dpc-3114	11	23	,	,	PUNCT
dpc-3114	11	24	approved	approve	VERB
dpc-3114	11	25	in	in	ADP
dpc-3114	11	26	2018	2018	NUM
dpc-3114	11	27	for	for	ADP
dpc-3114	11	28	the	the	DET
dpc-3114	11	29	treatment	treatment	NOUN
dpc-3114	11	30	of	of	ADP
dpc-3114	11	31	patients	patient	NOUN
dpc-3114	11	32	with	with	ADP
dpc-3114	11	33	moderate	moderate	ADJ
dpc-3114	11	34	-	-	PUNCT
dpc-3114	11	35	to	to	ADP
dpc-3114	11	36	-	-	PUNCT
dpc-3114	11	37	severe	severe	ADJ
dpc-3114	11	38	chronic	chronic	ADJ
dpc-3114	11	39	plaque	plaque	NOUN
dpc-3114	11	40	psoriasis	psoriasis	NOUN
dpc-3114	11	41	.	.	PUNCT
dpc-3114	12	1	objectives	objective	NOUN
dpc-3114	12	2	:	:	PUNCT
dpc-3114	12	3	this	this	DET
dpc-3114	12	4	study	study	NOUN
dpc-3114	12	5	aimed	aim	VERB
dpc-3114	12	6	to	to	PART
dpc-3114	12	7	evaluate	evaluate	VERB
dpc-3114	12	8	the	the	DET
dpc-3114	12	9	effectiveness	effectiveness	NOUN
dpc-3114	12	10	,	,	PUNCT
dpc-3114	12	11	safety	safety	NOUN
dpc-3114	12	12	and	and	CCONJ
dpc-3114	12	13	survival	survival	NOUN
dpc-3114	12	14	of	of	ADP
dpc-3114	12	15	tildrakizumab	tildrakizumab	NOUN
dpc-3114	12	16	in	in	ADP
dpc-3114	12	17	the	the	DET
dpc-3114	12	18	medium	medium	ADJ
dpc-3114	12	19	term	term	NOUN
dpc-3114	12	20	(	(	PUNCT
dpc-3114	12	21	48	48	NUM
dpc-3114	12	22	weeks	week	NOUN
dpc-3114	12	23	)	)	PUNCT
dpc-3114	12	24	in	in	ADP
dpc-3114	12	25	psoriatic	psoriatic	ADJ
dpc-3114	12	26	patients	patient	NOUN
dpc-3114	12	27	failure	failure	NOUN
dpc-3114	12	28	to	to	ADP
dpc-3114	12	29	previous	previous	ADJ
dpc-3114	12	30	biologic	biologic	NOUN
dpc-3114	12	31	treatment	treatment	NOUN
dpc-3114	12	32	in	in	ADP
dpc-3114	12	33	a	a	DET
dpc-3114	12	34	real	real	ADJ
dpc-3114	12	35	world	world	NOUN
dpc-3114	12	36	setting	setting	NOUN
dpc-3114	12	37	.	.	PUNCT
dpc-3114	13	1	methods	method	NOUN
dpc-3114	13	2	:	:	PUNCT
dpc-3114	13	3	this	this	PRON
dpc-3114	13	4	was	be	AUX
dpc-3114	13	5	a	a	DET
dpc-3114	13	6	retrospective	retrospective	ADJ
dpc-3114	13	7	,	,	PUNCT
dpc-3114	13	8	multicenter	multicenter	ADJ
dpc-3114	13	9	observational	observational	ADJ
dpc-3114	13	10	study	study	NOUN
dpc-3114	13	11	that	that	PRON
dpc-3114	13	12	included	include	VERB
dpc-3114	13	13	adult	adult	NOUN
dpc-3114	13	14	patients	patient	NOUN
dpc-3114	13	15	with	with	ADP
dpc-3114	13	16	moderate	moderate	ADJ
dpc-3114	13	17	-	-	PUNCT
dpc-3114	13	18	to	to	ADP
dpc-3114	13	19	-	-	PUNCT
dpc-3114	13	20	severe	severe	ADJ
dpc-3114	13	21	plaque	plaque	NOUN
dpc-3114	13	22	psoriasis	psoriasis	NOUN
dpc-3114	13	23	,	,	PUNCT
dpc-3114	13	24	failure	failure	NOUN
dpc-3114	13	25	to	to	ADP
dpc-3114	13	26	previous	previous	ADJ
dpc-3114	13	27	biologic	biologic	NOUN
dpc-3114	13	28	therapy	therapy	NOUN
dpc-3114	13	29	,	,	PUNCT
dpc-3114	13	30	consecutively	consecutively	ADV
dpc-3114	13	31	treated	treat	VERB
dpc-3114	13	32	with	with	ADP
dpc-3114	13	33	tildrakizumab	tildrakizumab	NOUN
dpc-3114	13	34	.	.	PUNCT
dpc-3114	14	1	psoriasis	psoriasis	NOUN
dpc-3114	14	2	area	area	NOUN
dpc-3114	14	3	severity	severity	NOUN
dpc-3114	14	4	index	index	NOUN
dpc-3114	14	5	(	(	PUNCT
dpc-3114	14	6	pasi	pasi	NOUN
dpc-3114	14	7	)	)	PUNCT
dpc-3114	14	8	and	and	CCONJ
dpc-3114	14	9	body	body	NOUN
dpc-3114	14	10	surface	surface	NOUN
dpc-3114	14	11	area	area	NOUN
dpc-3114	14	12	(	(	PUNCT
dpc-3114	14	13	bsa	bsa	PROPN
dpc-3114	14	14	)	)	PUNCT
dpc-3114	14	15	values	value	NOUN
dpc-3114	14	16	were	be	AUX
dpc-3114	14	17	recorded	record	VERB
dpc-3114	14	18	at	at	ADP
dpc-3114	14	19	baseline	baseline	NOUN
dpc-3114	14	20	,	,	PUNCT
dpc-3114	14	21	at	at	ADP
dpc-3114	14	22	12	12	NUM
dpc-3114	14	23	and	and	CCONJ
dpc-3114	14	24	48	48	NUM
dpc-3114	14	25	weeks	week	NOUN
dpc-3114	14	26	of	of	ADP
dpc-3114	14	27	treatment	treatment	NOUN
dpc-3114	14	28	.	.	PUNCT
dpc-3114	15	1	safety	safety	NOUN
dpc-3114	15	2	and	and	CCONJ
dpc-3114	15	3	tolerability	tolerability	NOUN
dpc-3114	15	4	of	of	ADP
dpc-3114	15	5	tildrakizumab	tildrakizumab	NOUN
dpc-3114	15	6	were	be	AUX
dpc-3114	15	7	investigated	investigate	VERB
dpc-3114	15	8	by	by	ADP
dpc-3114	15	9	examining	examine	VERB
dpc-3114	15	10	the	the	DET
dpc-3114	15	11	presence	presence	NOUN
dpc-3114	15	12	of	of	ADP
dpc-3114	15	13	any	any	DET
dpc-3114	15	14	adverse	adverse	ADJ
dpc-3114	15	15	events	event	NOUN
dpc-3114	15	16	.	.	PUNCT
dpc-3114	16	1	results	result	NOUN
dpc-3114	16	2	:	:	PUNCT
dpc-3114	16	3	overall	overall	ADJ
dpc-3114	16	4	51	51	NUM
dpc-3114	16	5	patients	patient	NOUN
dpc-3114	16	6	were	be	AUX
dpc-3114	16	7	enrolled	enrol	VERB
dpc-3114	16	8	.	.	PUNCT
dpc-3114	17	1	baseline	baseline	PROPN
dpc-3114	17	2	disease	disease	NOUN
dpc-3114	17	3	severity	severity	NOUN
dpc-3114	17	4	was	be	AUX
dpc-3114	17	5	moderate	moderate	ADJ
dpc-3114	17	6	to	to	PART
dpc-3114	17	7	severe	severe	VERB
dpc-3114	17	8	with	with	ADP
dpc-3114	17	9	a	a	DET
dpc-3114	17	10	mean	mean	ADJ
dpc-3114	17	11	pasi	pasi	NOUN
dpc-3114	17	12	score	score	NOUN
dpc-3114	17	13	of	of	ADP
dpc-3114	17	14	19.2	19.2	NUM
dpc-3114	17	15	±	±	NUM
dpc-3114	17	16	8.5	8.5	NUM
dpc-3114	17	17	,	,	PUNCT
dpc-3114	17	18	mean	mean	PROPN
dpc-3114	17	19	bsa	bsa	NOUN
dpc-3114	17	20	of	of	ADP
dpc-3114	17	21	16	16	NUM
dpc-3114	17	22	±	±	NUM
dpc-3114	17	23	10.4	10.4	NUM
dpc-3114	17	24	,	,	PUNCT
dpc-3114	17	25	and	and	CCONJ
dpc-3114	17	26	mean	mean	VERB
dpc-3114	17	27	dermatology	dermatology	NOUN
dpc-3114	17	28	life	life	NOUN
dpc-3114	17	29	quality	quality	NOUN
dpc-3114	17	30	index	index	NOUN
dpc-3114	17	31	abstract	abstract	ADJ
dpc-3114	17	32	2	2	NUM
dpc-3114	17	33	original	original	ADJ
dpc-3114	17	34	article	article	NOUN
dpc-3114	17	35	|	|	ADV
dpc-3114	17	36	dermatol	dermatol	ADJ
dpc-3114	17	37	pract	pract	NOUN
dpc-3114	17	38	concept	concept	NOUN
dpc-3114	17	39	.	.	PUNCT
dpc-3114	18	1	2023;13(4):e2023215	2023;13(4):e2023215	NUM
dpc-3114	18	2	introduction	introduction	NOUN
dpc-3114	18	3	psoriasis	psoriasis	NOUN
dpc-3114	18	4	is	be	AUX
dpc-3114	18	5	a	a	DET
dpc-3114	18	6	chronic	chronic	ADJ
dpc-3114	18	7	immune	immune	NOUN
dpc-3114	18	8	-	-	PUNCT
dpc-3114	18	9	mediated	mediate	VERB
dpc-3114	18	10	disease	disease	NOUN
dpc-3114	18	11	with	with	ADP
dpc-3114	18	12	the	the	DET
dpc-3114	18	13	il-23	il-23	NOUN
dpc-3114	18	14	/	/	SYM
dpc-3114	18	15	il-17	il-17	NUM
dpc-3114	18	16	axis	axis	NOUN
dpc-3114	18	17	playing	play	VERB
dpc-3114	18	18	the	the	DET
dpc-3114	18	19	leading	lead	VERB
dpc-3114	18	20	role	role	NOUN
dpc-3114	18	21	[	[	X
dpc-3114	18	22	1	1	NUM
dpc-3114	18	23	]	]	PUNCT
dpc-3114	18	24	.	.	PUNCT
dpc-3114	19	1	tildrakizumab	tildrakizumab	NOUN
dpc-3114	19	2	is	be	AUX
dpc-3114	19	3	a	a	DET
dpc-3114	19	4	humanized	humanize	VERB
dpc-3114	19	5	igg1κ	igg1κ	PRON
dpc-3114	19	6	monoclonal	monoclonal	NOUN
dpc-3114	19	7	antibody	antibody	NOUN
dpc-3114	19	8	targeting	target	VERB
dpc-3114	19	9	the	the	DET
dpc-3114	19	10	p19	p19	ADJ
dpc-3114	19	11	subunit	subunit	NOUN
dpc-3114	19	12	of	of	ADP
dpc-3114	19	13	interleukin	interleukin	NOUN
dpc-3114	19	14	(	(	PUNCT
dpc-3114	19	15	il)-23	il)-23	PROPN
dpc-3114	19	16	,	,	PUNCT
dpc-3114	19	17	approved	approve	VERB
dpc-3114	19	18	in	in	ADP
dpc-3114	19	19	2018	2018	NUM
dpc-3114	19	20	for	for	ADP
dpc-3114	19	21	the	the	DET
dpc-3114	19	22	treatment	treatment	NOUN
dpc-3114	19	23	of	of	ADP
dpc-3114	19	24	patients	patient	NOUN
dpc-3114	19	25	with	with	ADP
dpc-3114	19	26	moderate	moderate	ADJ
dpc-3114	19	27	-	-	PUNCT
dpc-3114	19	28	to	to	ADP
dpc-3114	19	29	-	-	PUNCT
dpc-3114	19	30	severe	severe	ADJ
dpc-3114	19	31	chronic	chronic	ADJ
dpc-3114	19	32	plaque	plaque	NOUN
dpc-3114	19	33	psoriasis	psoriasis	NOUN
dpc-3114	19	34	[	[	X
dpc-3114	19	35	2	2	NUM
dpc-3114	19	36	]	]	PUNCT
dpc-3114	19	37	.	.	PUNCT
dpc-3114	20	1	the	the	DET
dpc-3114	20	2	effectiveness	effectiveness	NOUN
dpc-3114	20	3	and	and	CCONJ
dpc-3114	20	4	safety	safety	NOUN
dpc-3114	20	5	of	of	ADP
dpc-3114	20	6	tildrakizumab	tildrakizumab	NOUN
dpc-3114	20	7	has	have	AUX
dpc-3114	20	8	been	be	AUX
dpc-3114	20	9	firstly	firstly	ADV
dpc-3114	20	10	evaluated	evaluate	VERB
dpc-3114	20	11	in	in	ADP
dpc-3114	20	12	a	a	DET
dpc-3114	20	13	phase	phase	NOUN
dpc-3114	20	14	2b	2b	NOUN
dpc-3114	20	15	randomized	randomize	VERB
dpc-3114	20	16	placebo	placebo	NOUN
dpc-3114	20	17	-	-	PUNCT
dpc-3114	20	18	controlled	control	VERB
dpc-3114	20	19	trial	trial	NOUN
dpc-3114	20	20	and	and	CCONJ
dpc-3114	20	21	in	in	ADP
dpc-3114	20	22	two	two	NUM
dpc-3114	20	23	randomized	randomized	ADJ
dpc-3114	20	24	phase	phase	NOUN
dpc-3114	20	25	3	3	NUM
dpc-3114	20	26	clinical	clinical	ADJ
dpc-3114	20	27	trials	trial	NOUN
dpc-3114	20	28	,	,	PUNCT
dpc-3114	20	29	compared	compare	VERB
dpc-3114	20	30	with	with	ADP
dpc-3114	20	31	both	both	DET
dpc-3114	20	32	placebo	placebo	NOUN
dpc-3114	20	33	(	(	PUNCT
dpc-3114	20	34	resurface	resurface	NOUN
dpc-3114	20	35	1	1	NUM
dpc-3114	20	36	and	and	CCONJ
dpc-3114	20	37	2	2	NUM
dpc-3114	20	38	)	)	PUNCT
dpc-3114	20	39	and	and	CCONJ
dpc-3114	20	40	etanercept	etanercept	NOUN
dpc-3114	20	41	(	(	PUNCT
dpc-3114	20	42	resurface	resurface	NOUN
dpc-3114	20	43	 	 	SPACE
dpc-3114	20	44	2	2	NUM
dpc-3114	20	45	)	)	PUNCT
dpc-3114	20	46	.	.	PUNCT
dpc-3114	21	1	tildrakizumab	tildrakizumab	NOUN
dpc-3114	21	2	has	have	AUX
dpc-3114	21	3	been	be	AUX
dpc-3114	21	4	also	also	ADV
dpc-3114	21	5	well	well	ADV
dpc-3114	21	6	-	-	PUNCT
dpc-3114	21	7	tolerated	tolerate	VERB
dpc-3114	21	8	,	,	PUNCT
dpc-3114	21	9	showing	show	VERB
dpc-3114	21	10	no	no	DET
dpc-3114	21	11	safety	safety	NOUN
dpc-3114	21	12	issues	issue	NOUN
dpc-3114	21	13	although	although	SCONJ
dpc-3114	21	14	the	the	DET
dpc-3114	21	15	discrete	discrete	ADJ
dpc-3114	21	16	higher	high	ADJ
dpc-3114	21	17	risk	risk	NOUN
dpc-3114	21	18	of	of	ADP
dpc-3114	21	19	nasopharyngitis	nasopharyngitis	NOUN
dpc-3114	21	20	[	[	X
dpc-3114	21	21	3,4	3,4	NUM
dpc-3114	21	22	]	]	PUNCT
dpc-3114	21	23	.	.	PUNCT
dpc-3114	22	1	recently	recently	ADV
dpc-3114	22	2	,	,	PUNCT
dpc-3114	22	3	confirmatory	confirmatory	NOUN
dpc-3114	22	4	data	datum	NOUN
dpc-3114	22	5	on	on	ADP
dpc-3114	22	6	efficacy	efficacy	NOUN
dpc-3114	22	7	and	and	CCONJ
dpc-3114	22	8	safety	safety	NOUN
dpc-3114	22	9	derived	derive	VERB
dpc-3114	22	10	from	from	ADP
dpc-3114	22	11	real	real	ADJ
dpc-3114	22	12	-	-	PUNCT
dpc-3114	22	13	world	world	NOUN
dpc-3114	22	14	studies	study	NOUN
dpc-3114	22	15	in	in	ADP
dpc-3114	22	16	patients	patient	NOUN
dpc-3114	22	17	affected	affect	VERB
dpc-3114	22	18	by	by	ADP
dpc-3114	22	19	psoriasis	psoriasis	NOUN
dpc-3114	22	20	,	,	PUNCT
dpc-3114	22	21	also	also	ADV
dpc-3114	22	22	involving	involve	VERB
dpc-3114	22	23	difficult	difficult	ADJ
dpc-3114	22	24	-	-	PUNCT
dpc-3114	22	25	to	to	ADP
dpc-3114	22	26	-	-	PUNCT
dpc-3114	22	27	treat	treat	VERB
dpc-3114	22	28	areas	area	NOUN
dpc-3114	22	29	as	as	ADP
dpc-3114	22	30	scalp	scalp	NOUN
dpc-3114	22	31	,	,	PUNCT
dpc-3114	22	32	nail	nail	NOUN
dpc-3114	22	33	,	,	PUNCT
dpc-3114	22	34	palmoplantar	palmoplantar	NOUN
dpc-3114	22	35	and	and	CCONJ
dpc-3114	22	36	genital	genital	ADJ
dpc-3114	22	37	psoriasis	psoriasis	NOUN
dpc-3114	22	38	are	be	AUX
dpc-3114	22	39	available	available	ADJ
dpc-3114	22	40	[	[	PUNCT
dpc-3114	22	41	5	5	NUM
dpc-3114	22	42	-	-	SYM
dpc-3114	22	43	10	10	NUM
dpc-3114	22	44	]	]	PUNCT
dpc-3114	22	45	.	.	PUNCT
dpc-3114	23	1	nevertheless	nevertheless	ADV
dpc-3114	23	2	,	,	PUNCT
dpc-3114	23	3	little	little	ADJ
dpc-3114	23	4	evidence	evidence	NOUN
dpc-3114	23	5	is	be	AUX
dpc-3114	23	6	currently	currently	ADV
dpc-3114	23	7	available	available	ADJ
dpc-3114	23	8	about	about	ADP
dpc-3114	23	9	the	the	DET
dpc-3114	23	10	impact	impact	NOUN
dpc-3114	23	11	of	of	ADP
dpc-3114	23	12	previous	previous	ADJ
dpc-3114	23	13	biologic	biologic	NOUN
dpc-3114	23	14	exposure	exposure	NOUN
dpc-3114	23	15	on	on	ADP
dpc-3114	23	16	subsequent	subsequent	ADJ
dpc-3114	23	17	treatment	treatment	NOUN
dpc-3114	23	18	with	with	ADP
dpc-3114	23	19	tildrakizumab	tildrakizumab	NOUN
dpc-3114	23	20	,	,	PUNCT
dpc-3114	23	21	unlike	unlike	ADP
dpc-3114	23	22	other	other	ADJ
dpc-3114	23	23	biologics	biologic	NOUN
dpc-3114	23	24	[	[	X
dpc-3114	23	25	11,12	11,12	NOUN
dpc-3114	23	26	]	]	PUNCT
dpc-3114	23	27	not	not	PART
dpc-3114	23	28	allowing	allow	VERB
dpc-3114	23	29	dermatologists	dermatologist	NOUN
dpc-3114	23	30	to	to	PART
dpc-3114	23	31	maximize	maximize	VERB
dpc-3114	23	32	patient	patient	ADJ
dpc-3114	23	33	therapeutic	therapeutic	ADJ
dpc-3114	23	34	management	management	NOUN
dpc-3114	23	35	after	after	ADP
dpc-3114	23	36	switching	switch	VERB
dpc-3114	23	37	within	within	ADP
dpc-3114	23	38	and	and	CCONJ
dpc-3114	23	39	between	between	ADP
dpc-3114	23	40	classes	class	NOUN
dpc-3114	23	41	.	.	PUNCT
dpc-3114	24	1	hence	hence	ADV
dpc-3114	24	2	,	,	PUNCT
dpc-3114	24	3	this	this	DET
dpc-3114	24	4	multicenter	multicenter	NOUN
dpc-3114	24	5	retrospective	retrospective	ADJ
dpc-3114	24	6	study	study	NOUN
dpc-3114	24	7	aimed	aim	VERB
dpc-3114	24	8	to	to	PART
dpc-3114	24	9	evaluate	evaluate	VERB
dpc-3114	24	10	the	the	DET
dpc-3114	24	11	effectiveness	effectiveness	NOUN
dpc-3114	24	12	,	,	PUNCT
dpc-3114	24	13	safety	safety	NOUN
dpc-3114	24	14	and	and	CCONJ
dpc-3114	24	15	survival	survival	NOUN
dpc-3114	24	16	of	of	ADP
dpc-3114	24	17	tildrakizumab	tildrakizumab	NOUN
dpc-3114	24	18	in	in	ADP
dpc-3114	24	19	the	the	DET
dpc-3114	24	20	medium	medium	ADJ
dpc-3114	24	21	term	term	NOUN
dpc-3114	24	22	(	(	PUNCT
dpc-3114	24	23	48	48	NUM
dpc-3114	24	24	weeks	week	NOUN
dpc-3114	24	25	)	)	PUNCT
dpc-3114	24	26	in	in	ADP
dpc-3114	24	27	psoriatic	psoriatic	ADJ
dpc-3114	24	28	patients	patient	NOUN
dpc-3114	24	29	failure	failure	NOUN
dpc-3114	24	30	to	to	ADP
dpc-3114	24	31	previous	previous	ADJ
dpc-3114	24	32	biologic	biologic	NOUN
dpc-3114	24	33	treatment	treatment	NOUN
dpc-3114	24	34	in	in	ADP
dpc-3114	24	35	a	a	DET
dpc-3114	24	36	real	real	ADJ
dpc-3114	24	37	world	world	NOUN
dpc-3114	24	38	setting	setting	NOUN
dpc-3114	24	39	.	.	PUNCT
dpc-3114	25	1	methods	method	NOUN
dpc-3114	25	2	study	study	NOUN
dpc-3114	25	3	design	design	NOUN
dpc-3114	25	4	,	,	PUNCT
dpc-3114	25	5	patients	patient	NOUN
dpc-3114	25	6	characteristics	characteristic	NOUN
dpc-3114	25	7	and	and	CCONJ
dpc-3114	25	8	data	datum	NOUN
dpc-3114	25	9	collection	collection	NOUN
dpc-3114	25	10	this	this	PRON
dpc-3114	25	11	was	be	AUX
dpc-3114	25	12	a	a	DET
dpc-3114	25	13	retrospective	retrospective	ADJ
dpc-3114	25	14	,	,	PUNCT
dpc-3114	25	15	multicenter	multicenter	ADJ
dpc-3114	25	16	observational	observational	ADJ
dpc-3114	25	17	study	study	NOUN
dpc-3114	25	18	that	that	PRON
dpc-3114	25	19	included	include	VERB
dpc-3114	25	20	adult	adult	NOUN
dpc-3114	25	21	patients	patient	NOUN
dpc-3114	25	22	with	with	ADP
dpc-3114	25	23	moderate	moderate	ADJ
dpc-3114	25	24	-	-	PUNCT
dpc-3114	25	25	to	to	ADP
dpc-3114	25	26	-	-	PUNCT
dpc-3114	25	27	severe	severe	ADJ
dpc-3114	25	28	plaque	plaque	NOUN
dpc-3114	25	29	psoriasis	psoriasis	NOUN
dpc-3114	25	30	consecutively	consecutively	ADV
dpc-3114	25	31	treated	treat	VERB
dpc-3114	25	32	with	with	ADP
dpc-3114	25	33	tildrakizumab	tildrakizumab	NOUN
dpc-3114	25	34	at	at	ADP
dpc-3114	25	35	seven	seven	NUM
dpc-3114	25	36	italian	italian	ADJ
dpc-3114	25	37	dermatology	dermatology	NOUN
dpc-3114	25	38	units	unit	NOUN
dpc-3114	25	39	with	with	ADP
dpc-3114	25	40	psoriasis	psoriasis	NOUN
dpc-3114	25	41	-	-	PUNCT
dpc-3114	25	42	specialized	specialized	ADJ
dpc-3114	25	43	units	unit	NOUN
dpc-3114	25	44	.	.	PUNCT
dpc-3114	26	1	the	the	DET
dpc-3114	26	2	study	study	NOUN
dpc-3114	26	3	was	be	AUX
dpc-3114	26	4	performed	perform	VERB
dpc-3114	26	5	in	in	ADP
dpc-3114	26	6	accordance	accordance	NOUN
dpc-3114	26	7	with	with	ADP
dpc-3114	26	8	the	the	DET
dpc-3114	26	9	principles	principle	NOUN
dpc-3114	26	10	of	of	ADP
dpc-3114	26	11	the	the	DET
dpc-3114	26	12	helsinki	helsinki	PROPN
dpc-3114	26	13	declaration	declaration	PROPN
dpc-3114	26	14	and	and	CCONJ
dpc-3114	26	15	informed	inform	VERB
dpc-3114	26	16	written	write	VERB
dpc-3114	26	17	consent	consent	NOUN
dpc-3114	26	18	has	have	AUX
dpc-3114	26	19	been	be	AUX
dpc-3114	26	20	obtained	obtain	VERB
dpc-3114	26	21	from	from	ADP
dpc-3114	26	22	the	the	DET
dpc-3114	26	23	patients	patient	NOUN
dpc-3114	26	24	for	for	ADP
dpc-3114	26	25	the	the	DET
dpc-3114	26	26	use	use	NOUN
dpc-3114	26	27	of	of	ADP
dpc-3114	26	28	retrospective	retrospective	ADJ
dpc-3114	26	29	data	datum	NOUN
dpc-3114	26	30	collected	collect	VERB
dpc-3114	26	31	during	during	ADP
dpc-3114	26	32	routine	routine	ADJ
dpc-3114	26	33	clinical	clinical	ADJ
dpc-3114	26	34	practice	practice	NOUN
dpc-3114	26	35	.	.	PUNCT
dpc-3114	27	1	inclusion	inclusion	NOUN
dpc-3114	27	2	criteria	criterion	NOUN
dpc-3114	27	3	were	be	AUX
dpc-3114	27	4	age	age	NOUN
dpc-3114	27	5	≥	≥	NUM
dpc-3114	27	6	18	18	NUM
dpc-3114	27	7	years	year	NOUN
dpc-3114	27	8	,	,	PUNCT
dpc-3114	27	9	concomitant	concomitant	ADJ
dpc-3114	27	10	presence	presence	NOUN
dpc-3114	27	11	of	of	ADP
dpc-3114	27	12	moderate	moderate	ADJ
dpc-3114	27	13	-	-	PUNCT
dpc-3114	27	14	to	to	ADP
dpc-3114	27	15	-	-	PUNCT
dpc-3114	27	16	severe	severe	ADJ
dpc-3114	27	17	psoriasis	psoriasis	NOUN
dpc-3114	27	18	(	(	PUNCT
dpc-3114	27	19	psoriasis	psoriasis	NOUN
dpc-3114	27	20	area	area	NOUN
dpc-3114	27	21	severity	severity	NOUN
dpc-3114	27	22	index	index	NOUN
dpc-3114	27	23	[	[	X
dpc-3114	27	24	pasi	pasi	X
dpc-3114	27	25	]	]	X
dpc-3114	27	26	≥	≥	NOUN
dpc-3114	27	27	10	10	NUM
dpc-3114	27	28	)	)	PUNCT
dpc-3114	27	29	,	,	PUNCT
dpc-3114	27	30	failure	failure	NOUN
dpc-3114	27	31	to	to	ADP
dpc-3114	27	32	previous	previous	ADJ
dpc-3114	27	33	biologic	biologic	NOUN
dpc-3114	27	34	therapy	therapy	NOUN
dpc-3114	27	35	.	.	PUNCT
dpc-3114	28	1	failure	failure	NOUN
dpc-3114	28	2	was	be	AUX
dpc-3114	28	3	defined	define	VERB
dpc-3114	28	4	as	as	ADP
dpc-3114	28	5	the	the	DET
dpc-3114	28	6	loss	loss	NOUN
dpc-3114	28	7	of	of	ADP
dpc-3114	28	8	at	at	ADV
dpc-3114	28	9	least	least	ADJ
dpc-3114	28	10	pasi	pasi	VERB
dpc-3114	28	11	50	50	NUM
dpc-3114	28	12	.	.	PUNCT
dpc-3114	29	1	a	a	DET
dpc-3114	29	2	washout	washout	NOUN
dpc-3114	29	3	period	period	NOUN
dpc-3114	29	4	of	of	ADP
dpc-3114	29	5	at	at	ADV
dpc-3114	29	6	least	least	ADV
dpc-3114	29	7	4	4	NUM
dpc-3114	29	8	weeks	week	NOUN
dpc-3114	29	9	from	from	ADP
dpc-3114	29	10	previous	previous	ADJ
dpc-3114	29	11	systemic	systemic	ADJ
dpc-3114	29	12	treatments	treatment	NOUN
dpc-3114	29	13	was	be	AUX
dpc-3114	29	14	required	require	VERB
dpc-3114	29	15	.	.	PUNCT
dpc-3114	30	1	exclusion	exclusion	NOUN
dpc-3114	30	2	criteria	criterion	NOUN
dpc-3114	30	3	were	be	AUX
dpc-3114	30	4	hepatitis	hepatitis	PROPN
dpc-3114	30	5	b	b	PROPN
dpc-3114	30	6	surface	surface	PROPN
dpc-3114	30	7	ag	ag	PROPN
dpc-3114	30	8	positive	positive	ADJ
dpc-3114	30	9	,	,	PUNCT
dpc-3114	30	10	hepatitis	hepatitis	PROPN
dpc-3114	30	11	c	c	PROPN
dpc-3114	30	12	ab	ab	PROPN
dpc-3114	30	13	positive	positive	ADJ
dpc-3114	30	14	,	,	PUNCT
dpc-3114	30	15	active	active	ADJ
dpc-3114	30	16	tuberculosis	tuberculosis	NOUN
dpc-3114	30	17	(	(	PUNCT
dpc-3114	30	18	tb	tb	NOUN
dpc-3114	30	19	)	)	PUNCT
dpc-3114	30	20	or	or	CCONJ
dpc-3114	30	21	history	history	NOUN
dpc-3114	30	22	of	of	ADP
dpc-3114	30	23	incompletely	incompletely	ADV
dpc-3114	30	24	treated	treat	VERB
dpc-3114	30	25	tb	tb	ADP
dpc-3114	30	26	,	,	PUNCT
dpc-3114	30	27	malignancy	malignancy	NOUN
dpc-3114	30	28	or	or	CCONJ
dpc-3114	30	29	history	history	NOUN
dpc-3114	30	30	of	of	ADP
dpc-3114	30	31	malignancy	malignancy	NOUN
dpc-3114	30	32	in	in	ADP
dpc-3114	30	33	the	the	DET
dpc-3114	30	34	last	last	ADJ
dpc-3114	30	35	5	5	NUM
dpc-3114	30	36	years	year	NOUN
dpc-3114	30	37	.	.	PUNCT
dpc-3114	31	1	after	after	ADP
dpc-3114	31	2	appropriate	appropriate	ADJ
dpc-3114	31	3	screening	screening	NOUN
dpc-3114	31	4	tests	test	NOUN
dpc-3114	31	5	,	,	PUNCT
dpc-3114	31	6	tildrakizumab	tildrakizumab	NOUN
dpc-3114	31	7	was	be	AUX
dpc-3114	31	8	administered	administer	VERB
dpc-3114	31	9	in	in	ADP
dpc-3114	31	10	monotherapy	monotherapy	NOUN
dpc-3114	31	11	at	at	ADP
dpc-3114	31	12	the	the	DET
dpc-3114	31	13	standard	standard	ADJ
dpc-3114	31	14	dose	dose	NOUN
dpc-3114	31	15	regimen	regiman	NOUN
dpc-3114	31	16	(	(	PUNCT
dpc-3114	31	17	induction	induction	NOUN
dpc-3114	31	18	phase	phase	NOUN
dpc-3114	31	19	:	:	PUNCT
dpc-3114	31	20	100	100	NUM
dpc-3114	31	21	mg	mg	ADV
dpc-3114	31	22	subcutaneously	subcutaneously	ADV
dpc-3114	31	23	at	at	ADP
dpc-3114	31	24	weeks	week	NOUN
dpc-3114	31	25	0	0	NUM
dpc-3114	31	26	and	and	CCONJ
dpc-3114	31	27	4	4	NUM
dpc-3114	31	28	,	,	PUNCT
dpc-3114	31	29	and	and	CCONJ
dpc-3114	31	30	a	a	DET
dpc-3114	31	31	maintenance	maintenance	NOUN
dpc-3114	31	32	dose	dose	VERB
dpc-3114	31	33	every	every	DET
dpc-3114	31	34	12	12	NUM
dpc-3114	31	35	weeks	week	NOUN
dpc-3114	31	36	thereafter	thereafter	ADV
dpc-3114	31	37	)	)	PUNCT
dpc-3114	31	38	.	.	PUNCT
dpc-3114	32	1	data	datum	NOUN
dpc-3114	32	2	collected	collect	VERB
dpc-3114	32	3	included	include	VERB
dpc-3114	32	4	demographic	demographic	ADJ
dpc-3114	32	5	data	datum	NOUN
dpc-3114	32	6	(	(	PUNCT
dpc-3114	32	7	eg	eg	NOUN
dpc-3114	32	8	,	,	PUNCT
dpc-3114	32	9	age	age	NOUN
dpc-3114	32	10	,	,	PUNCT
dpc-3114	32	11	gender	gender	NOUN
dpc-3114	32	12	,	,	PUNCT
dpc-3114	32	13	height	height	NOUN
dpc-3114	32	14	,	,	PUNCT
dpc-3114	32	15	weight	weight	NOUN
dpc-3114	32	16	and	and	CCONJ
dpc-3114	32	17	body	body	NOUN
dpc-3114	32	18	mass	mass	NOUN
dpc-3114	32	19	index	index	NOUN
dpc-3114	32	20	[	[	X
dpc-3114	32	21	bmi	bmi	X
dpc-3114	32	22	]	]	X
dpc-3114	32	23	)	)	PUNCT
dpc-3114	32	24	,	,	PUNCT
dpc-3114	32	25	disease	disease	NOUN
dpc-3114	32	26	duration	duration	NOUN
dpc-3114	32	27	(	(	PUNCT
dpc-3114	32	28	defined	define	VERB
dpc-3114	32	29	as	as	ADP
dpc-3114	32	30	the	the	DET
dpc-3114	32	31	time	time	NOUN
dpc-3114	32	32	from	from	ADP
dpc-3114	32	33	diagnosis	diagnosis	NOUN
dpc-3114	32	34	to	to	PART
dpc-3114	32	35	start	start	VERB
dpc-3114	32	36	of	of	ADP
dpc-3114	32	37	tildrakizumab	tildrakizumab	NOUN
dpc-3114	32	38	treatment	treatment	NOUN
dpc-3114	32	39	)	)	PUNCT
dpc-3114	32	40	,	,	PUNCT
dpc-3114	32	41	associated	associate	VERB
dpc-3114	32	42	comorbidities	comorbiditie	NOUN
dpc-3114	32	43	and	and	CCONJ
dpc-3114	32	44	previous	previous	ADJ
dpc-3114	32	45	systemic	systemic	NOUN
dpc-3114	32	46	,	,	PUNCT
dpc-3114	32	47	including	include	VERB
dpc-3114	32	48	biological	biological	ADJ
dpc-3114	32	49	therapies	therapy	NOUN
dpc-3114	32	50	.	.	PUNCT
dpc-3114	33	1	outcome	outcome	NOUN
dpc-3114	33	2	measures	measure	NOUN
dpc-3114	33	3	pasi	pasi	NOUN
dpc-3114	33	4	and	and	CCONJ
dpc-3114	33	5	body	body	NOUN
dpc-3114	33	6	surface	surface	NOUN
dpc-3114	33	7	area	area	NOUN
dpc-3114	33	8	(	(	PUNCT
dpc-3114	33	9	bsa	bsa	PROPN
dpc-3114	33	10	)	)	PUNCT
dpc-3114	33	11	values	value	NOUN
dpc-3114	33	12	were	be	AUX
dpc-3114	33	13	recorded	record	VERB
dpc-3114	33	14	at	at	ADP
dpc-3114	33	15	baseline	baseline	PROPN
dpc-3114	33	16	(	(	PUNCT
dpc-3114	33	17	prior	prior	ADV
dpc-3114	33	18	to	to	ADP
dpc-3114	33	19	treatment	treatment	NOUN
dpc-3114	33	20	with	with	ADP
dpc-3114	33	21	tildrakizumab	tildrakizumab	NOUN
dpc-3114	33	22	)	)	PUNCT
dpc-3114	33	23	at	at	ADP
dpc-3114	33	24	12	12	NUM
dpc-3114	33	25	and	and	CCONJ
dpc-3114	33	26	48	48	NUM
dpc-3114	33	27	weeks	week	NOUN
dpc-3114	33	28	of	of	ADP
dpc-3114	33	29	treatment	treatment	NOUN
dpc-3114	33	30	.	.	PUNCT
dpc-3114	34	1	the	the	DET
dpc-3114	34	2	effectiveness	effectiveness	NOUN
dpc-3114	34	3	of	of	ADP
dpc-3114	34	4	tildrakizumab	tildrakizumab	NOUN
dpc-3114	34	5	was	be	AUX
dpc-3114	34	6	reported	report	VERB
dpc-3114	34	7	as	as	ADP
dpc-3114	34	8	the	the	DET
dpc-3114	34	9	absolute	absolute	ADJ
dpc-3114	34	10	pasi	pasi	NOUN
dpc-3114	34	11	score	score	NOUN
dpc-3114	34	12	as	as	ADV
dpc-3114	34	13	well	well	ADV
dpc-3114	34	14	as	as	ADP
dpc-3114	34	15	the	the	DET
dpc-3114	34	16	relative	relative	ADJ
dpc-3114	34	17	percentage	percentage	NOUN
dpc-3114	34	18	of	of	ADP
dpc-3114	34	19	patients	patient	NOUN
dpc-3114	34	20	achieving	achieve	VERB
dpc-3114	34	21	75	75	NUM
dpc-3114	34	22	%	%	NOUN
dpc-3114	34	23	,	,	PUNCT
dpc-3114	34	24	90	90	NUM
dpc-3114	34	25	%	%	NOUN
dpc-3114	34	26	,	,	PUNCT
dpc-3114	34	27	and	and	CCONJ
dpc-3114	34	28	100	100	NUM
dpc-3114	34	29	%	%	NOUN
dpc-3114	34	30	improvement	improvement	NOUN
dpc-3114	34	31	from	from	ADP
dpc-3114	34	32	baseline	baseline	NOUN
dpc-3114	34	33	pasi	pasi	NOUN
dpc-3114	34	34	(	(	PUNCT
dpc-3114	34	35	pasi	pasi	NOUN
dpc-3114	34	36	75	75	NUM
dpc-3114	34	37	,	,	PUNCT
dpc-3114	34	38	pasi	pasi	NOUN
dpc-3114	34	39	90	90	NUM
dpc-3114	34	40	,	,	PUNCT
dpc-3114	34	41	and	and	CCONJ
dpc-3114	34	42	pasi	pasi	NOUN
dpc-3114	34	43	100	100	NUM
dpc-3114	34	44	,	,	PUNCT
dpc-3114	34	45	respectively	respectively	ADV
dpc-3114	34	46	)	)	PUNCT
dpc-3114	34	47	at	at	ADP
dpc-3114	34	48	12	12	NUM
dpc-3114	34	49	and	and	CCONJ
dpc-3114	34	50	48	48	NUM
dpc-3114	34	51	weeks	week	NOUN
dpc-3114	34	52	.	.	PUNCT
dpc-3114	35	1	the	the	DET
dpc-3114	35	2	impact	impact	NOUN
dpc-3114	35	3	on	on	ADP
dpc-3114	35	4	patients	patient	NOUN
dpc-3114	35	5	quality	quality	NOUN
dpc-3114	35	6	of	of	ADP
dpc-3114	35	7	life	life	NOUN
dpc-3114	35	8	(	(	PUNCT
dpc-3114	35	9	qol	qol	NOUN
dpc-3114	35	10	)	)	PUNCT
dpc-3114	35	11	was	be	AUX
dpc-3114	35	12	assessed	assess	VERB
dpc-3114	35	13	through	through	ADP
dpc-3114	35	14	dermatology	dermatology	NOUN
dpc-3114	35	15	life	life	NOUN
dpc-3114	35	16	quality	quality	NOUN
dpc-3114	35	17	index	index	NOUN
dpc-3114	35	18	(	(	PUNCT
dpc-3114	35	19	dlqi	dlqi	ADJ
dpc-3114	35	20	)	)	PUNCT
dpc-3114	35	21	at	at	ADP
dpc-3114	35	22	each	each	DET
dpc-3114	35	23	visit	visit	NOUN
dpc-3114	35	24	(	(	PUNCT
dpc-3114	35	25	baseline	baseline	NOUN
dpc-3114	35	26	,	,	PUNCT
dpc-3114	35	27	weeks	week	NOUN
dpc-3114	35	28	12	12	NUM
dpc-3114	35	29	and	and	CCONJ
dpc-3114	35	30	48	48	NUM
dpc-3114	35	31	)	)	PUNCT
dpc-3114	35	32	.	.	PUNCT
dpc-3114	36	1	safety	safety	NOUN
dpc-3114	36	2	safety	safety	NOUN
dpc-3114	36	3	and	and	CCONJ
dpc-3114	36	4	tolerability	tolerability	NOUN
dpc-3114	36	5	of	of	ADP
dpc-3114	36	6	tildrakizumab	tildrakizumab	NOUN
dpc-3114	36	7	were	be	AUX
dpc-3114	36	8	investigated	investigate	VERB
dpc-3114	36	9	by	by	ADP
dpc-3114	36	10	examining	examine	VERB
dpc-3114	36	11	the	the	DET
dpc-3114	36	12	presence	presence	NOUN
dpc-3114	36	13	of	of	ADP
dpc-3114	36	14	any	any	DET
dpc-3114	36	15	adverse	adverse	ADJ
dpc-3114	36	16	events	event	NOUN
dpc-3114	36	17	(	(	PUNCT
dpc-3114	36	18	aes	aes	NOUN
dpc-3114	36	19	)	)	PUNCT
dpc-3114	36	20	,	,	PUNCT
dpc-3114	36	21	including	include	VERB
dpc-3114	36	22	mild	mild	ADJ
dpc-3114	36	23	and	and	CCONJ
dpc-3114	36	24	serious	serious	ADJ
dpc-3114	36	25	aes	aes	PROPN
dpc-3114	36	26	,	,	PUNCT
dpc-3114	36	27	laboratory	laboratory	NOUN
dpc-3114	36	28	values	value	NOUN
dpc-3114	36	29	(	(	PUNCT
dpc-3114	36	30	hematology	hematology	NOUN
dpc-3114	36	31	,	,	PUNCT
dpc-3114	36	32	clinical	clinical	ADJ
dpc-3114	36	33	chemistry	chemistry	NOUN
dpc-3114	36	34	and	and	CCONJ
dpc-3114	36	35	urinalysis	urinalysis	NOUN
dpc-3114	36	36	)	)	PUNCT
dpc-3114	36	37	,	,	PUNCT
dpc-3114	36	38	physical	physical	ADJ
dpc-3114	36	39	examination	examination	NOUN
dpc-3114	36	40	and	and	CCONJ
dpc-3114	36	41	local	local	ADJ
dpc-3114	36	42	tolerability	tolerability	NOUN
dpc-3114	36	43	.	.	PUNCT
dpc-3114	37	1	the	the	DET
dpc-3114	37	2	occurrence	occurrence	NOUN
dpc-3114	37	3	of	of	ADP
dpc-3114	37	4	aes	aes	PROPN
dpc-3114	37	5	was	be	AUX
dpc-3114	37	6	collected	collect	VERB
dpc-3114	37	7	at	at	ADP
dpc-3114	37	8	weeks	week	NOUN
dpc-3114	37	9	12	12	NUM
dpc-3114	37	10	and	and	CCONJ
dpc-3114	37	11	48	48	NUM
dpc-3114	37	12	.	.	PUNCT
dpc-3114	38	1	reasons	reason	NOUN
dpc-3114	38	2	for	for	ADP
dpc-3114	38	3	tildrakizumab	tildrakizumab	NOUN
dpc-3114	38	4	withdrawal	withdrawal	NOUN
dpc-3114	38	5	were	be	AUX
dpc-3114	38	6	also	also	ADV
dpc-3114	38	7	collected	collect	VERB
dpc-3114	38	8	and	and	CCONJ
dpc-3114	38	9	classified	classify	VERB
dpc-3114	38	10	as	as	ADP
dpc-3114	38	11	(	(	PUNCT
dpc-3114	38	12	i	i	NOUN
dpc-3114	38	13	)	)	PUNCT
dpc-3114	38	14	lack	lack	NOUN
dpc-3114	38	15	or	or	CCONJ
dpc-3114	38	16	loss	loss	NOUN
dpc-3114	38	17	of	of	ADP
dpc-3114	38	18	efficacy	efficacy	NOUN
dpc-3114	38	19	;	;	PUNCT
dpc-3114	38	20	(	(	PUNCT
dpc-3114	38	21	ii	ii	NOUN
dpc-3114	38	22	)	)	PUNCT
dpc-3114	38	23	aes	aes	PROPN
dpc-3114	38	24	;	;	PUNCT
dpc-3114	38	25	and	and	CCONJ
dpc-3114	38	26	(	(	PUNCT
dpc-3114	38	27	iii	iii	X
dpc-3114	38	28	)	)	PUNCT
dpc-3114	38	29	other	other	ADJ
dpc-3114	38	30	reasons	reason	NOUN
dpc-3114	38	31	(	(	PUNCT
dpc-3114	38	32	lost	lose	VERB
dpc-3114	38	33	to	to	PART
dpc-3114	38	34	follow	follow	VERB
dpc-3114	38	35	-	-	PUNCT
dpc-3114	38	36	up	up	NOUN
dpc-3114	38	37	,	,	PUNCT
dpc-3114	38	38	etc	etc	X
dpc-3114	38	39	)	)	PUNCT
dpc-3114	38	40	(	(	PUNCT
dpc-3114	38	41	dlqi	dlqi	PROPN
dpc-3114	38	42	)	)	PUNCT
dpc-3114	38	43	of	of	ADP
dpc-3114	38	44	18.2	18.2	NUM
dpc-3114	38	45	±	±	NUM
dpc-3114	38	46	6.8	6.8	NUM
dpc-3114	38	47	.	.	PUNCT
dpc-3114	39	1	a	a	DET
dpc-3114	39	2	significant	significant	ADJ
dpc-3114	39	3	reduction	reduction	NOUN
dpc-3114	39	4	in	in	ADP
dpc-3114	39	5	the	the	DET
dpc-3114	39	6	mean	mean	ADJ
dpc-3114	39	7	pasi	pasi	NOUN
dpc-3114	39	8	score	score	NOUN
dpc-3114	39	9	was	be	AUX
dpc-3114	39	10	detected	detect	VERB
dpc-3114	39	11	at	at	ADP
dpc-3114	39	12	12	12	NUM
dpc-3114	39	13	weeks	week	NOUN
dpc-3114	39	14	of	of	ADP
dpc-3114	39	15	tildrakizumab	tildrakizumab	NOUN
dpc-3114	39	16	therapy	therapy	NOUN
dpc-3114	39	17	(	(	PUNCT
dpc-3114	39	18	3.5	3.5	NUM
dpc-3114	39	19	±	±	NUM
dpc-3114	39	20	2.7	2.7	NUM
dpc-3114	39	21	,	,	PUNCT
dpc-3114	39	22	p	p	X
dpc-3114	39	23	<	<	X
dpc-3114	39	24	0.001	0.001	NUM
dpc-3114	39	25	)	)	PUNCT
dpc-3114	39	26	,	,	PUNCT
dpc-3114	39	27	with	with	ADP
dpc-3114	39	28	a	a	DET
dpc-3114	39	29	further	further	ADJ
dpc-3114	39	30	improvement	improvement	NOUN
dpc-3114	39	31	at	at	ADP
dpc-3114	39	32	week	week	NOUN
dpc-3114	39	33	48	48	NUM
dpc-3114	39	34	(	(	PUNCT
dpc-3114	39	35	0.6	0.6	NUM
dpc-3114	39	36	±	±	NUM
dpc-3114	39	37	1.5	1.5	NUM
dpc-3114	39	38	,	,	PUNCT
dpc-3114	39	39	p	p	X
dpc-3114	39	40	<	<	X
dpc-3114	39	41	0.001	0.001	NUM
dpc-3114	39	42	)	)	PUNCT
dpc-3114	39	43	.	.	PUNCT
dpc-3114	40	1	at	at	ADP
dpc-3114	40	2	week	week	NOUN
dpc-3114	40	3	12	12	NUM
dpc-3114	40	4	,	,	PUNCT
dpc-3114	40	5	there	there	PRON
dpc-3114	40	6	was	be	VERB
dpc-3114	40	7	a	a	DET
dpc-3114	40	8	great	great	ADJ
dpc-3114	40	9	improvement	improvement	NOUN
dpc-3114	40	10	in	in	ADP
dpc-3114	40	11	bsa	bsa	PROPN
dpc-3114	40	12	score	score	VERB
dpc-3114	40	13	for	for	ADP
dpc-3114	40	14	all	all	DET
dpc-3114	40	15	groups	group	NOUN
dpc-3114	40	16	(	(	PUNCT
dpc-3114	40	17	p	p	X
dpc-3114	40	18	<	<	NOUN
dpc-3114	40	19	0.001	0.001	NUM
dpc-3114	40	20	)	)	PUNCT
dpc-3114	40	21	with	with	ADP
dpc-3114	40	22	further	further	ADJ
dpc-3114	40	23	increase	increase	NOUN
dpc-3114	40	24	at	at	ADP
dpc-3114	40	25	week	week	NOUN
dpc-3114	40	26	48	48	NUM
dpc-3114	40	27	.	.	PUNCT
dpc-3114	41	1	the	the	DET
dpc-3114	41	2	effectiveness	effectiveness	NOUN
dpc-3114	41	3	was	be	AUX
dpc-3114	41	4	confirmed	confirm	VERB
dpc-3114	41	5	also	also	ADV
dpc-3114	41	6	by	by	ADP
dpc-3114	41	7	dlqi	dlqi	ADJ
dpc-3114	41	8	assessment	assessment	NOUN
dpc-3114	41	9	,	,	PUNCT
dpc-3114	41	10	with	with	ADP
dpc-3114	41	11	a	a	DET
dpc-3114	41	12	significant	significant	ADJ
dpc-3114	41	13	decrease	decrease	NOUN
dpc-3114	41	14	at	at	ADP
dpc-3114	41	15	week	week	NOUN
dpc-3114	41	16	12	12	NUM
dpc-3114	41	17	and	and	CCONJ
dpc-3114	41	18	even	even	ADV
dpc-3114	41	19	more	more	ADV
dpc-3114	41	20	at	at	ADP
dpc-3114	41	21	week	week	NOUN
dpc-3114	41	22	48	48	NUM
dpc-3114	41	23	(	(	PUNCT
dpc-3114	41	24	p	p	X
dpc-3114	41	25	<	<	X
dpc-3114	41	26	0.001	0.001	NUM
dpc-3114	41	27	)	)	PUNCT
dpc-3114	41	28	.	.	PUNCT
dpc-3114	42	1	conclusions	conclusion	NOUN
dpc-3114	42	2	:	:	PUNCT
dpc-3114	42	3	this	this	DET
dpc-3114	42	4	study	study	NOUN
dpc-3114	42	5	confirms	confirm	VERB
dpc-3114	42	6	the	the	DET
dpc-3114	42	7	effectiveness	effectiveness	NOUN
dpc-3114	42	8	of	of	ADP
dpc-3114	42	9	tildrakizumab	tildrakizumab	NOUN
dpc-3114	42	10	in	in	ADP
dpc-3114	42	11	daily	daily	ADJ
dpc-3114	42	12	clinical	clinical	ADJ
dpc-3114	42	13	practice	practice	NOUN
dpc-3114	42	14	in	in	ADP
dpc-3114	42	15	patients	patient	NOUN
dpc-3114	42	16	with	with	ADP
dpc-3114	42	17	moderate	moderate	ADJ
dpc-3114	42	18	-	-	PUNCT
dpc-3114	42	19	to	to	ADP
dpc-3114	42	20	-	-	PUNCT
dpc-3114	42	21	severe	severe	ADJ
dpc-3114	42	22	plaque	plaque	NOUN
dpc-3114	42	23	psoriasis	psoriasis	NOUN
dpc-3114	42	24	.	.	PUNCT
dpc-3114	43	1	original	original	ADJ
dpc-3114	43	2	article	article	NOUN
dpc-3114	43	3	|	|	ADV
dpc-3114	43	4	dermatol	dermatol	ADJ
dpc-3114	43	5	pract	pract	NOUN
dpc-3114	43	6	concept	concept	NOUN
dpc-3114	43	7	.	.	PUNCT
dpc-3114	44	1	2023;13(4):e2023215	2023;13(4):e2023215	NUM
dpc-3114	44	2	3	3	NUM
dpc-3114	44	3	statistical	statistical	ADJ
dpc-3114	44	4	analysis	analysis	NOUN
dpc-3114	44	5	patient	patient	NOUN
dpc-3114	44	6	demographics	demographic	NOUN
dpc-3114	44	7	,	,	PUNCT
dpc-3114	44	8	clinical	clinical	ADJ
dpc-3114	44	9	characteristics	characteristic	NOUN
dpc-3114	44	10	,	,	PUNCT
dpc-3114	44	11	and	and	CCONJ
dpc-3114	44	12	primary	primary	ADJ
dpc-3114	44	13	outcome	outcome	NOUN
dpc-3114	44	14	measures	measure	NOUN
dpc-3114	44	15	at	at	ADP
dpc-3114	44	16	the	the	DET
dpc-3114	44	17	baseline	baseline	NOUN
dpc-3114	44	18	visit	visit	NOUN
dpc-3114	44	19	were	be	AUX
dpc-3114	44	20	summarized	summarize	VERB
dpc-3114	44	21	using	use	VERB
dpc-3114	44	22	descriptive	descriptive	ADJ
dpc-3114	44	23	statistics	statistic	NOUN
dpc-3114	44	24	.	.	PUNCT
dpc-3114	45	1	descriptive	descriptive	ADJ
dpc-3114	45	2	data	datum	NOUN
dpc-3114	45	3	were	be	AUX
dpc-3114	45	4	reported	report	VERB
dpc-3114	45	5	using	use	VERB
dpc-3114	45	6	frequencies	frequency	NOUN
dpc-3114	45	7	and	and	CCONJ
dpc-3114	45	8	percentage	percentage	NOUN
dpc-3114	45	9	for	for	ADP
dpc-3114	45	10	categorical	categorical	ADJ
dpc-3114	45	11	variables	variable	NOUN
dpc-3114	45	12	and	and	CCONJ
dpc-3114	45	13	mean	mean	VERB
dpc-3114	45	14	values	value	NOUN
dpc-3114	45	15	±	±	NOUN
dpc-3114	45	16	standard	standard	ADJ
dpc-3114	45	17	deviation	deviation	NOUN
dpc-3114	45	18	for	for	ADP
dpc-3114	45	19	continuous	continuous	ADJ
dpc-3114	45	20	ones	one	NOUN
dpc-3114	45	21	.	.	PUNCT
dpc-3114	46	1	the	the	DET
dpc-3114	46	2	wilcoxon	wilcoxon	ADJ
dpc-3114	46	3	matched	match	VERB
dpc-3114	46	4	pairs	pair	NOUN
dpc-3114	46	5	signed	sign	VERB
dpc-3114	46	6	rank	rank	NOUN
dpc-3114	46	7	test	test	NOUN
dpc-3114	46	8	was	be	AUX
dpc-3114	46	9	used	use	VERB
dpc-3114	46	10	for	for	ADP
dpc-3114	46	11	continuous	continuous	ADJ
dpc-3114	46	12	variables	variable	NOUN
dpc-3114	46	13	at	at	ADP
dpc-3114	46	14	different	different	ADJ
dpc-3114	46	15	scheduled	schedule	VERB
dpc-3114	46	16	visits	visit	NOUN
dpc-3114	46	17	.	.	PUNCT
dpc-3114	47	1	univariate	univariate	ADJ
dpc-3114	47	2	regression	regression	NOUN
dpc-3114	47	3	analysis	analysis	NOUN
dpc-3114	47	4	was	be	AUX
dpc-3114	47	5	conducted	conduct	VERB
dpc-3114	47	6	to	to	PART
dpc-3114	47	7	evaluate	evaluate	VERB
dpc-3114	47	8	the	the	DET
dpc-3114	47	9	relationship	relationship	NOUN
dpc-3114	47	10	between	between	ADP
dpc-3114	47	11	the	the	DET
dpc-3114	47	12	variables	variable	NOUN
dpc-3114	47	13	age	age	NOUN
dpc-3114	47	14	,	,	PUNCT
dpc-3114	47	15	obesity	obesity	NOUN
dpc-3114	47	16	,	,	PUNCT
dpc-3114	47	17	gender	gender	NOUN
dpc-3114	47	18	,	,	PUNCT
dpc-3114	47	19	previous	previous	ADJ
dpc-3114	47	20	use	use	NOUN
dpc-3114	47	21	of	of	ADP
dpc-3114	47	22	biological	biological	ADJ
dpc-3114	47	23	treatment	treatment	NOUN
dpc-3114	47	24	(	(	PUNCT
dpc-3114	47	25	anti	anti	ADJ
dpc-3114	47	26	-	-	ADJ
dpc-3114	47	27	tnfα	tnfα	ADJ
dpc-3114	47	28	,	,	PUNCT
dpc-3114	47	29	anti	anti	ADJ
dpc-3114	47	30	-	-	ADJ
dpc-3114	47	31	il17	il17	ADJ
dpc-3114	47	32	,	,	PUNCT
dpc-3114	47	33	anti	anti	ADJ
dpc-3114	47	34	-	-	NOUN
dpc-3114	47	35	il12/23	il12/23	NOUN
dpc-3114	47	36	)	)	PUNCT
dpc-3114	47	37	and	and	CCONJ
dpc-3114	47	38	tildrakizumab	tildrakizumab	VERB
dpc-3114	47	39	clinical	clinical	ADJ
dpc-3114	47	40	efficacy	efficacy	NOUN
dpc-3114	47	41	expressed	express	VERB
dpc-3114	47	42	in	in	ADP
dpc-3114	47	43	terms	term	NOUN
dpc-3114	47	44	of	of	ADP
dpc-3114	47	45	pasi	pasi	NOUN
dpc-3114	47	46	,	,	PUNCT
dpc-3114	47	47	bsa	bsa	PROPN
dpc-3114	47	48	and	and	CCONJ
dpc-3114	47	49	dlqi	dlqi	ADJ
dpc-3114	47	50	values	value	NOUN
dpc-3114	47	51	.	.	PUNCT
dpc-3114	48	1	a	a	DET
dpc-3114	48	2	p	p	NOUN
dpc-3114	48	3	value	value	NOUN
dpc-3114	48	4	less	less	ADJ
dpc-3114	48	5	than	than	ADP
dpc-3114	48	6	0.05	0.05	NUM
dpc-3114	48	7	was	be	AUX
dpc-3114	48	8	considered	consider	VERB
dpc-3114	48	9	statistically	statistically	ADV
dpc-3114	48	10	significant	significant	ADJ
dpc-3114	48	11	.	.	PUNCT
dpc-3114	49	1	statistical	statistical	ADJ
dpc-3114	49	2	analyses	analysis	NOUN
dpc-3114	49	3	were	be	AUX
dpc-3114	49	4	computed	compute	VERB
dpc-3114	49	5	using	use	VERB
dpc-3114	49	6	graphpad	graphpad	NOUN
dpc-3114	49	7	prism	prism	NOUN
dpc-3114	49	8	6.0	6.0	NUM
dpc-3114	49	9	(	(	PUNCT
dpc-3114	49	10	graphpad	graphpad	PROPN
dpc-3114	49	11	software	software	PROPN
dpc-3114	49	12	inc	inc	PROPN
dpc-3114	49	13	.	.	PROPN
dpc-3114	49	14	)	)	PUNCT
dpc-3114	49	15	and	and	CCONJ
dpc-3114	49	16	sas	sa	VERB
dpc-3114	49	17	®	®	NOUN
dpc-3114	49	18	software	software	NOUN
dpc-3114	49	19	version	version	NOUN
dpc-3114	49	20	9.3	9.3	NUM
dpc-3114	49	21	(	(	PUNCT
dpc-3114	49	22	sas	sas	PROPN
dpc-3114	49	23	institute	institute	PROPN
dpc-3114	49	24	inc	inc	PROPN
dpc-3114	49	25	.	.	PROPN
dpc-3114	49	26	)	)	PUNCT
dpc-3114	49	27	.	.	PUNCT
dpc-3114	50	1	results	result	VERB
dpc-3114	50	2	overall	overall	ADV
dpc-3114	50	3	,	,	PUNCT
dpc-3114	50	4	51	51	NUM
dpc-3114	50	5	patients	patient	NOUN
dpc-3114	50	6	were	be	AUX
dpc-3114	50	7	enrolled	enrol	VERB
dpc-3114	50	8	;	;	PUNCT
dpc-3114	50	9	most	most	ADJ
dpc-3114	50	10	were	be	AUX
dpc-3114	50	11	male	male	ADJ
dpc-3114	50	12	(	(	PUNCT
dpc-3114	50	13	76.5	76.5	NUM
dpc-3114	50	14	%	%	NOUN
dpc-3114	50	15	,	,	PUNCT
dpc-3114	50	16	39/51	39/51	NUM
dpc-3114	50	17	)	)	PUNCT
dpc-3114	50	18	with	with	ADP
dpc-3114	50	19	a	a	DET
dpc-3114	50	20	mean	mean	ADJ
dpc-3114	50	21	age	age	NOUN
dpc-3114	50	22	at	at	ADP
dpc-3114	50	23	the	the	DET
dpc-3114	50	24	time	time	NOUN
dpc-3114	50	25	of	of	ADP
dpc-3114	50	26	starting	start	VERB
dpc-3114	50	27	tildrakizumab	tildrakizumab	NOUN
dpc-3114	50	28	of	of	ADP
dpc-3114	50	29	52.3	52.3	NUM
dpc-3114	50	30	±	±	NUM
dpc-3114	50	31	14.7	14.7	NUM
dpc-3114	50	32	years	year	NOUN
dpc-3114	50	33	(	(	PUNCT
dpc-3114	50	34	table	table	NOUN
dpc-3114	50	35	1	1	NUM
dpc-3114	50	36	)	)	PUNCT
dpc-3114	50	37	.	.	PUNCT
dpc-3114	51	1	baseline	baseline	PROPN
dpc-3114	51	2	disease	disease	NOUN
dpc-3114	51	3	severity	severity	NOUN
dpc-3114	51	4	was	be	AUX
dpc-3114	51	5	moderate	moderate	ADJ
dpc-3114	51	6	to	to	PART
dpc-3114	51	7	severe	severe	VERB
dpc-3114	51	8	with	with	ADP
dpc-3114	51	9	a	a	DET
dpc-3114	51	10	mean	mean	ADJ
dpc-3114	51	11	pasi	pasi	NOUN
dpc-3114	51	12	score	score	NOUN
dpc-3114	51	13	of	of	ADP
dpc-3114	51	14	19.2	19.2	NUM
dpc-3114	51	15	±	±	NUM
dpc-3114	51	16	8.5	8.5	NUM
dpc-3114	51	17	,	,	PUNCT
dpc-3114	51	18	mean	mean	PROPN
dpc-3114	51	19	bsa	bsa	NOUN
dpc-3114	51	20	of	of	ADP
dpc-3114	51	21	16	16	NUM
dpc-3114	51	22	±	±	NUM
dpc-3114	51	23	10.4	10.4	NUM
dpc-3114	51	24	,	,	PUNCT
dpc-3114	51	25	and	and	CCONJ
dpc-3114	51	26	mean	mean	VERB
dpc-3114	51	27	dlqi	dlqi	NOUN
dpc-3114	51	28	of	of	ADP
dpc-3114	51	29	18.2	18.2	NUM
dpc-3114	51	30	±	±	NUM
dpc-3114	51	31	6.8	6.8	NUM
dpc-3114	51	32	.	.	PUNCT
dpc-3114	52	1	mean	mean	ADJ
dpc-3114	52	2	body	body	NOUN
dpc-3114	52	3	mass	mass	NOUN
dpc-3114	52	4	index	index	NOUN
dpc-3114	52	5	(	(	PUNCT
dpc-3114	52	6	bmi	bmi	PROPN
dpc-3114	52	7	)	)	PUNCT
dpc-3114	52	8	was	be	AUX
dpc-3114	52	9	29.8	29.8	NUM
dpc-3114	52	10	±	±	NUM
dpc-3114	52	11	11.9	11.9	NUM
dpc-3114	52	12	kg	kg	NOUN
dpc-3114	52	13	/	/	SYM
dpc-3114	52	14	m2	m2	PROPN
dpc-3114	52	15	,	,	PUNCT
dpc-3114	52	16	and	and	CCONJ
dpc-3114	52	17	27.5	27.5	NUM
dpc-3114	52	18	%	%	NOUN
dpc-3114	52	19	(	(	PUNCT
dpc-3114	52	20	14/51	14/51	NUM
dpc-3114	52	21	)	)	PUNCT
dpc-3114	52	22	of	of	ADP
dpc-3114	52	23	patients	patient	NOUN
dpc-3114	52	24	were	be	AUX
dpc-3114	52	25	obese	obese	ADJ
dpc-3114	52	26	(	(	PUNCT
dpc-3114	52	27	bmi	bmi	X
dpc-3114	52	28	≥	≥	NUM
dpc-3114	52	29	30	30	NUM
dpc-3114	52	30	)	)	PUNCT
dpc-3114	52	31	.	.	PUNCT
dpc-3114	53	1	comorbid	comorbid	NOUN
dpc-3114	53	2	conditions	condition	NOUN
dpc-3114	53	3	were	be	AUX
dpc-3114	53	4	reported	report	VERB
dpc-3114	53	5	in	in	ADP
dpc-3114	53	6	66.7	66.7	NUM
dpc-3114	53	7	%	%	NOUN
dpc-3114	53	8	(	(	PUNCT
dpc-3114	53	9	34/51	34/51	NUM
dpc-3114	53	10	)	)	PUNCT
dpc-3114	53	11	of	of	ADP
dpc-3114	53	12	patients	patient	NOUN
dpc-3114	53	13	.	.	PUNCT
dpc-3114	54	1	in	in	ADP
dpc-3114	54	2	particular	particular	ADJ
dpc-3114	54	3	,	,	PUNCT
dpc-3114	54	4	17.6	17.6	NUM
dpc-3114	54	5	%	%	NOUN
dpc-3114	54	6	(	(	PUNCT
dpc-3114	54	7	9/51	9/51	NUM
dpc-3114	54	8	)	)	PUNCT
dpc-3114	54	9	were	be	AUX
dpc-3114	54	10	affected	affect	VERB
dpc-3114	54	11	by	by	ADP
dpc-3114	54	12	psoriatic	psoriatic	ADJ
dpc-3114	54	13	arthritis	arthritis	NOUN
dpc-3114	54	14	(	(	PUNCT
dpc-3114	54	15	psa	psa	NOUN
dpc-3114	54	16	)	)	PUNCT
dpc-3114	54	17	with	with	ADP
dpc-3114	54	18	the	the	DET
dpc-3114	54	19	mean	mean	ADJ
dpc-3114	54	20	disease	disease	NOUN
dpc-3114	54	21	duration	duration	NOUN
dpc-3114	54	22	of	of	ADP
dpc-3114	54	23	10.4	10.4	NUM
dpc-3114	54	24	±	±	NUM
dpc-3114	54	25	9.7	9.7	NUM
dpc-3114	54	26	,	,	PUNCT
dpc-3114	54	27	the	the	DET
dpc-3114	54	28	baseline	baseline	NOUN
dpc-3114	54	29	disease	disease	NOUN
dpc-3114	54	30	severity	severity	NOUN
dpc-3114	54	31	was	be	AUX
dpc-3114	54	32	measured	measure	VERB
dpc-3114	54	33	as	as	ADP
dpc-3114	54	34	das	das	PROPN
dpc-3114	54	35	28	28	NUM
dpc-3114	54	36	of	of	ADP
dpc-3114	54	37	4.9	4.9	NUM
dpc-3114	54	38	±	±	NUM
dpc-3114	54	39	5.2	5.2	NUM
dpc-3114	54	40	;	;	PUNCT
dpc-3114	54	41	patients	patient	NOUN
dpc-3114	54	42	were	be	AUX
dpc-3114	54	43	not	not	PART
dpc-3114	54	44	doing	do	VERB
dpc-3114	54	45	other	other	ADJ
dpc-3114	54	46	arthritis	arthritis	NOUN
dpc-3114	54	47	therapies	therapy	NOUN
dpc-3114	54	48	other	other	ADJ
dpc-3114	54	49	than	than	ADP
dpc-3114	54	50	tildrakizumab	tildrakizumab	NOUN
dpc-3114	54	51	.	.	PUNCT
dpc-3114	55	1	hypertension	hypertension	NOUN
dpc-3114	55	2	and	and	CCONJ
dpc-3114	55	3	dyslipidemia	dyslipidemia	NOUN
dpc-3114	55	4	were	be	AUX
dpc-3114	55	5	among	among	ADP
dpc-3114	55	6	the	the	DET
dpc-3114	55	7	most	most	ADV
dpc-3114	55	8	frequent	frequent	ADJ
dpc-3114	55	9	comorbidities	comorbiditie	NOUN
dpc-3114	55	10	.	.	PUNCT
dpc-3114	56	1	regarding	regard	VERB
dpc-3114	56	2	previous	previous	ADJ
dpc-3114	56	3	systemic	systemic	ADJ
dpc-3114	56	4	therapy	therapy	NOUN
dpc-3114	56	5	,	,	PUNCT
dpc-3114	56	6	and	and	CCONJ
dpc-3114	56	7	in	in	ADP
dpc-3114	56	8	particular	particular	ADJ
dpc-3114	56	9	conventional	conventional	ADJ
dpc-3114	56	10	non	non	ADJ
dpc-3114	56	11	-	-	ADJ
dpc-3114	56	12	biologic	biologic	ADJ
dpc-3114	56	13	one	one	NUM
dpc-3114	56	14	,	,	PUNCT
dpc-3114	56	15	the	the	DET
dpc-3114	56	16	majority	majority	NOUN
dpc-3114	56	17	of	of	ADP
dpc-3114	56	18	patients	patient	NOUN
dpc-3114	56	19	were	be	AUX
dpc-3114	56	20	treated	treat	VERB
dpc-3114	56	21	with	with	ADP
dpc-3114	56	22	cyclosporine	cyclosporine	NOUN
dpc-3114	56	23	.	.	PUNCT
dpc-3114	57	1	obviously	obviously	ADV
dpc-3114	57	2	,	,	PUNCT
dpc-3114	57	3	all	all	DET
dpc-3114	57	4	patients	patient	NOUN
dpc-3114	57	5	have	have	AUX
dpc-3114	57	6	been	be	AUX
dpc-3114	57	7	administered	administer	VERB
dpc-3114	57	8	at	at	ADP
dpc-3114	57	9	least	least	ADJ
dpc-3114	57	10	1	1	NUM
dpc-3114	57	11	biologic	biologic	NOUN
dpc-3114	57	12	drug	drug	NOUN
dpc-3114	57	13	,	,	PUNCT
dpc-3114	57	14	since	since	SCONJ
dpc-3114	57	15	this	this	PRON
dpc-3114	57	16	represented	represent	VERB
dpc-3114	57	17	an	an	DET
dpc-3114	57	18	inclusion	inclusion	NOUN
dpc-3114	57	19	criterion	criterion	NOUN
dpc-3114	57	20	.	.	PUNCT
dpc-3114	58	1	furthermore	furthermore	ADV
dpc-3114	58	2	,	,	PUNCT
dpc-3114	58	3	54.9	54.9	NUM
dpc-3114	58	4	%	%	NOUN
dpc-3114	58	5	(	(	PUNCT
dpc-3114	58	6	28/51	28/51	NUM
dpc-3114	58	7	)	)	PUNCT
dpc-3114	58	8	of	of	ADP
dpc-3114	58	9	patients	patient	NOUN
dpc-3114	58	10	had	have	AUX
dpc-3114	58	11	already	already	ADV
dpc-3114	58	12	received	receive	VERB
dpc-3114	58	13	at	at	ADV
dpc-3114	58	14	least	least	ADJ
dpc-3114	58	15	2	2	NUM
dpc-3114	58	16	biologic	biologic	NOUN
dpc-3114	58	17	treatments	treatment	NOUN
dpc-3114	58	18	.	.	PUNCT
dpc-3114	59	1	the	the	DET
dpc-3114	59	2	most	most	ADV
dpc-3114	59	3	common	common	ADJ
dpc-3114	59	4	biologic	biologic	NOUN
dpc-3114	59	5	class	class	NOUN
dpc-3114	59	6	that	that	PRON
dpc-3114	59	7	patients	patient	NOUN
dpc-3114	59	8	had	have	AUX
dpc-3114	59	9	been	be	AUX
dpc-3114	59	10	exposed	expose	VERB
dpc-3114	59	11	previously	previously	ADV
dpc-3114	59	12	was	be	AUX
dpc-3114	59	13	anti	anti	ADJ
dpc-3114	59	14	-	-	ADJ
dpc-3114	59	15	tnf	tnf	ADJ
dpc-3114	59	16	with	with	ADP
dpc-3114	59	17	44/51	44/51	NUM
dpc-3114	59	18	(	(	PUNCT
dpc-3114	59	19	86.3	86.3	NUM
dpc-3114	59	20	%	%	NOUN
dpc-3114	59	21	)	)	PUNCT
dpc-3114	59	22	patients	patient	NOUN
dpc-3114	59	23	having	having	AUX
dpc-3114	59	24	received	receive	VERB
dpc-3114	59	25	it	it	PRON
dpc-3114	59	26	(	(	PUNCT
dpc-3114	59	27	table	table	NOUN
dpc-3114	59	28	1	1	NUM
dpc-3114	59	29	)	)	PUNCT
dpc-3114	59	30	.	.	PUNCT
dpc-3114	60	1	the	the	DET
dpc-3114	60	2	last	last	ADJ
dpc-3114	60	3	biological	biological	ADJ
dpc-3114	60	4	therapy	therapy	NOUN
dpc-3114	60	5	before	before	ADP
dpc-3114	60	6	starting	start	VERB
dpc-3114	60	7	tildrakizumab	tildrakizumab	NOUN
dpc-3114	60	8	was	be	AUX
dpc-3114	60	9	distributed	distribute	VERB
dpc-3114	60	10	as	as	SCONJ
dpc-3114	60	11	follows	follow	VERB
dpc-3114	60	12	:	:	PUNCT
dpc-3114	60	13	47	47	NUM
dpc-3114	60	14	%	%	NOUN
dpc-3114	60	15	of	of	ADP
dpc-3114	60	16	patients	patient	NOUN
dpc-3114	60	17	on	on	ADP
dpc-3114	60	18	anti	anti	ADJ
dpc-3114	60	19	-	-	ADJ
dpc-3114	60	20	tnf	tnf	ADJ
dpc-3114	60	21	(	(	PUNCT
dpc-3114	60	22	24/51	24/51	NUM
dpc-3114	60	23	)	)	PUNCT
dpc-3114	60	24	,	,	PUNCT
dpc-3114	60	25	31.4	31.4	NUM
dpc-3114	60	26	%	%	NOUN
dpc-3114	60	27	on	on	ADP
dpc-3114	60	28	anti	anti	ADJ
dpc-3114	60	29	-	-	ADJ
dpc-3114	60	30	il-17	il-17	ADJ
dpc-3114	60	31	(	(	PUNCT
dpc-3114	60	32	16/51	16/51	NUM
dpc-3114	60	33	)	)	PUNCT
dpc-3114	60	34	and	and	CCONJ
dpc-3114	60	35	21.6	21.6	NUM
dpc-3114	60	36	%	%	NOUN
dpc-3114	60	37	on	on	ADP
dpc-3114	60	38	anti	anti	ADJ
dpc-3114	60	39	-	-	ADJ
dpc-3114	60	40	il-12/23	il-12/23	ADJ
dpc-3114	60	41	(	(	PUNCT
dpc-3114	60	42	11/51	11/51	NUM
dpc-3114	60	43	)	)	PUNCT
dpc-3114	60	44	.	.	PUNCT
dpc-3114	61	1	treatment	treatment	NOUN
dpc-3114	61	2	withdrawal	withdrawal	NOUN
dpc-3114	61	3	was	be	AUX
dpc-3114	61	4	reported	report	VERB
dpc-3114	61	5	in	in	ADP
dpc-3114	61	6	5.8	5.8	NUM
dpc-3114	61	7	%	%	NOUN
dpc-3114	61	8	(	(	PUNCT
dpc-3114	61	9	3/51	3/51	NUM
dpc-3114	61	10	)	)	PUNCT
dpc-3114	61	11	of	of	ADP
dpc-3114	61	12	patients	patient	NOUN
dpc-3114	61	13	due	due	ADP
dpc-3114	61	14	to	to	ADP
dpc-3114	61	15	lack	lack	NOUN
dpc-3114	61	16	of	of	ADP
dpc-3114	61	17	efficacy	efficacy	NOUN
dpc-3114	61	18	(	(	PUNCT
dpc-3114	61	19	1/3	1/3	NUM
dpc-3114	61	20	patients	patient	NOUN
dpc-3114	61	21	at	at	ADP
dpc-3114	61	22	week	week	NOUN
dpc-3114	61	23	12	12	NUM
dpc-3114	61	24	)	)	PUNCT
dpc-3114	61	25	,	,	PUNCT
dpc-3114	61	26	loss	loss	NOUN
dpc-3114	61	27	of	of	ADP
dpc-3114	61	28	efficacy	efficacy	NOUN
dpc-3114	61	29	(	(	PUNCT
dpc-3114	61	30	1/6	1/6	NUM
dpc-3114	61	31	patients	patient	NOUN
dpc-3114	61	32	at	at	ADP
dpc-3114	61	33	week	week	NOUN
dpc-3114	61	34	48	48	NUM
dpc-3114	61	35	)	)	PUNCT
dpc-3114	61	36	and	and	CCONJ
dpc-3114	61	37	lost	lose	VERB
dpc-3114	61	38	to	to	PART
dpc-3114	61	39	follow	follow	VERB
dpc-3114	61	40	up	up	ADP
dpc-3114	61	41	(	(	PUNCT
dpc-3114	61	42	1/6	1/6	NUM
dpc-3114	61	43	patient	patient	NOUN
dpc-3114	61	44	at	at	ADP
dpc-3114	61	45	week	week	NOUN
dpc-3114	61	46	48	48	NUM
dpc-3114	61	47	)	)	PUNCT
dpc-3114	61	48	.	.	PUNCT
dpc-3114	62	1	patients	patient	NOUN
dpc-3114	62	2	withdrawing	withdraw	VERB
dpc-3114	62	3	from	from	ADP
dpc-3114	62	4	the	the	DET
dpc-3114	62	5	study	study	NOUN
dpc-3114	62	6	were	be	AUX
dpc-3114	62	7	defined	define	VERB
dpc-3114	62	8	as	as	ADP
dpc-3114	62	9	non	non	NOUN
dpc-3114	62	10	-	-	NOUN
dpc-3114	62	11	responders	responder	NOUN
dpc-3114	62	12	according	accord	VERB
dpc-3114	62	13	to	to	ADP
dpc-3114	62	14	the	the	DET
dpc-3114	62	15	non	non	ADJ
dpc-3114	62	16	-	-	ADJ
dpc-3114	62	17	responder	responder	ADJ
dpc-3114	62	18	imputation	imputation	NOUN
dpc-3114	62	19	method	method	NOUN
dpc-3114	62	20	.	.	PUNCT
dpc-3114	63	1	no	no	DET
dpc-3114	63	2	treatment	treatment	NOUN
dpc-3114	63	3	table	table	NOUN
dpc-3114	63	4	1	1	NUM
dpc-3114	63	5	.	.	X
dpc-3114	63	6	demographic	demographic	ADJ
dpc-3114	63	7	and	and	CCONJ
dpc-3114	63	8	baseline	baseline	ADJ
dpc-3114	63	9	characteristics	characteristic	NOUN
dpc-3114	63	10	of	of	ADP
dpc-3114	63	11	the	the	DET
dpc-3114	63	12	study	study	NOUN
dpc-3114	63	13	population	population	NOUN
dpc-3114	63	14	.	.	PUNCT
dpc-3114	64	1	characteristics	characteristic	NOUN
dpc-3114	64	2	all	all	DET
dpc-3114	64	3	patients	patient	NOUN
dpc-3114	64	4	(	(	PUNCT
dpc-3114	64	5	n	n	NOUN
dpc-3114	64	6	=	=	SYM
dpc-3114	64	7	51	51	NUM
dpc-3114	64	8	)	)	PUNCT
dpc-3114	65	1	[	[	X
dpc-3114	65	2	n	n	X
dpc-3114	65	3	(	(	PUNCT
dpc-3114	65	4	%	%	INTJ
dpc-3114	65	5	)	)	PUNCT
dpc-3114	65	6	or	or	CCONJ
dpc-3114	65	7	mean	mean	VERB
dpc-3114	65	8	±	±	NUM
dpc-3114	65	9	sd	sd	NOUN
dpc-3114	65	10	]	]	PUNCT
dpc-3114	65	11	demographics	demographic	NOUN
dpc-3114	65	12	male	male	NOUN
dpc-3114	65	13	39	39	NUM
dpc-3114	65	14	(	(	PUNCT
dpc-3114	65	15	76.5	76.5	NUM
dpc-3114	65	16	)	)	PUNCT
dpc-3114	65	17	age	age	NOUN
dpc-3114	65	18	(	(	PUNCT
dpc-3114	65	19	years	year	NOUN
dpc-3114	65	20	)	)	PUNCT
dpc-3114	65	21	52.3±	52.3±	ADP
dpc-3114	65	22	14.7	14.7	NUM
dpc-3114	65	23	weight	weight	NOUN
dpc-3114	65	24	(	(	PUNCT
dpc-3114	65	25	kg	kg	NOUN
dpc-3114	65	26	)	)	PUNCT
dpc-3114	65	27	82.6±	82.6±	NOUN
dpc-3114	65	28	16.9	16.9	NUM
dpc-3114	65	29	bmi	bmi	NOUN
dpc-3114	65	30	(	(	PUNCT
dpc-3114	65	31	kg	kg	NOUN
dpc-3114	65	32	/	/	SYM
dpc-3114	65	33	m2	m2	PROPN
dpc-3114	65	34	)	)	PUNCT
dpc-3114	65	35	29.8±	29.8±	NUM
dpc-3114	65	36	11.9	11.9	NUM
dpc-3114	65	37	bmi	bmi	NOUN
dpc-3114	65	38	>	>	X
dpc-3114	65	39	30	30	NUM
dpc-3114	65	40	14	14	NUM
dpc-3114	65	41	(	(	PUNCT
dpc-3114	65	42	27.5	27.5	NUM
dpc-3114	65	43	)	)	PUNCT
dpc-3114	65	44	difficult	difficult	ADJ
dpc-3114	65	45	-	-	PUNCT
dpc-3114	65	46	to	to	ADP
dpc-3114	65	47	-	-	PUNCT
dpc-3114	65	48	treat	treat	VERB
dpc-3114	65	49	locations	location	NOUN
dpc-3114	65	50	genital	genital	ADJ
dpc-3114	65	51	scalp	scalp	NOUN
dpc-3114	65	52	nails	nail	NOUN
dpc-3114	65	53	palmar	palmar	X
dpc-3114	65	54	/	/	SYM
dpc-3114	65	55	plantar	plantar	NOUN
dpc-3114	65	56	12	12	NUM
dpc-3114	65	57	(	(	PUNCT
dpc-3114	65	58	23.5	23.5	NUM
dpc-3114	65	59	)	)	PUNCT
dpc-3114	65	60	19	19	NUM
dpc-3114	65	61	(	(	PUNCT
dpc-3114	65	62	37.3	37.3	NUM
dpc-3114	65	63	)	)	PUNCT
dpc-3114	65	64	15	15	NUM
dpc-3114	65	65	(	(	PUNCT
dpc-3114	65	66	29.4	29.4	NUM
dpc-3114	65	67	)	)	SYM
dpc-3114	65	68	8	8	NUM
dpc-3114	65	69	(	(	PUNCT
dpc-3114	65	70	15.7	15.7	NUM
dpc-3114	65	71	)	)	PUNCT
dpc-3114	65	72	comorbidities	comorbiditie	NOUN
dpc-3114	65	73	yes	yes	INTJ
dpc-3114	65	74	34	34	NUM
dpc-3114	65	75	(	(	PUNCT
dpc-3114	65	76	66.7	66.7	NUM
dpc-3114	65	77	)	)	PUNCT
dpc-3114	65	78	diabetes	diabetes	NOUN
dpc-3114	65	79	mellitus	mellitus	NOUN
dpc-3114	65	80	8	8	NUM
dpc-3114	65	81	(	(	PUNCT
dpc-3114	65	82	15.7	15.7	NUM
dpc-3114	65	83	)	)	PUNCT
dpc-3114	65	84	dyslipidemia	dyslipidemia	VERB
dpc-3114	65	85	17	17	NUM
dpc-3114	65	86	(	(	PUNCT
dpc-3114	65	87	33.3	33.3	NUM
dpc-3114	65	88	)	)	PUNCT
dpc-3114	65	89	hypertension	hypertension	NOUN
dpc-3114	65	90	24	24	NUM
dpc-3114	65	91	(	(	PUNCT
dpc-3114	65	92	47.1	47.1	NUM
dpc-3114	65	93	)	)	PUNCT
dpc-3114	65	94	cardiopathy	cardiopathy	ADJ
dpc-3114	65	95	11	11	NUM
dpc-3114	65	96	(	(	PUNCT
dpc-3114	65	97	21.6	21.6	NUM
dpc-3114	65	98	)	)	PUNCT
dpc-3114	65	99	other	other	ADJ
dpc-3114	65	100	psoriatic	psoriatic	ADJ
dpc-3114	65	101	arthritis	arthritis	NOUN
dpc-3114	65	102	yes	yes	ADP
dpc-3114	65	103	9	9	NUM
dpc-3114	65	104	(	(	PUNCT
dpc-3114	65	105	17.6	17.6	NUM
dpc-3114	65	106	)	)	PUNCT
dpc-3114	65	107	age	age	NOUN
dpc-3114	65	108	of	of	ADP
dpc-3114	65	109	onset	onset	NOUN
dpc-3114	65	110	(	(	PUNCT
dpc-3114	65	111	years	year	NOUN
dpc-3114	65	112	)	)	PUNCT
dpc-3114	65	113	53.2±	53.2±	NOUN
dpc-3114	65	114	11.4	11.4	NUM
dpc-3114	65	115	duration	duration	NOUN
dpc-3114	65	116	of	of	ADP
dpc-3114	65	117	disease	disease	NOUN
dpc-3114	65	118	(	(	PUNCT
dpc-3114	65	119	years	year	NOUN
dpc-3114	65	120	)	)	PUNCT
dpc-3114	65	121	10.4±	10.4±	NOUN
dpc-3114	65	122	9.7	9.7	NUM
dpc-3114	65	123	psoriasis	psoriasis	NOUN
dpc-3114	65	124	age	age	NOUN
dpc-3114	65	125	of	of	ADP
dpc-3114	65	126	onset	onset	NOUN
dpc-3114	65	127	(	(	PUNCT
dpc-3114	65	128	years	year	NOUN
dpc-3114	65	129	)	)	PUNCT
dpc-3114	65	130	22.9±	22.9±	NOUN
dpc-3114	65	131	10.3	10.3	NUM
dpc-3114	65	132	duration	duration	NOUN
dpc-3114	65	133	of	of	ADP
dpc-3114	65	134	disease	disease	NOUN
dpc-3114	65	135	(	(	PUNCT
dpc-3114	65	136	years	year	NOUN
dpc-3114	65	137	)	)	PUNCT
dpc-3114	65	138	21.7±	21.7±	PROPN
dpc-3114	65	139	10.9	10.9	NUM
dpc-3114	65	140	pasi	pasi	NOUN
dpc-3114	65	141	19.2±	19.2±	NOUN
dpc-3114	65	142	8.5	8.5	NUM
dpc-3114	65	143	bsa	bsa	PROPN
dpc-3114	65	144	16±	16±	PROPN
dpc-3114	65	145	10.4	10.4	NUM
dpc-3114	65	146	dlqi	dlqi	VERB
dpc-3114	65	147	18.2±	18.2±	NUM
dpc-3114	65	148	6.8	6.8	NUM
dpc-3114	65	149	previous	previous	ADJ
dpc-3114	65	150	therapies	therapy	NOUN
dpc-3114	65	151	phototherapy	phototherapy	NOUN
dpc-3114	65	152	cyclosporine	cyclosporine	NOUN
dpc-3114	65	153	methotrexate	methotrexate	VERB
dpc-3114	65	154	acitretin	acitretin	PROPN
dpc-3114	65	155	anti	anti	PROPN
dpc-3114	65	156	-	-	ADJ
dpc-3114	65	157	tnf	tnf	ADJ
dpc-3114	65	158	anti	anti	ADJ
dpc-3114	65	159	-	-	ADJ
dpc-3114	65	160	il-17	il-17	PRON
dpc-3114	65	161	anti	anti	ADJ
dpc-3114	65	162	-	-	ADJ
dpc-3114	65	163	il-12/23	il-12/23	ADJ
dpc-3114	65	164	anti	anti	ADJ
dpc-3114	65	165	-	-	ADJ
dpc-3114	65	166	il23	il23	ADJ
dpc-3114	65	167	number	number	NOUN
dpc-3114	65	168	of	of	ADP
dpc-3114	65	169	prevoius	prevoius	ADJ
dpc-3114	65	170	biologic	biologic	NOUN
dpc-3114	65	171	therapies	therapy	NOUN
dpc-3114	65	172	1	1	NUM
dpc-3114	65	173	biologic	biologic	NOUN
dpc-3114	65	174	agent	agent	NOUN
dpc-3114	65	175	≥	≥	NOUN
dpc-3114	65	176	2	2	NUM
dpc-3114	65	177	biologic	biologic	NOUN
dpc-3114	65	178	agents	agent	NOUN
dpc-3114	65	179	28	28	NUM
dpc-3114	65	180	43	43	NUM
dpc-3114	65	181	19	19	NUM
dpc-3114	65	182	16	16	NUM
dpc-3114	65	183	44	44	NUM
dpc-3114	65	184	18	18	NUM
dpc-3114	65	185	11	11	NUM
dpc-3114	65	186	0	0	NUM
dpc-3114	65	187	23	23	NUM
dpc-3114	65	188	28	28	NUM
dpc-3114	65	189	bmi	bmi	NOUN
dpc-3114	65	190	=	=	PUNCT
dpc-3114	65	191	body	body	NOUN
dpc-3114	65	192	mass	mass	PROPN
dpc-3114	65	193	index	index	NOUN
dpc-3114	65	194	;	;	PUNCT
dpc-3114	65	195	bsa	bsa	PROPN
dpc-3114	65	196	=	=	PROPN
dpc-3114	65	197	body	body	PROPN
dpc-3114	65	198	surface	surface	NOUN
dpc-3114	65	199	area	area	NOUN
dpc-3114	65	200	;	;	PUNCT
dpc-3114	65	201	dlqi	dlqi	ADJ
dpc-3114	65	202	=	=	PUNCT
dpc-3114	65	203	dermatology	dermatology	NOUN
dpc-3114	65	204	quality	quality	NOUN
dpc-3114	65	205	of	of	ADP
dpc-3114	65	206	life	life	NOUN
dpc-3114	65	207	impairment	impairment	NOUN
dpc-3114	65	208	;	;	PUNCT
dpc-3114	65	209	pasi	pasi	NOUN
dpc-3114	65	210	=	=	SYM
dpc-3114	65	211	psoriasis	psoriasis	NOUN
dpc-3114	65	212	area	area	NOUN
dpc-3114	65	213	severity	severity	NOUN
dpc-3114	65	214	index	index	NOUN
dpc-3114	65	215	;	;	PUNCT
dpc-3114	65	216	sd	sd	NOUN
dpc-3114	65	217	=	=	SYM
dpc-3114	65	218	standard	standard	ADJ
dpc-3114	65	219	deviation	deviation	NOUN
dpc-3114	65	220	.	.	PUNCT
dpc-3114	66	1	withdrawal	withdrawal	NOUN
dpc-3114	66	2	was	be	AUX
dpc-3114	66	3	observed	observe	VERB
dpc-3114	66	4	to	to	ADP
dpc-3114	66	5	aes	aes	PROPN
dpc-3114	66	6	.	.	PUNCT
dpc-3114	67	1	aes	aes	PROPN
dpc-3114	67	2	that	that	PRON
dpc-3114	67	3	did	do	AUX
dpc-3114	67	4	not	not	PART
dpc-3114	67	5	require	require	VERB
dpc-3114	67	6	tildrakizumab	tildrakizumab	ADJ
dpc-3114	67	7	discontinuation	discontinuation	NOUN
dpc-3114	67	8	were	be	AUX
dpc-3114	67	9	reported	report	VERB
dpc-3114	67	10	in	in	ADP
dpc-3114	67	11	3.9	3.9	NUM
dpc-3114	67	12	%	%	NOUN
dpc-3114	67	13	(	(	PUNCT
dpc-3114	67	14	2/51	2/51	NUM
dpc-3114	67	15	)	)	PUNCT
dpc-3114	67	16	of	of	ADP
dpc-3114	67	17	patients	patient	NOUN
dpc-3114	67	18	and	and	CCONJ
dpc-3114	67	19	were	be	AUX
dpc-3114	67	20	represented	represent	VERB
dpc-3114	67	21	by	by	ADP
dpc-3114	67	22	injection	injection	NOUN
dpc-3114	67	23	-	-	PUNCT
dpc-3114	67	24	site	site	NOUN
dpc-3114	67	25	reactions	reaction	NOUN
dpc-3114	67	26	,	,	PUNCT
dpc-3114	67	27	4	4	NUM
dpc-3114	67	28	original	original	ADJ
dpc-3114	67	29	article	article	NOUN
dpc-3114	67	30	|	|	ADV
dpc-3114	67	31	dermatol	dermatol	ADJ
dpc-3114	67	32	pract	pract	NOUN
dpc-3114	67	33	concept	concept	NOUN
dpc-3114	67	34	.	.	PUNCT
dpc-3114	68	1	2023;13(4):e2023215	2023;13(4):e2023215	NUM
dpc-3114	68	2	one	one	NUM
dpc-3114	68	3	.	.	PUNCT
dpc-3114	69	1	at	at	ADP
dpc-3114	69	2	week	week	NOUN
dpc-3114	69	3	12	12	NUM
dpc-3114	69	4	,	,	PUNCT
dpc-3114	69	5	the	the	DET
dpc-3114	69	6	3	3	NUM
dpc-3114	69	7	groups	group	NOUN
dpc-3114	69	8	(	(	PUNCT
dpc-3114	69	9	previous	previous	ADJ
dpc-3114	69	10	anti	anti	ADJ
dpc-3114	69	11	-	-	NOUN
dpc-3114	69	12	tnfα	tnfα	ADJ
dpc-3114	69	13	,	,	PUNCT
dpc-3114	69	14	anti	anti	ADJ
dpc-3114	69	15	-	-	ADJ
dpc-3114	69	16	il17	il17	ADJ
dpc-3114	69	17	,	,	PUNCT
dpc-3114	69	18	anti	anti	ADJ
dpc-3114	69	19	-	-	NOUN
dpc-3114	69	20	il12/23	il12/23	NOUN
dpc-3114	69	21	)	)	PUNCT
dpc-3114	69	22	showed	show	VERB
dpc-3114	69	23	a	a	DET
dpc-3114	69	24	dramatic	dramatic	ADJ
dpc-3114	69	25	improvement	improvement	NOUN
dpc-3114	69	26	(	(	PUNCT
dpc-3114	69	27	p	p	X
dpc-3114	69	28	<	<	X
dpc-3114	69	29	0.001	0.001	NUM
dpc-3114	69	30	)	)	PUNCT
dpc-3114	69	31	.	.	PUNCT
dpc-3114	70	1	no	no	DET
dpc-3114	70	2	differences	difference	NOUN
dpc-3114	70	3	were	be	AUX
dpc-3114	70	4	found	find	VERB
dpc-3114	70	5	between	between	ADP
dpc-3114	70	6	groups	group	NOUN
dpc-3114	70	7	also	also	ADV
dpc-3114	70	8	at	at	ADP
dpc-3114	70	9	week	week	NOUN
dpc-3114	70	10	48	48	NUM
dpc-3114	70	11	.	.	PUNCT
dpc-3114	71	1	similarly	similarly	ADV
dpc-3114	71	2	,	,	PUNCT
dpc-3114	71	3	a	a	DET
dpc-3114	71	4	difference	difference	NOUN
dpc-3114	71	5	in	in	ADP
dpc-3114	71	6	bsa	bsa	PROPN
dpc-3114	71	7	score	score	NOUN
dpc-3114	71	8	was	be	AUX
dpc-3114	71	9	also	also	ADV
dpc-3114	71	10	detected	detect	VERB
dpc-3114	71	11	at	at	ADP
dpc-3114	71	12	baseline	baseline	NOUN
dpc-3114	71	13	with	with	ADP
dpc-3114	71	14	the	the	DET
dpc-3114	71	15	group	group	NOUN
dpc-3114	71	16	on	on	ADP
dpc-3114	71	17	anti	anti	NOUN
dpc-3114	71	18	-	-	ADJ
dpc-3114	71	19	il-17	il-17	ADV
dpc-3114	71	20	having	have	VERB
dpc-3114	71	21	a	a	DET
dpc-3114	71	22	greater	great	ADJ
dpc-3114	71	23	score	score	NOUN
dpc-3114	71	24	than	than	ADP
dpc-3114	71	25	the	the	DET
dpc-3114	71	26	anti	anti	ADJ
dpc-3114	71	27	-	-	ADJ
dpc-3114	71	28	il-12/23	il-12/23	ADJ
dpc-3114	71	29	group	group	NOUN
dpc-3114	71	30	(	(	PUNCT
dpc-3114	71	31	p	p	X
dpc-3114	71	32	<	<	X
dpc-3114	71	33	0.001	0.001	NUM
dpc-3114	71	34	)	)	PUNCT
dpc-3114	71	35	.	.	PUNCT
dpc-3114	72	1	at	at	ADP
dpc-3114	72	2	week	week	NOUN
dpc-3114	72	3	12	12	NUM
dpc-3114	72	4	,	,	PUNCT
dpc-3114	72	5	there	there	PRON
dpc-3114	72	6	was	be	VERB
dpc-3114	72	7	a	a	DET
dpc-3114	72	8	great	great	ADJ
dpc-3114	72	9	improvement	improvement	NOUN
dpc-3114	72	10	in	in	ADP
dpc-3114	72	11	bsa	bsa	PROPN
dpc-3114	72	12	score	score	VERB
dpc-3114	72	13	for	for	ADP
dpc-3114	72	14	all	all	DET
dpc-3114	72	15	groups	group	NOUN
dpc-3114	72	16	(	(	PUNCT
dpc-3114	72	17	p	p	X
dpc-3114	72	18	<	<	NOUN
dpc-3114	72	19	0.001	0.001	NUM
dpc-3114	72	20	)	)	PUNCT
dpc-3114	72	21	with	with	ADP
dpc-3114	72	22	further	further	ADJ
dpc-3114	72	23	increase	increase	NOUN
dpc-3114	72	24	at	at	ADP
dpc-3114	72	25	week	week	NOUN
dpc-3114	72	26	48	48	NUM
dpc-3114	72	27	.	.	PUNCT
dpc-3114	73	1	the	the	DET
dpc-3114	73	2	effectiveness	effectiveness	NOUN
dpc-3114	73	3	was	be	AUX
dpc-3114	73	4	confirmed	confirm	VERB
dpc-3114	73	5	also	also	ADV
dpc-3114	73	6	by	by	ADP
dpc-3114	73	7	dlqi	dlqi	ADJ
dpc-3114	73	8	assessment	assessment	NOUN
dpc-3114	73	9	,	,	PUNCT
dpc-3114	73	10	with	with	ADP
dpc-3114	73	11	a	a	DET
dpc-3114	73	12	significant	significant	ADJ
dpc-3114	73	13	decrease	decrease	NOUN
dpc-3114	73	14	at	at	ADP
dpc-3114	73	15	week	week	NOUN
dpc-3114	73	16	12	12	NUM
dpc-3114	73	17	and	and	CCONJ
dpc-3114	73	18	even	even	ADV
dpc-3114	73	19	more	more	ADV
dpc-3114	73	20	at	at	ADP
dpc-3114	73	21	week	week	NOUN
dpc-3114	73	22	48	48	NUM
dpc-3114	73	23	(	(	PUNCT
dpc-3114	73	24	p	p	X
dpc-3114	73	25	<	<	X
dpc-3114	73	26	0.001	0.001	NUM
dpc-3114	73	27	)	)	PUNCT
dpc-3114	73	28	.	.	PUNCT
dpc-3114	74	1	no	no	DET
dpc-3114	74	2	differences	difference	NOUN
dpc-3114	74	3	were	be	AUX
dpc-3114	74	4	found	find	VERB
dpc-3114	74	5	among	among	ADP
dpc-3114	74	6	the	the	DET
dpc-3114	74	7	3	3	NUM
dpc-3114	74	8	groups	group	NOUN
dpc-3114	74	9	at	at	ADP
dpc-3114	74	10	all	all	DET
dpc-3114	74	11	time	time	NOUN
dpc-3114	74	12	points	point	NOUN
dpc-3114	74	13	.	.	PUNCT
dpc-3114	75	1	conclusions	conclusion	NOUN
dpc-3114	75	2	tildrakizumab	tildrakizumab	NOUN
dpc-3114	75	3	has	have	AUX
dpc-3114	75	4	been	be	AUX
dpc-3114	75	5	shown	show	VERB
dpc-3114	75	6	to	to	PART
dpc-3114	75	7	be	be	AUX
dpc-3114	75	8	well	well	ADV
dpc-3114	75	9	-	-	PUNCT
dpc-3114	75	10	tolerated	tolerate	VERB
dpc-3114	75	11	and	and	CCONJ
dpc-3114	75	12	effective	effective	ADJ
dpc-3114	75	13	in	in	ADP
dpc-3114	75	14	treating	treat	VERB
dpc-3114	75	15	patients	patient	NOUN
dpc-3114	75	16	with	with	ADP
dpc-3114	75	17	plaque	plaque	NOUN
dpc-3114	75	18	psoriasis	psoriasis	NOUN
dpc-3114	75	19	in	in	ADP
dpc-3114	75	20	multiple	multiple	ADJ
dpc-3114	75	21	clinical	clinical	ADJ
dpc-3114	75	22	trials	trial	NOUN
dpc-3114	75	23	,	,	PUNCT
dpc-3114	75	24	but	but	CCONJ
dpc-3114	75	25	a	a	DET
dpc-3114	75	26	limited	limited	ADJ
dpc-3114	75	27	number	number	NOUN
dpc-3114	75	28	of	of	ADP
dpc-3114	75	29	real	real	ADJ
dpc-3114	75	30	-	-	PUNCT
dpc-3114	75	31	world	world	NOUN
dpc-3114	75	32	studies	study	NOUN
dpc-3114	75	33	describing	describe	VERB
dpc-3114	75	34	its	its	PRON
dpc-3114	75	35	safety	safety	NOUN
dpc-3114	75	36	and	and	CCONJ
dpc-3114	75	37	effectiveness	effectiveness	NOUN
dpc-3114	75	38	have	have	AUX
dpc-3114	75	39	been	be	AUX
dpc-3114	75	40	published	publish	VERB
dpc-3114	75	41	[	[	PUNCT
dpc-3114	75	42	5	5	NUM
dpc-3114	75	43	-	-	SYM
dpc-3114	75	44	10	10	NUM
dpc-3114	75	45	]	]	PUNCT
dpc-3114	75	46	.	.	PUNCT
dpc-3114	76	1	our	our	PRON
dpc-3114	76	2	study	study	NOUN
dpc-3114	76	3	confirmed	confirm	VERB
dpc-3114	76	4	the	the	DET
dpc-3114	76	5	elevated	elevated	ADJ
dpc-3114	76	6	effectiveness	effectiveness	NOUN
dpc-3114	76	7	of	of	ADP
dpc-3114	76	8	tildrakizumab	tildrakizumab	NOUN
dpc-3114	76	9	in	in	ADP
dpc-3114	76	10	treating	treat	VERB
dpc-3114	76	11	moderate	moderate	ADJ
dpc-3114	76	12	-	-	PUNCT
dpc-3114	76	13	to	to	ADP
dpc-3114	76	14	-	-	PUNCT
dpc-3114	76	15	severe	severe	ADJ
dpc-3114	76	16	plaque	plaque	NOUN
dpc-3114	76	17	psoriasis	psoriasis	NOUN
dpc-3114	76	18	,	,	PUNCT
dpc-3114	76	19	as	as	SCONJ
dpc-3114	76	20	demonstrated	demonstrate	VERB
dpc-3114	76	21	by	by	ADP
dpc-3114	76	22	the	the	DET
dpc-3114	76	23	reduction	reduction	NOUN
dpc-3114	76	24	of	of	ADP
dpc-3114	76	25	pasi	pasi	NOUN
dpc-3114	76	26	,	,	PUNCT
dpc-3114	76	27	in	in	ADP
dpc-3114	76	28	terms	term	NOUN
dpc-3114	76	29	headache	headache	NOUN
dpc-3114	76	30	and	and	CCONJ
dpc-3114	76	31	nausea	nausea	NOUN
dpc-3114	76	32	/	/	SYM
dpc-3114	76	33	fatigue	fatigue	NOUN
dpc-3114	76	34	the	the	DET
dpc-3114	76	35	day	day	NOUN
dpc-3114	76	36	after	after	ADP
dpc-3114	76	37	injection	injection	NOUN
dpc-3114	76	38	.	.	PUNCT
dpc-3114	77	1	a	a	DET
dpc-3114	77	2	significant	significant	ADJ
dpc-3114	77	3	reduction	reduction	NOUN
dpc-3114	77	4	in	in	ADP
dpc-3114	77	5	the	the	DET
dpc-3114	77	6	mean	mean	ADJ
dpc-3114	77	7	baseline	baseline	NOUN
dpc-3114	77	8	pasi	pasi	PROPN
dpc-3114	77	9	score	score	NOUN
dpc-3114	77	10	(	(	PUNCT
dpc-3114	77	11	19.2	19.2	NUM
dpc-3114	77	12	±	±	NUM
dpc-3114	77	13	8.5	8.5	NUM
dpc-3114	77	14	)	)	PUNCT
dpc-3114	77	15	was	be	AUX
dpc-3114	77	16	detected	detect	VERB
dpc-3114	77	17	at	at	ADP
dpc-3114	77	18	12	12	NUM
dpc-3114	77	19	weeks	week	NOUN
dpc-3114	77	20	of	of	ADP
dpc-3114	77	21	tildrakizumab	tildrakizumab	NOUN
dpc-3114	77	22	therapy	therapy	NOUN
dpc-3114	77	23	(	(	PUNCT
dpc-3114	77	24	3.5	3.5	NUM
dpc-3114	77	25	±	±	NUM
dpc-3114	77	26	2.7	2.7	NUM
dpc-3114	77	27	,	,	PUNCT
dpc-3114	77	28	p	p	X
dpc-3114	77	29	<	<	X
dpc-3114	77	30	0.001	0.001	NUM
dpc-3114	77	31	)	)	PUNCT
dpc-3114	77	32	,	,	PUNCT
dpc-3114	77	33	with	with	ADP
dpc-3114	77	34	a	a	DET
dpc-3114	77	35	further	further	ADJ
dpc-3114	77	36	improvement	improvement	NOUN
dpc-3114	77	37	at	at	ADP
dpc-3114	77	38	week	week	NOUN
dpc-3114	77	39	48	48	NUM
dpc-3114	77	40	(	(	PUNCT
dpc-3114	77	41	0.6	0.6	NUM
dpc-3114	77	42	±	±	NUM
dpc-3114	77	43	1.5	1.5	NUM
dpc-3114	77	44	,	,	PUNCT
dpc-3114	77	45	p	p	X
dpc-3114	77	46	<	<	X
dpc-3114	77	47	0.001	0.001	NUM
dpc-3114	77	48	)	)	PUNCT
dpc-3114	77	49	.	.	PUNCT
dpc-3114	78	1	the	the	DET
dpc-3114	78	2	pasi	pasi	PROPN
dpc-3114	78	3	score	score	NOUN
dpc-3114	78	4	reduction	reduction	NOUN
dpc-3114	78	5	was	be	AUX
dpc-3114	78	6	associated	associate	VERB
dpc-3114	78	7	with	with	ADP
dpc-3114	78	8	significant	significant	ADJ
dpc-3114	78	9	decrease	decrease	NOUN
dpc-3114	78	10	in	in	ADP
dpc-3114	78	11	both	both	DET
dpc-3114	78	12	baseline	baseline	PROPN
dpc-3114	78	13	bsa	bsa	PROPN
dpc-3114	78	14	and	and	CCONJ
dpc-3114	78	15	dlqi	dlqi	ADJ
dpc-3114	78	16	scores	score	NOUN
dpc-3114	78	17	(	(	PUNCT
dpc-3114	78	18	figure	figure	NOUN
dpc-3114	78	19	1	1	NUM
dpc-3114	78	20	)	)	PUNCT
dpc-3114	78	21	.	.	PUNCT
dpc-3114	79	1	absolute	absolute	ADJ
dpc-3114	79	2	pasi	pasi	NOUN
dpc-3114	79	3	scores	score	NOUN
dpc-3114	79	4	of	of	ADP
dpc-3114	79	5	≤	≤	NUM
dpc-3114	79	6	2	2	NUM
dpc-3114	79	7	and	and	CCONJ
dpc-3114	79	8	≤	≤	NUM
dpc-3114	79	9	5	5	NUM
dpc-3114	79	10	were	be	AUX
dpc-3114	79	11	achieved	achieve	VERB
dpc-3114	79	12	by	by	ADP
dpc-3114	79	13	43	43	NUM
dpc-3114	79	14	%	%	NOUN
dpc-3114	79	15	and	and	CCONJ
dpc-3114	79	16	90	90	NUM
dpc-3114	79	17	%	%	NOUN
dpc-3114	79	18	of	of	ADP
dpc-3114	79	19	patients	patient	NOUN
dpc-3114	79	20	at	at	ADP
dpc-3114	79	21	week	week	NOUN
dpc-3114	79	22	12	12	NUM
dpc-3114	79	23	,	,	PUNCT
dpc-3114	79	24	respectively	respectively	ADV
dpc-3114	79	25	.	.	PUNCT
dpc-3114	80	1	a	a	DET
dpc-3114	80	2	progressively	progressively	ADV
dpc-3114	80	3	higher	high	ADJ
dpc-3114	80	4	proportion	proportion	NOUN
dpc-3114	80	5	of	of	ADP
dpc-3114	80	6	patients	patient	NOUN
dpc-3114	80	7	achieved	achieve	VERB
dpc-3114	80	8	absolute	absolute	ADJ
dpc-3114	80	9	pasi	pasi	NOUN
dpc-3114	80	10	scores	score	NOUN
dpc-3114	80	11	at	at	ADP
dpc-3114	80	12	weeks	week	NOUN
dpc-3114	80	13	48	48	NUM
dpc-3114	80	14	.	.	PUNCT
dpc-3114	81	1	data	datum	NOUN
dpc-3114	81	2	were	be	AUX
dpc-3114	81	3	analyzed	analyze	VERB
dpc-3114	81	4	according	accord	VERB
dpc-3114	81	5	to	to	ADP
dpc-3114	81	6	the	the	DET
dpc-3114	81	7	non	non	ADJ
dpc-3114	81	8	-	-	ADJ
dpc-3114	81	9	responder	responder	ADJ
dpc-3114	81	10	imputation	imputation	NOUN
dpc-3114	81	11	analysis	analysis	NOUN
dpc-3114	81	12	and	and	CCONJ
dpc-3114	81	13	are	be	AUX
dpc-3114	81	14	shown	show	VERB
dpc-3114	81	15	in	in	ADP
dpc-3114	81	16	table	table	NOUN
dpc-3114	81	17	2	2	NUM
dpc-3114	81	18	.	.	PUNCT
dpc-3114	81	19	clinical	clinical	ADJ
dpc-3114	81	20	amelioration	amelioration	NOUN
dpc-3114	81	21	was	be	AUX
dpc-3114	81	22	also	also	ADV
dpc-3114	81	23	confirmed	confirm	VERB
dpc-3114	81	24	by	by	ADP
dpc-3114	81	25	the	the	DET
dpc-3114	81	26	high	high	ADJ
dpc-3114	81	27	percentage	percentage	NOUN
dpc-3114	81	28	of	of	ADP
dpc-3114	81	29	patients	patient	NOUN
dpc-3114	81	30	(	(	PUNCT
dpc-3114	81	31	67	67	NUM
dpc-3114	81	32	%	%	NOUN
dpc-3114	81	33	,	,	PUNCT
dpc-3114	81	34	30	30	NUM
dpc-3114	81	35	%	%	NOUN
dpc-3114	81	36	and	and	CCONJ
dpc-3114	81	37	22	22	NUM
dpc-3114	81	38	%	%	NOUN
dpc-3114	81	39	)	)	PUNCT
dpc-3114	81	40	achieving	achieve	VERB
dpc-3114	81	41	pasi	pasi	NOUN
dpc-3114	81	42	score	score	NOUN
dpc-3114	81	43	improvement	improvement	NOUN
dpc-3114	81	44	(	(	PUNCT
dpc-3114	81	45	pasi	pasi	NOUN
dpc-3114	81	46	≥	≥	NUM
dpc-3114	81	47	75	75	NUM
dpc-3114	81	48	,	,	PUNCT
dpc-3114	81	49	pasi	pasi	NOUN
dpc-3114	81	50	≥	≥	NUM
dpc-3114	81	51	90	90	NUM
dpc-3114	81	52	,	,	PUNCT
dpc-3114	81	53	and	and	CCONJ
dpc-3114	81	54	pasi	pasi	NOUN
dpc-3114	81	55	100	100	NUM
dpc-3114	81	56	)	)	PUNCT
dpc-3114	81	57	at	at	ADP
dpc-3114	81	58	week	week	NOUN
dpc-3114	81	59	12	12	NUM
dpc-3114	81	60	.	.	PUNCT
dpc-3114	82	1	an	an	DET
dpc-3114	82	2	increase	increase	NOUN
dpc-3114	82	3	result	result	NOUN
dpc-3114	82	4	over	over	ADP
dpc-3114	82	5	time	time	NOUN
dpc-3114	82	6	up	up	ADP
dpc-3114	82	7	to	to	ADP
dpc-3114	82	8	week	week	NOUN
dpc-3114	82	9	48	48	NUM
dpc-3114	82	10	was	be	AUX
dpc-3114	82	11	observed	observe	VERB
dpc-3114	82	12	.	.	PUNCT
dpc-3114	83	1	detailed	detailed	ADJ
dpc-3114	83	2	data	datum	NOUN
dpc-3114	83	3	analyzed	analyze	VERB
dpc-3114	83	4	according	accord	VERB
dpc-3114	83	5	to	to	ADP
dpc-3114	83	6	the	the	DET
dpc-3114	83	7	non	non	ADJ
dpc-3114	83	8	-	-	ADJ
dpc-3114	83	9	responder	responder	ADJ
dpc-3114	83	10	imputation	imputation	NOUN
dpc-3114	83	11	analysis	analysis	NOUN
dpc-3114	83	12	are	be	AUX
dpc-3114	83	13	summarized	summarize	VERB
dpc-3114	83	14	in	in	ADP
dpc-3114	83	15	table	table	NOUN
dpc-3114	83	16	3	3	NUM
dpc-3114	83	17	.	.	PUNCT
dpc-3114	84	1	the	the	DET
dpc-3114	84	2	evolution	evolution	NOUN
dpc-3114	84	3	of	of	ADP
dpc-3114	84	4	clinical	clinical	ADJ
dpc-3114	84	5	parameters	parameter	NOUN
dpc-3114	84	6	during	during	ADP
dpc-3114	84	7	treatment	treatment	NOUN
dpc-3114	84	8	with	with	ADP
dpc-3114	84	9	tildrakizumab	tildrakizumab	NOUN
dpc-3114	84	10	in	in	ADP
dpc-3114	84	11	patients	patient	NOUN
dpc-3114	84	12	whose	whose	DET
dpc-3114	84	13	last	last	ADJ
dpc-3114	84	14	treatment	treatment	NOUN
dpc-3114	84	15	was	be	AUX
dpc-3114	84	16	anti	anti	ADJ
dpc-3114	84	17	-	-	ADJ
dpc-3114	84	18	tnfα	tnfα	ADJ
dpc-3114	84	19	,	,	PUNCT
dpc-3114	84	20	anti	anti	ADJ
dpc-3114	84	21	-	-	ADJ
dpc-3114	84	22	il-17	il-17	ADV
dpc-3114	84	23	and/or	and/or	CCONJ
dpc-3114	84	24	anti	anti	ADJ
dpc-3114	84	25	-	-	ADJ
dpc-3114	84	26	il-12/23	il-12/23	ADJ
dpc-3114	84	27	are	be	AUX
dpc-3114	84	28	shown	show	VERB
dpc-3114	84	29	in	in	ADP
dpc-3114	84	30	figure	figure	NOUN
dpc-3114	84	31	2	2	NUM
dpc-3114	84	32	.	.	PUNCT
dpc-3114	84	33	a	a	DET
dpc-3114	84	34	significant	significant	ADJ
dpc-3114	84	35	difference	difference	NOUN
dpc-3114	84	36	in	in	ADP
dpc-3114	84	37	pasi	pasi	NOUN
dpc-3114	84	38	baseline	baseline	PROPN
dpc-3114	84	39	values	value	NOUN
dpc-3114	84	40	was	be	AUX
dpc-3114	84	41	detected	detect	VERB
dpc-3114	84	42	in	in	ADP
dpc-3114	84	43	the	the	DET
dpc-3114	84	44	anti	anti	ADJ
dpc-3114	84	45	-	-	ADJ
dpc-3114	84	46	il-12/23	il-12/23	ADJ
dpc-3114	84	47	group	group	NOUN
dpc-3114	84	48	respect	respect	NOUN
dpc-3114	84	49	to	to	ADP
dpc-3114	84	50	anti	anti	ADJ
dpc-3114	84	51	-	-	ADJ
dpc-3114	84	52	il17	il17	ADJ
dpc-3114	84	53	figure	figure	NOUN
dpc-3114	84	54	1	1	NUM
dpc-3114	84	55	.	.	PUNCT
dpc-3114	85	1	mean	mean	VERB
dpc-3114	85	2	psoriasis	psoriasis	NOUN
dpc-3114	85	3	area	area	NOUN
dpc-3114	85	4	severity	severity	NOUN
dpc-3114	85	5	index	index	NOUN
dpc-3114	85	6	(	(	PUNCT
dpc-3114	85	7	pasi	pasi	NOUN
dpc-3114	85	8	)	)	PUNCT
dpc-3114	85	9	,	,	PUNCT
dpc-3114	85	10	body	body	NOUN
dpc-3114	85	11	surface	surface	NOUN
dpc-3114	85	12	area	area	NOUN
dpc-3114	85	13	(	(	PUNCT
dpc-3114	85	14	bsa	bsa	PROPN
dpc-3114	85	15	)	)	PUNCT
dpc-3114	85	16	,	,	PUNCT
dpc-3114	85	17	and	and	CCONJ
dpc-3114	85	18	dermatology	dermatology	NOUN
dpc-3114	85	19	life	life	NOUN
dpc-3114	85	20	quality	quality	NOUN
dpc-3114	85	21	index	index	NOUN
dpc-3114	85	22	(	(	PUNCT
dpc-3114	85	23	dlqi	dlqi	ADJ
dpc-3114	85	24	)	)	PUNCT
dpc-3114	85	25	score	score	NOUN
dpc-3114	85	26	values	value	NOUN
dpc-3114	85	27	.	.	PUNCT
dpc-3114	86	1	table	table	NOUN
dpc-3114	86	2	2	2	NUM
dpc-3114	86	3	.	.	PUNCT
dpc-3114	87	1	patients	patient	NOUN
dpc-3114	87	2	achieving	achieve	VERB
dpc-3114	87	3	residual	residual	ADJ
dpc-3114	87	4	absolute	absolute	ADJ
dpc-3114	87	5	psoriasis	psoriasis	NOUN
dpc-3114	87	6	area	area	NOUN
dpc-3114	87	7	severity	severity	NOUN
dpc-3114	87	8	index	index	NOUN
dpc-3114	87	9	scores	score	NOUN
dpc-3114	87	10	of	of	ADP
dpc-3114	87	11	≤	≤	ADJ
dpc-3114	87	12	2	2	NUM
dpc-3114	87	13	,	,	PUNCT
dpc-3114	87	14	≤	≤	NUM
dpc-3114	87	15	5	5	NUM
dpc-3114	87	16	and	and	CCONJ
dpc-3114	87	17	>	>	X
dpc-3114	87	18	 	 	SPACE
dpc-3114	87	19	5	5	NUM
dpc-3114	87	20	 	 	SPACE
dpc-3114	87	21	after	after	ADP
dpc-3114	87	22	12	12	NUM
dpc-3114	87	23	and	and	CCONJ
dpc-3114	87	24	48	48	NUM
dpc-3114	87	25	weeks	week	NOUN
dpc-3114	87	26	of	of	ADP
dpc-3114	87	27	tildrakizumab	tildrakizumab	NOUN
dpc-3114	87	28	therapy	therapy	NOUN
dpc-3114	87	29	.	.	PUNCT
dpc-3114	88	1	non	non	ADJ
dpc-3114	88	2	-	-	ADJ
dpc-3114	88	3	responder	responder	ADJ
dpc-3114	88	4	imputation	imputation	NOUN
dpc-3114	88	5	analysis	analysis	NOUN
dpc-3114	88	6	.	.	PUNCT
dpc-3114	89	1	week	week	NOUN
dpc-3114	89	2	total	total	ADJ
dpc-3114	89	3	patients	patient	NOUN
dpc-3114	89	4	(	(	PUNCT
dpc-3114	89	5	n	n	CCONJ
dpc-3114	89	6	)	)	PUNCT
dpc-3114	89	7	ongoing	ongoing	ADJ
dpc-3114	89	8	patients	patient	NOUN
dpc-3114	89	9	(	(	PUNCT
dpc-3114	89	10	n	n	CCONJ
dpc-3114	89	11	)	)	PUNCT
dpc-3114	89	12	withdrawals	withdrawal	NOUN
dpc-3114	89	13	(	(	PUNCT
dpc-3114	89	14	n	n	CCONJ
dpc-3114	89	15	)	)	PUNCT
dpc-3114	89	16	pasi	pasi	NOUN
dpc-3114	89	17	,	,	PUNCT
dpc-3114	89	18	n	n	PROPN
dpc-3114	89	19	(	(	PUNCT
dpc-3114	89	20	%	%	INTJ
dpc-3114	89	21	)	)	PUNCT
dpc-3114	89	22	≤2	≤2	PUNCT
dpc-3114	89	23	≤5	≤5	VERB
dpc-3114	89	24	>	>	X
dpc-3114	89	25	5	5	NUM
dpc-3114	89	26	12	12	NUM
dpc-3114	89	27	51	51	NUM
dpc-3114	89	28	50	50	NUM
dpc-3114	89	29	1	1	NUM
dpc-3114	89	30	22	22	NUM
dpc-3114	89	31	(	(	PUNCT
dpc-3114	89	32	43	43	NUM
dpc-3114	89	33	)	)	PUNCT
dpc-3114	89	34	46	46	NUM
dpc-3114	89	35	(	(	PUNCT
dpc-3114	89	36	90	90	NUM
dpc-3114	89	37	)	)	SYM
dpc-3114	89	38	5	5	NUM
dpc-3114	89	39	(	(	PUNCT
dpc-3114	89	40	10	10	NUM
dpc-3114	89	41	)	)	PUNCT
dpc-3114	89	42	48	48	NUM
dpc-3114	89	43	51	51	NUM
dpc-3114	89	44	48	48	NUM
dpc-3114	89	45	2	2	NUM
dpc-3114	89	46	46	46	NUM
dpc-3114	89	47	(	(	PUNCT
dpc-3114	89	48	90	90	NUM
dpc-3114	89	49	)	)	PUNCT
dpc-3114	89	50	48	48	NUM
dpc-3114	89	51	(	(	PUNCT
dpc-3114	89	52	94	94	NUM
dpc-3114	89	53	)	)	PUNCT
dpc-3114	89	54	3	3	NUM
dpc-3114	89	55	(	(	PUNCT
dpc-3114	89	56	6	6	NUM
dpc-3114	89	57	)	)	PUNCT
dpc-3114	89	58	pasi	pasi	NOUN
dpc-3114	89	59	=	=	SYM
dpc-3114	89	60	psoriasis	psoriasis	NOUN
dpc-3114	89	61	area	area	NOUN
dpc-3114	89	62	severity	severity	PROPN
dpc-3114	89	63	index	index	NOUN
dpc-3114	89	64	.	.	PUNCT
dpc-3114	90	1	table	table	NOUN
dpc-3114	90	2	3	3	NUM
dpc-3114	90	3	.	.	PUNCT
dpc-3114	91	1	patients	patient	NOUN
dpc-3114	91	2	achieving	achieve	VERB
dpc-3114	91	3	pasi	pasi	NOUN
dpc-3114	91	4	<	<	X
dpc-3114	91	5	75	75	NUM
dpc-3114	91	6	,	,	PUNCT
dpc-3114	91	7	pasi	pasi	NOUN
dpc-3114	91	8	≥	≥	PRON
dpc-3114	91	9	75	75	NUM
dpc-3114	91	10	,	,	PUNCT
dpc-3114	91	11	pasi	pasi	NOUN
dpc-3114	91	12	≥	≥	NUM
dpc-3114	91	13	90	90	NUM
dpc-3114	91	14	and	and	CCONJ
dpc-3114	91	15	pasi	pasi	VERB
dpc-3114	91	16	100	100	NUM
dpc-3114	91	17	response	response	NOUN
dpc-3114	91	18	rates	rate	NOUN
dpc-3114	91	19	at	at	ADP
dpc-3114	91	20	12	12	NUM
dpc-3114	91	21	and	and	CCONJ
dpc-3114	91	22	48	48	NUM
dpc-3114	91	23	weeks	week	NOUN
dpc-3114	91	24	of	of	ADP
dpc-3114	91	25	treatment	treatment	NOUN
dpc-3114	91	26	with	with	ADP
dpc-3114	91	27	tildrakizumab	tildrakizumab	NOUN
dpc-3114	91	28	.	.	PUNCT
dpc-3114	92	1	non	non	ADJ
dpc-3114	92	2	-	-	ADJ
dpc-3114	92	3	responder	responder	ADJ
dpc-3114	92	4	imputation	imputation	NOUN
dpc-3114	92	5	analysis	analysis	NOUN
dpc-3114	92	6	.	.	PUNCT
dpc-3114	93	1	week	week	NOUN
dpc-3114	93	2	total	total	ADJ
dpc-3114	93	3	patients	patient	NOUN
dpc-3114	93	4	(	(	PUNCT
dpc-3114	93	5	n	n	CCONJ
dpc-3114	93	6	ongoing	ongoing	ADJ
dpc-3114	93	7	patients	patient	NOUN
dpc-3114	93	8	(	(	PUNCT
dpc-3114	93	9	n	n	CCONJ
dpc-3114	93	10	)	)	PUNCT
dpc-3114	93	11	withdrawals	withdrawal	NOUN
dpc-3114	93	12	(	(	PUNCT
dpc-3114	93	13	n	n	CCONJ
dpc-3114	93	14	)	)	PUNCT
dpc-3114	93	15	pasi	pasi	NOUN
dpc-3114	93	16	,	,	PUNCT
dpc-3114	93	17	n	n	PROPN
dpc-3114	93	18	(	(	PUNCT
dpc-3114	93	19	%	%	INTJ
dpc-3114	93	20	)	)	PUNCT
dpc-3114	94	1	<	<	X
dpc-3114	94	2	75	75	NUM
dpc-3114	94	3	≥75	≥75	PROPN
dpc-3114	94	4	≥90	≥90	PROPN
dpc-3114	94	5	100	100	NUM
dpc-3114	94	6	12	12	NUM
dpc-3114	94	7	51	51	NUM
dpc-3114	94	8	50	50	NUM
dpc-3114	94	9	1	1	NUM
dpc-3114	94	10	17	17	NUM
dpc-3114	94	11	(	(	PUNCT
dpc-3114	94	12	33	33	NUM
dpc-3114	94	13	)	)	PUNCT
dpc-3114	94	14	34	34	NUM
dpc-3114	94	15	(	(	PUNCT
dpc-3114	94	16	67	67	NUM
dpc-3114	94	17	)	)	SYM
dpc-3114	94	18	15	15	NUM
dpc-3114	94	19	(	(	PUNCT
dpc-3114	94	20	30	30	NUM
dpc-3114	94	21	)	)	PUNCT
dpc-3114	94	22	11	11	NUM
dpc-3114	94	23	(	(	PUNCT
dpc-3114	94	24	22	22	NUM
dpc-3114	94	25	)	)	PUNCT
dpc-3114	94	26	48	48	NUM
dpc-3114	94	27	51	51	NUM
dpc-3114	94	28	48	48	NUM
dpc-3114	94	29	2	2	NUM
dpc-3114	94	30	5	5	NUM
dpc-3114	94	31	(	(	PUNCT
dpc-3114	94	32	10	10	NUM
dpc-3114	94	33	)	)	PUNCT
dpc-3114	94	34	46	46	NUM
dpc-3114	94	35	(	(	PUNCT
dpc-3114	94	36	90	90	NUM
dpc-3114	94	37	)	)	SYM
dpc-3114	94	38	35	35	NUM
dpc-3114	94	39	(	(	PUNCT
dpc-3114	94	40	68	68	NUM
dpc-3114	94	41	)	)	PUNCT
dpc-3114	94	42	32	32	NUM
dpc-3114	94	43	(	(	PUNCT
dpc-3114	94	44	63	63	NUM
dpc-3114	94	45	)	)	PUNCT
dpc-3114	94	46	pasi	pasi	NOUN
dpc-3114	94	47	=	=	SYM
dpc-3114	94	48	psoriasis	psoriasis	NOUN
dpc-3114	94	49	area	area	NOUN
dpc-3114	94	50	severity	severity	PROPN
dpc-3114	94	51	index	index	NOUN
dpc-3114	94	52	.	.	PUNCT
dpc-3114	95	1	original	original	ADJ
dpc-3114	95	2	article	article	NOUN
dpc-3114	95	3	|	|	ADV
dpc-3114	95	4	dermatol	dermatol	ADJ
dpc-3114	95	5	pract	pract	NOUN
dpc-3114	95	6	concept	concept	NOUN
dpc-3114	95	7	.	.	PUNCT
dpc-3114	96	1	2023;13(4):e2023215	2023;13(4):e2023215	NUM
dpc-3114	96	2	5	5	NUM
dpc-3114	96	3	that	that	PRON
dpc-3114	96	4	we	we	PRON
dpc-3114	96	5	assessed	assess	VERB
dpc-3114	96	6	tildrakizumab	tildrakizumab	NOUN
dpc-3114	96	7	effectiveness	effectiveness	NOUN
dpc-3114	96	8	in	in	ADP
dpc-3114	96	9	psoriasis	psoriasis	NOUN
dpc-3114	96	10	patients	patient	NOUN
dpc-3114	96	11	who	who	PRON
dpc-3114	96	12	all	all	PRON
dpc-3114	96	13	switched	switch	VERB
dpc-3114	96	14	from	from	ADP
dpc-3114	96	15	anti	anti	ADJ
dpc-3114	96	16	-	-	ADJ
dpc-3114	96	17	tnfα	tnfα	ADJ
dpc-3114	96	18	,	,	PUNCT
dpc-3114	96	19	anti	anti	ADJ
dpc-3114	96	20	-	-	ADJ
dpc-3114	96	21	il-17	il-17	ADV
dpc-3114	96	22	and/or	and/or	CCONJ
dpc-3114	96	23	anti	anti	ADJ
dpc-3114	96	24	-	-	ADJ
dpc-3114	96	25	il-12/23	il-12/23	ADJ
dpc-3114	96	26	.	.	PUNCT
dpc-3114	97	1	a	a	DET
dpc-3114	97	2	much	much	ADV
dpc-3114	97	3	larger	large	ADJ
dpc-3114	97	4	retrospective	retrospective	ADJ
dpc-3114	97	5	sub	sub	ADJ
dpc-3114	97	6	-	-	ADJ
dpc-3114	97	7	group	group	NOUN
dpc-3114	97	8	analysis	analysis	NOUN
dpc-3114	97	9	of	of	ADP
dpc-3114	97	10	a	a	DET
dpc-3114	97	11	phase	phase	NOUN
dpc-3114	97	12	2	2	NUM
dpc-3114	97	13	study	study	NOUN
dpc-3114	97	14	and	and	CCONJ
dpc-3114	97	15	two	two	NUM
dpc-3114	97	16	phase	phase	NOUN
dpc-3114	97	17	3	3	NUM
dpc-3114	97	18	studies	study	NOUN
dpc-3114	97	19	of	of	ADP
dpc-3114	97	20	tildrakizumab	tildrakizumab	NOUN
dpc-3114	97	21	featuring	feature	VERB
dpc-3114	97	22	2217	2217	NUM
dpc-3114	97	23	patients	patient	NOUN
dpc-3114	97	24	found	find	VERB
dpc-3114	97	25	no	no	DET
dpc-3114	97	26	association	association	NOUN
dpc-3114	97	27	between	between	ADP
dpc-3114	97	28	prior	prior	ADJ
dpc-3114	97	29	exposure	exposure	NOUN
dpc-3114	97	30	to	to	ADP
dpc-3114	97	31	biological	biological	ADJ
dpc-3114	97	32	therapies	therapy	NOUN
dpc-3114	97	33	and	and	CCONJ
dpc-3114	97	34	effectiveness	effectiveness	NOUN
dpc-3114	97	35	;	;	PUNCT
dpc-3114	97	36	there	there	PRON
dpc-3114	97	37	was	be	VERB
dpc-3114	97	38	a	a	DET
dpc-3114	97	39	numerically	numerically	ADV
dpc-3114	97	40	greater	great	ADJ
dpc-3114	97	41	response	response	NOUN
dpc-3114	97	42	to	to	PART
dpc-3114	97	43	tildrakizumab	tildrakizumab	NOUN
dpc-3114	97	44	in	in	ADP
dpc-3114	97	45	bionaïve	bionaïve	NOUN
dpc-3114	97	46	patients	patient	NOUN
dpc-3114	97	47	than	than	ADP
dpc-3114	97	48	bio	bio	ADV
dpc-3114	97	49	-	-	ADJ
dpc-3114	97	50	experienced	experienced	ADJ
dpc-3114	97	51	patients	patient	NOUN
dpc-3114	97	52	,	,	PUNCT
dpc-3114	97	53	but	but	CCONJ
dpc-3114	97	54	it	it	PRON
dpc-3114	97	55	was	be	AUX
dpc-3114	97	56	not	not	PART
dpc-3114	97	57	statistically	statistically	ADV
dpc-3114	97	58	significant	significant	ADJ
dpc-3114	97	59	[	[	X
dpc-3114	97	60	15	15	NUM
dpc-3114	97	61	]	]	PUNCT
dpc-3114	97	62	.	.	PUNCT
dpc-3114	98	1	data	datum	NOUN
dpc-3114	98	2	from	from	ADP
dpc-3114	98	3	197	197	NUM
dpc-3114	98	4	patients	patient	NOUN
dpc-3114	98	5	(	(	PUNCT
dpc-3114	98	6	52.3	52.3	NUM
dpc-3114	98	7	%	%	NOUN
dpc-3114	98	8	biologic	biologic	NOUN
dpc-3114	98	9	non	non	ADJ
dpc-3114	98	10	-	-	ADJ
dpc-3114	98	11	naïve	naïve	ADJ
dpc-3114	98	12	)	)	PUNCT
dpc-3114	98	13	,	,	PUNCT
dpc-3114	98	14	who	who	PRON
dpc-3114	98	15	were	be	AUX
dpc-3114	98	16	treated	treat	VERB
dpc-3114	98	17	with	with	ADP
dpc-3114	98	18	anti	anti	ADJ
dpc-3114	98	19	-	-	ADJ
dpc-3114	98	20	il-23p19	il-23p19	ADJ
dpc-3114	98	21	antibodies	antibody	NOUN
dpc-3114	98	22	(	(	PUNCT
dpc-3114	98	23	127	127	NUM
dpc-3114	98	24	guselkumab	guselkumab	NOUN
dpc-3114	98	25	,	,	PUNCT
dpc-3114	98	26	55	55	NUM
dpc-3114	98	27	risankizumab	risankizumab	NOUN
dpc-3114	98	28	and	and	CCONJ
dpc-3114	98	29	15	15	NUM
dpc-3114	98	30	tildrakizumab	tildrakizumab	NOUN
dpc-3114	98	31	)	)	PUNCT
dpc-3114	98	32	for	for	ADP
dpc-3114	98	33	at	at	ADV
dpc-3114	98	34	least	least	ADV
dpc-3114	98	35	3	3	NUM
dpc-3114	98	36	months	month	NOUN
dpc-3114	98	37	,	,	PUNCT
dpc-3114	98	38	were	be	AUX
dpc-3114	98	39	analyzed	analyze	VERB
dpc-3114	98	40	from	from	ADP
dpc-3114	98	41	the	the	DET
dpc-3114	98	42	psoriasis	psoriasis	NOUN
dpc-3114	98	43	registry	registry	NOUN
dpc-3114	98	44	austria	austria	PROPN
dpc-3114	98	45	(	(	PUNCT
dpc-3114	98	46	psora	psora	PROPN
dpc-3114	98	47	)	)	PUNCT
dpc-3114	98	48	.	.	PUNCT
dpc-3114	99	1	results	result	NOUN
dpc-3114	99	2	from	from	ADP
dpc-3114	99	3	this	this	DET
dpc-3114	99	4	study	study	NOUN
dpc-3114	99	5	indicated	indicate	VERB
dpc-3114	99	6	that	that	SCONJ
dpc-3114	99	7	biologic	biologic	NOUN
dpc-3114	99	8	-	-	PUNCT
dpc-3114	99	9	non	non	ADJ
dpc-3114	99	10	-	-	ADJ
dpc-3114	99	11	naïve	naïve	ADJ
dpc-3114	99	12	patients	patient	NOUN
dpc-3114	99	13	displayed	display	VERB
dpc-3114	99	14	a	a	DET
dpc-3114	99	15	less	less	ADV
dpc-3114	99	16	favorable	favorable	ADJ
dpc-3114	99	17	response	response	NOUN
dpc-3114	99	18	to	to	ADP
dpc-3114	99	19	anti	anti	ADJ
dpc-3114	99	20	il-23	il-23	NOUN
dpc-3114	99	21	treatment	treatment	NOUN
dpc-3114	99	22	as	as	ADP
dpc-3114	99	23	compared	compare	VERB
dpc-3114	99	24	to	to	ADP
dpc-3114	99	25	biologic	biologic	ADJ
dpc-3114	99	26	-	-	PUNCT
dpc-3114	99	27	naïve	naïve	ADJ
dpc-3114	99	28	patients	patient	NOUN
dpc-3114	99	29	.	.	PUNCT
dpc-3114	100	1	however	however	ADV
dpc-3114	100	2	,	,	PUNCT
dpc-3114	100	3	after	after	ADP
dpc-3114	100	4	correction	correction	NOUN
dpc-3114	100	5	for	for	ADP
dpc-3114	100	6	previous	previous	ADJ
dpc-3114	100	7	biologic	biologic	NOUN
dpc-3114	100	8	exposure	exposure	NOUN
dpc-3114	100	9	,	,	PUNCT
dpc-3114	100	10	few	few	ADJ
dpc-3114	100	11	differences	difference	NOUN
dpc-3114	100	12	in	in	ADP
dpc-3114	100	13	pasi	pasi	NOUN
dpc-3114	100	14	improvement	improvement	NOUN
dpc-3114	100	15	were	be	AUX
dpc-3114	100	16	detected	detect	VERB
dpc-3114	100	17	among	among	ADP
dpc-3114	100	18	biologic	biologic	NOUN
dpc-3114	100	19	-	-	PUNCT
dpc-3114	100	20	naïve	naïve	ADJ
dpc-3114	100	21	and	and	CCONJ
dpc-3114	100	22	-non	-non	NOUN
dpc-3114	100	23	-	-	ADJ
dpc-3114	100	24	naïve	naïve	ADJ
dpc-3114	100	25	patients	patient	NOUN
dpc-3114	100	26	treated	treat	VERB
dpc-3114	100	27	with	with	ADP
dpc-3114	100	28	different	different	ADJ
dpc-3114	100	29	il-23p19	il-23p19	PROPN
dpc-3114	100	30	inhibitors	inhibitor	NOUN
dpc-3114	100	31	.	.	PUNCT
dpc-3114	101	1	the	the	DET
dpc-3114	101	2	authors	author	NOUN
dpc-3114	101	3	concluded	conclude	VERB
dpc-3114	101	4	that	that	SCONJ
dpc-3114	101	5	treatment	treatment	NOUN
dpc-3114	101	6	effectiveness	effectiveness	NOUN
dpc-3114	101	7	was	be	AUX
dpc-3114	101	8	not	not	PART
dpc-3114	101	9	related	relate	VERB
dpc-3114	101	10	to	to	ADP
dpc-3114	101	11	the	the	DET
dpc-3114	101	12	class	class	NOUN
dpc-3114	101	13	of	of	ADP
dpc-3114	101	14	the	the	DET
dpc-3114	101	15	previously	previously	ADV
dpc-3114	101	16	administered	administer	VERB
dpc-3114	101	17	therapy	therapy	NOUN
dpc-3114	101	18	in	in	ADP
dpc-3114	101	19	biologic	biologic	NOUN
dpc-3114	101	20	-	-	PUNCT
dpc-3114	101	21	non	non	ADJ
dpc-3114	101	22	-	-	ADJ
dpc-3114	101	23	naïve	naïve	ADJ
dpc-3114	101	24	patients	patient	NOUN
dpc-3114	101	25	[	[	X
dpc-3114	101	26	16	16	NUM
dpc-3114	101	27	]	]	PUNCT
dpc-3114	101	28	.	.	PUNCT
dpc-3114	102	1	in	in	ADP
dpc-3114	102	2	our	our	PRON
dpc-3114	102	3	study	study	NOUN
dpc-3114	102	4	,	,	PUNCT
dpc-3114	102	5	patients	patient	NOUN
dpc-3114	102	6	who	who	PRON
dpc-3114	102	7	switched	switch	VERB
dpc-3114	102	8	from	from	ADP
dpc-3114	102	9	anti	anti	ADJ
dpc-3114	102	10	-	-	ADJ
dpc-3114	102	11	il	il	ADJ
dpc-3114	102	12	17	17	NUM
dpc-3114	102	13	drugs	drug	NOUN
dpc-3114	102	14	to	to	PART
dpc-3114	102	15	tildrakizumab	tildrakizumab	NOUN
dpc-3114	102	16	had	have	VERB
dpc-3114	102	17	a	a	DET
dpc-3114	102	18	more	more	ADV
dpc-3114	102	19	severe	severe	ADJ
dpc-3114	102	20	disease	disease	NOUN
dpc-3114	102	21	.	.	PUNCT
dpc-3114	103	1	anyhow	anyhow	ADV
dpc-3114	103	2	,	,	PUNCT
dpc-3114	103	3	this	this	DET
dpc-3114	103	4	difference	difference	NOUN
dpc-3114	103	5	did	do	AUX
dpc-3114	103	6	not	not	PART
dpc-3114	103	7	affect	affect	VERB
dpc-3114	103	8	the	the	DET
dpc-3114	103	9	response	response	NOUN
dpc-3114	103	10	to	to	PART
dpc-3114	103	11	tildrakizumab	tildrakizumab	VERB
dpc-3114	103	12	respect	respect	NOUN
dpc-3114	103	13	to	to	ADP
dpc-3114	103	14	the	the	DET
dpc-3114	103	15	other	other	ADJ
dpc-3114	103	16	groups	group	NOUN
dpc-3114	103	17	.	.	PUNCT
dpc-3114	104	1	in	in	ADP
dpc-3114	104	2	general	general	ADJ
dpc-3114	104	3	,	,	PUNCT
dpc-3114	104	4	the	the	DET
dpc-3114	104	5	rate	rate	NOUN
dpc-3114	104	6	of	of	ADP
dpc-3114	104	7	adverse	adverse	ADJ
dpc-3114	104	8	events	event	NOUN
dpc-3114	104	9	(	(	PUNCT
dpc-3114	104	10	3.9	3.9	NUM
dpc-3114	104	11	%	%	NOUN
dpc-3114	104	12	)	)	PUNCT
dpc-3114	104	13	observed	observe	VERB
dpc-3114	104	14	in	in	ADP
dpc-3114	104	15	this	this	DET
dpc-3114	104	16	study	study	NOUN
dpc-3114	104	17	was	be	AUX
dpc-3114	104	18	lower	low	ADJ
dpc-3114	104	19	than	than	ADP
dpc-3114	104	20	what	what	PRON
dpc-3114	104	21	reported	report	VERB
dpc-3114	104	22	in	in	ADP
dpc-3114	104	23	clinical	clinical	ADJ
dpc-3114	104	24	trials	trial	NOUN
dpc-3114	104	25	,	,	PUNCT
dpc-3114	104	26	but	but	CCONJ
dpc-3114	104	27	similar	similar	ADJ
dpc-3114	104	28	or	or	CCONJ
dpc-3114	104	29	lower	low	ADJ
dpc-3114	104	30	compared	compare	VERB
dpc-3114	104	31	to	to	ADP
dpc-3114	104	32	real	real	ADJ
dpc-3114	104	33	-	-	PUNCT
dpc-3114	104	34	world	world	NOUN
dpc-3114	104	35	patients	patient	NOUN
dpc-3114	104	36	.	.	PUNCT
dpc-3114	105	1	[	[	X
dpc-3114	105	2	3	3	NUM
dpc-3114	105	3	-	-	PUNCT
dpc-3114	105	4	10,13	10,13	NUM
dpc-3114	105	5	-	-	SYM
dpc-3114	105	6	16	16	NUM
dpc-3114	105	7	]	]	PUNCT
dpc-3114	105	8	thus	thus	ADV
dpc-3114	105	9	,	,	PUNCT
dpc-3114	105	10	a	a	DET
dpc-3114	105	11	good	good	ADJ
dpc-3114	105	12	safety	safety	NOUN
dpc-3114	105	13	profile	profile	NOUN
dpc-3114	105	14	was	be	AUX
dpc-3114	105	15	observed	observe	VERB
dpc-3114	105	16	for	for	ADP
dpc-3114	105	17	tildrakizumab	tildrakizumab	NOUN
dpc-3114	105	18	in	in	ADP
dpc-3114	105	19	our	our	PRON
dpc-3114	105	20	cohort	cohort	NOUN
dpc-3114	105	21	of	of	ADP
dpc-3114	105	22	patients	patient	NOUN
dpc-3114	105	23	.	.	PUNCT
dpc-3114	106	1	this	this	DET
dpc-3114	106	2	study	study	NOUN
dpc-3114	106	3	has	have	VERB
dpc-3114	106	4	some	some	DET
dpc-3114	106	5	limitations	limitation	NOUN
dpc-3114	106	6	,	,	PUNCT
dpc-3114	106	7	firstly	firstly	ADV
dpc-3114	106	8	consisting	consist	VERB
dpc-3114	106	9	of	of	ADP
dpc-3114	106	10	the	the	DET
dpc-3114	106	11	retrospective	retrospective	ADJ
dpc-3114	106	12	design	design	NOUN
dpc-3114	106	13	,	,	PUNCT
dpc-3114	106	14	which	which	PRON
dpc-3114	106	15	does	do	AUX
dpc-3114	106	16	not	not	PART
dpc-3114	106	17	allow	allow	VERB
dpc-3114	106	18	collection	collection	NOUN
dpc-3114	106	19	of	of	ADP
dpc-3114	106	20	missing	miss	VERB
dpc-3114	106	21	data	datum	NOUN
dpc-3114	106	22	.	.	PUNCT
dpc-3114	107	1	other	other	ADJ
dpc-3114	107	2	significant	significant	ADJ
dpc-3114	107	3	limitations	limitation	NOUN
dpc-3114	107	4	are	be	AUX
dpc-3114	107	5	the	the	DET
dpc-3114	107	6	relatively	relatively	ADV
dpc-3114	107	7	small	small	ADJ
dpc-3114	107	8	size	size	NOUN
dpc-3114	107	9	of	of	ADP
dpc-3114	107	10	the	the	DET
dpc-3114	107	11	sample	sample	NOUN
dpc-3114	107	12	,	,	PUNCT
dpc-3114	107	13	the	the	DET
dpc-3114	107	14	lack	lack	NOUN
dpc-3114	107	15	of	of	ADP
dpc-3114	107	16	a	a	DET
dpc-3114	107	17	randomized	randomized	ADJ
dpc-3114	107	18	controlled	control	VERB
dpc-3114	107	19	setting	setting	NOUN
dpc-3114	107	20	,	,	PUNCT
dpc-3114	107	21	and	and	CCONJ
dpc-3114	107	22	the	the	DET
dpc-3114	107	23	heterogeneity	heterogeneity	NOUN
dpc-3114	107	24	of	of	ADP
dpc-3114	107	25	clinical	clinical	ADJ
dpc-3114	107	26	assessment	assessment	NOUN
dpc-3114	107	27	among	among	ADP
dpc-3114	107	28	clinicians	clinician	NOUN
dpc-3114	107	29	from	from	ADP
dpc-3114	107	30	different	different	ADJ
dpc-3114	107	31	centers	center	NOUN
dpc-3114	107	32	.	.	PUNCT
dpc-3114	108	1	this	this	DET
dpc-3114	108	2	study	study	NOUN
dpc-3114	108	3	confirms	confirm	VERB
dpc-3114	108	4	the	the	DET
dpc-3114	108	5	effectiveness	effectiveness	NOUN
dpc-3114	108	6	of	of	ADP
dpc-3114	108	7	tildrakizumab	tildrakizumab	NOUN
dpc-3114	108	8	in	in	ADP
dpc-3114	108	9	daily	daily	ADJ
dpc-3114	108	10	clinical	clinical	ADJ
dpc-3114	108	11	practice	practice	NOUN
dpc-3114	108	12	in	in	ADP
dpc-3114	108	13	patients	patient	NOUN
dpc-3114	108	14	with	with	ADP
dpc-3114	108	15	moderate	moderate	ADJ
dpc-3114	108	16	-	-	PUNCT
dpc-3114	108	17	to	to	ADP
dpc-3114	108	18	-	-	PUNCT
dpc-3114	108	19	severe	severe	ADJ
dpc-3114	108	20	plaque	plaque	NOUN
dpc-3114	108	21	psoriasis	psoriasis	NOUN
dpc-3114	108	22	.	.	PUNCT
dpc-3114	109	1	moreover	moreover	ADV
dpc-3114	109	2	,	,	PUNCT
dpc-3114	109	3	our	our	PRON
dpc-3114	109	4	observation	observation	NOUN
dpc-3114	109	5	period	period	NOUN
dpc-3114	109	6	up	up	ADP
dpc-3114	109	7	to	to	ADP
dpc-3114	109	8	week	week	NOUN
dpc-3114	109	9	48	48	NUM
dpc-3114	109	10	confirms	confirm	VERB
dpc-3114	109	11	that	that	SCONJ
dpc-3114	109	12	the	the	DET
dpc-3114	109	13	efficacy	efficacy	NOUN
dpc-3114	109	14	of	of	ADP
dpc-3114	109	15	tildrakizumab	tildrakizumab	NOUN
dpc-3114	109	16	was	be	AUX
dpc-3114	109	17	maintained	maintain	VERB
dpc-3114	109	18	over	over	ADP
dpc-3114	109	19	time	time	NOUN
dpc-3114	109	20	.	.	PUNCT
dpc-3114	110	1	all	all	DET
dpc-3114	110	2	the	the	DET
dpc-3114	110	3	enrolled	enrol	VERB
dpc-3114	110	4	patients	patient	NOUN
dpc-3114	110	5	were	be	AUX
dpc-3114	110	6	biologic	biologic	NOUN
dpc-3114	110	7	-	-	PUNCT
dpc-3114	110	8	exposed	expose	VERB
dpc-3114	110	9	,	,	PUNCT
dpc-3114	110	10	and	and	CCONJ
dpc-3114	110	11	the	the	DET
dpc-3114	110	12	treatment	treatment	NOUN
dpc-3114	110	13	effectiveness	effectiveness	NOUN
dpc-3114	110	14	was	be	AUX
dpc-3114	110	15	not	not	PART
dpc-3114	110	16	related	relate	VERB
dpc-3114	110	17	to	to	ADP
dpc-3114	110	18	the	the	DET
dpc-3114	110	19	class	class	NOUN
dpc-3114	110	20	of	of	ADP
dpc-3114	110	21	the	the	DET
dpc-3114	110	22	previously	previously	ADV
dpc-3114	110	23	administered	administer	VERB
dpc-3114	110	24	therapy	therapy	NOUN
dpc-3114	110	25	.	.	PUNCT
dpc-3114	111	1	therefore	therefore	ADV
dpc-3114	111	2	,	,	PUNCT
dpc-3114	111	3	this	this	DET
dpc-3114	111	4	il-23p19	il-23p19	PROPN
dpc-3114	111	5	inhibitor	inhibitor	NOUN
dpc-3114	111	6	represents	represent	VERB
dpc-3114	111	7	a	a	DET
dpc-3114	111	8	promising	promising	ADJ
dpc-3114	111	9	treatment	treatment	NOUN
dpc-3114	111	10	alternative	alternative	NOUN
dpc-3114	111	11	for	for	ADP
dpc-3114	111	12	patients	patient	NOUN
dpc-3114	111	13	who	who	PRON
dpc-3114	111	14	have	have	AUX
dpc-3114	111	15	not	not	PART
dpc-3114	111	16	responded	respond	VERB
dpc-3114	111	17	to	to	ADP
dpc-3114	111	18	previous	previous	ADJ
dpc-3114	111	19	biologics	biologic	NOUN
dpc-3114	111	20	.	.	PUNCT
dpc-3114	112	1	informed	informed	ADJ
dpc-3114	112	2	consent	consent	NOUN
dpc-3114	112	3	:	:	PUNCT
dpc-3114	112	4	informed	inform	VERB
dpc-3114	112	5	consent	consent	NOUN
dpc-3114	112	6	was	be	AUX
dpc-3114	112	7	taken	take	VERB
dpc-3114	112	8	from	from	ADP
dpc-3114	112	9	all	all	DET
dpc-3114	112	10	the	the	DET
dpc-3114	112	11	patients	patient	NOUN
dpc-3114	112	12	for	for	ADP
dpc-3114	112	13	the	the	DET
dpc-3114	112	14	application	application	NOUN
dpc-3114	112	15	of	of	ADP
dpc-3114	112	16	treatment	treatment	NOUN
dpc-3114	112	17	and	and	CCONJ
dpc-3114	112	18	for	for	ADP
dpc-3114	112	19	the	the	DET
dpc-3114	112	20	use	use	NOUN
dpc-3114	112	21	of	of	ADP
dpc-3114	112	22	data	datum	NOUN
dpc-3114	112	23	and	and	CCONJ
dpc-3114	112	24	photographs	photograph	NOUN
dpc-3114	112	25	.	.	PUNCT
dpc-3114	113	1	figure	figure	NOUN
dpc-3114	113	2	2	2	NUM
dpc-3114	113	3	.	.	PUNCT
dpc-3114	114	1	mean	mean	VERB
dpc-3114	114	2	psoriasis	psoriasis	NOUN
dpc-3114	114	3	area	area	NOUN
dpc-3114	114	4	severity	severity	NOUN
dpc-3114	114	5	index	index	NOUN
dpc-3114	114	6	(	(	PUNCT
dpc-3114	114	7	pasi	pasi	NOUN
dpc-3114	114	8	)	)	PUNCT
dpc-3114	114	9	,	,	PUNCT
dpc-3114	114	10	body	body	NOUN
dpc-3114	114	11	surface	surface	NOUN
dpc-3114	114	12	area	area	NOUN
dpc-3114	114	13	(	(	PUNCT
dpc-3114	114	14	bsa	bsa	PROPN
dpc-3114	114	15	)	)	PUNCT
dpc-3114	114	16	,	,	PUNCT
dpc-3114	114	17	and	and	CCONJ
dpc-3114	114	18	dermatology	dermatology	NOUN
dpc-3114	114	19	life	life	NOUN
dpc-3114	114	20	quality	quality	NOUN
dpc-3114	114	21	index	index	NOUN
dpc-3114	114	22	(	(	PUNCT
dpc-3114	114	23	dlqi	dlqi	ADJ
dpc-3114	114	24	)	)	PUNCT
dpc-3114	114	25	score	score	NOUN
dpc-3114	114	26	values	value	NOUN
dpc-3114	114	27	in	in	ADP
dpc-3114	114	28	the	the	DET
dpc-3114	114	29	whole	whole	ADJ
dpc-3114	114	30	population	population	NOUN
dpc-3114	114	31	stratified	stratify	VERB
dpc-3114	114	32	by	by	ADP
dpc-3114	114	33	last	last	ADJ
dpc-3114	114	34	treatment	treatment	NOUN
dpc-3114	114	35	before	before	ADP
dpc-3114	114	36	tildrakizumab	tildrakizumab	NOUN
dpc-3114	114	37	(	(	PUNCT
dpc-3114	114	38	anti	anti	ADJ
dpc-3114	114	39	-	-	ADJ
dpc-3114	114	40	tnfα	tnfα	ADJ
dpc-3114	114	41	,	,	PUNCT
dpc-3114	114	42	anti	anti	ADJ
dpc-3114	114	43	-	-	ADJ
dpc-3114	114	44	il17	il17	ADJ
dpc-3114	114	45	,	,	PUNCT
dpc-3114	114	46	anti	anti	ADJ
dpc-3114	114	47	-	-	NOUN
dpc-3114	114	48	il12/23	il12/23	NOUN
dpc-3114	114	49	)	)	PUNCT
dpc-3114	114	50	.	.	PUNCT
dpc-3114	115	1	of	of	ADP
dpc-3114	115	2	both	both	DET
dpc-3114	115	3	mean	mean	VERB
dpc-3114	115	4	pasi	pasi	NOUN
dpc-3114	115	5	scores	score	NOUN
dpc-3114	115	6	(	(	PUNCT
dpc-3114	115	7	mean	mean	INTJ
dpc-3114	115	8	baseline	baseline	NOUN
dpc-3114	115	9	pasi	pasi	NOUN
dpc-3114	115	10	:	:	PUNCT
dpc-3114	115	11	19.2	19.2	NUM
dpc-3114	115	12	,	,	PUNCT
dpc-3114	115	13	mean	mean	VERB
dpc-3114	115	14	pasi	pasi	NOUN
dpc-3114	115	15	score	score	NOUN
dpc-3114	115	16	at	at	ADP
dpc-3114	115	17	week	week	NOUN
dpc-3114	115	18	48	48	NUM
dpc-3114	115	19	:	:	SYM
dpc-3114	115	20	0.6	0.6	NUM
dpc-3114	115	21	)	)	PUNCT
dpc-3114	115	22	and	and	CCONJ
dpc-3114	115	23	percentage	percentage	NOUN
dpc-3114	115	24	of	of	ADP
dpc-3114	115	25	patients	patient	NOUN
dpc-3114	115	26	obtaining	obtain	VERB
dpc-3114	115	27	pasi	pasi	NOUN
dpc-3114	115	28	75	75	NUM
dpc-3114	115	29	,	,	PUNCT
dpc-3114	115	30	90	90	NUM
dpc-3114	115	31	,	,	PUNCT
dpc-3114	115	32	and	and	CCONJ
dpc-3114	115	33	100	100	NUM
dpc-3114	115	34	responses	response	NOUN
dpc-3114	115	35	.	.	PUNCT
dpc-3114	116	1	our	our	PRON
dpc-3114	116	2	findings	finding	NOUN
dpc-3114	116	3	also	also	ADV
dpc-3114	116	4	showed	show	VERB
dpc-3114	116	5	a	a	DET
dpc-3114	116	6	marked	mark	VERB
dpc-3114	116	7	improvement	improvement	NOUN
dpc-3114	116	8	in	in	ADP
dpc-3114	116	9	bsa	bsa	PROPN
dpc-3114	116	10	and	and	CCONJ
dpc-3114	116	11	dlqi	dlqi	ADJ
dpc-3114	116	12	scores	score	NOUN
dpc-3114	116	13	.	.	PUNCT
dpc-3114	117	1	our	our	PRON
dpc-3114	117	2	findings	finding	NOUN
dpc-3114	117	3	are	be	AUX
dpc-3114	117	4	in	in	ADP
dpc-3114	117	5	line	line	NOUN
dpc-3114	117	6	with	with	ADP
dpc-3114	117	7	other	other	ADJ
dpc-3114	117	8	real	real	ADJ
dpc-3114	117	9	-	-	PUNCT
dpc-3114	117	10	world	world	NOUN
dpc-3114	117	11	studies	study	NOUN
dpc-3114	117	12	.	.	PUNCT
dpc-3114	118	1	a	a	DET
dpc-3114	118	2	retrospective	retrospective	ADJ
dpc-3114	118	3	chart	chart	NOUN
dpc-3114	118	4	review	review	NOUN
dpc-3114	118	5	of	of	ADP
dpc-3114	118	6	30	30	NUM
dpc-3114	118	7	patients	patient	NOUN
dpc-3114	118	8	treated	treat	VERB
dpc-3114	118	9	with	with	ADP
dpc-3114	118	10	tildrakizumab	tildrakizumab	NOUN
dpc-3114	118	11	for	for	ADP
dpc-3114	118	12	moderate	moderate	ADJ
dpc-3114	118	13	-	-	PUNCT
dpc-3114	118	14	to	to	ADP
dpc-3114	118	15	-	-	PUNCT
dpc-3114	118	16	severe	severe	ADJ
dpc-3114	118	17	plaque	plaque	NOUN
dpc-3114	118	18	psoriasis	psoriasis	NOUN
dpc-3114	118	19	from	from	ADP
dpc-3114	118	20	initial	initial	ADJ
dpc-3114	118	21	presentation	presentation	NOUN
dpc-3114	118	22	to	to	ADP
dpc-3114	118	23	12	12	NUM
dpc-3114	118	24	-	-	PUNCT
dpc-3114	118	25	month	month	NOUN
dpc-3114	118	26	follow	follow	NOUN
dpc-3114	118	27	-	-	PUNCT
dpc-3114	118	28	up	up	NOUN
dpc-3114	118	29	found	find	VERB
dpc-3114	118	30	that	that	SCONJ
dpc-3114	118	31	,	,	PUNCT
dpc-3114	118	32	similar	similar	ADJ
dpc-3114	118	33	to	to	ADP
dpc-3114	118	34	our	our	PRON
dpc-3114	118	35	study	study	NOUN
dpc-3114	118	36	,	,	PUNCT
dpc-3114	118	37	the	the	DET
dpc-3114	118	38	mean	mean	ADJ
dpc-3114	118	39	pasi	pasi	NOUN
dpc-3114	118	40	reduced	reduce	VERB
dpc-3114	118	41	from	from	ADP
dpc-3114	118	42	16	16	NUM
dpc-3114	118	43	to	to	ADP
dpc-3114	118	44	1.5	1.5	NUM
dpc-3114	118	45	and	and	CCONJ
dpc-3114	118	46	that	that	SCONJ
dpc-3114	118	47	no	no	DET
dpc-3114	118	48	serious	serious	ADJ
dpc-3114	118	49	adverse	adverse	ADJ
dpc-3114	118	50	events	event	NOUN
dpc-3114	118	51	were	be	AUX
dpc-3114	118	52	reported	report	VERB
dpc-3114	118	53	[	[	X
dpc-3114	118	54	13	13	NUM
dpc-3114	118	55	]	]	PUNCT
dpc-3114	118	56	.	.	PUNCT
dpc-3114	119	1	another	another	DET
dpc-3114	119	2	real	real	ADJ
dpc-3114	119	3	-	-	PUNCT
dpc-3114	119	4	world	world	NOUN
dpc-3114	119	5	data	datum	NOUN
dpc-3114	119	6	study	study	NOUN
dpc-3114	119	7	involving	involve	VERB
dpc-3114	119	8	59	59	NUM
dpc-3114	119	9	psoriatic	psoriatic	ADJ
dpc-3114	119	10	patients	patient	NOUN
dpc-3114	119	11	also	also	ADV
dpc-3114	119	12	reported	report	VERB
dpc-3114	119	13	a	a	DET
dpc-3114	119	14	favorable	favorable	ADJ
dpc-3114	119	15	response	response	NOUN
dpc-3114	119	16	to	to	ADP
dpc-3114	119	17	tildrakizumab	tildrakizumab	NOUN
dpc-3114	119	18	,	,	PUNCT
dpc-3114	119	19	with	with	ADP
dpc-3114	119	20	a	a	DET
dpc-3114	119	21	pasi	pasi	NOUN
dpc-3114	119	22	≤	≤	NOUN
dpc-3114	119	23	3	3	NUM
dpc-3114	119	24	being	be	AUX
dpc-3114	119	25	achieved	achieve	VERB
dpc-3114	119	26	at	at	ADP
dpc-3114	119	27	28	28	NUM
dpc-3114	119	28	weeks	week	NOUN
dpc-3114	119	29	in	in	ADP
dpc-3114	119	30	80	80	NUM
dpc-3114	119	31	%	%	NOUN
dpc-3114	119	32	of	of	ADP
dpc-3114	119	33	patients	patient	NOUN
dpc-3114	119	34	.	.	PUNCT
dpc-3114	120	1	in	in	ADP
dpc-3114	120	2	addition	addition	NOUN
dpc-3114	120	3	,	,	PUNCT
dpc-3114	120	4	the	the	DET
dpc-3114	120	5	authors	author	NOUN
dpc-3114	120	6	reported	report	VERB
dpc-3114	120	7	no	no	DET
dpc-3114	120	8	statistically	statistically	ADV
dpc-3114	120	9	significant	significant	ADJ
dpc-3114	120	10	association	association	NOUN
dpc-3114	120	11	between	between	ADP
dpc-3114	120	12	prior	prior	ADJ
dpc-3114	120	13	exposure	exposure	NOUN
dpc-3114	120	14	to	to	ADP
dpc-3114	120	15	biological	biological	ADJ
dpc-3114	120	16	therapies	therapy	NOUN
dpc-3114	120	17	and	and	CCONJ
dpc-3114	120	18	effectiveness	effectiveness	NOUN
dpc-3114	120	19	,	,	PUNCT
dpc-3114	120	20	since	since	SCONJ
dpc-3114	120	21	pasi90	pasi90	NOUN
dpc-3114	120	22	at	at	ADP
dpc-3114	120	23	28	28	NUM
dpc-3114	120	24	weeks	week	NOUN
dpc-3114	120	25	was	be	AUX
dpc-3114	120	26	achieved	achieve	VERB
dpc-3114	120	27	by	by	ADP
dpc-3114	120	28	68	68	NUM
dpc-3114	120	29	%	%	NOUN
dpc-3114	120	30	of	of	ADP
dpc-3114	120	31	bio	bio	ADJ
dpc-3114	120	32	-	-	ADJ
dpc-3114	120	33	naïve	naïve	ADJ
dpc-3114	120	34	patients	patient	NOUN
dpc-3114	120	35	and	and	CCONJ
dpc-3114	120	36	by	by	ADP
dpc-3114	120	37	60	60	NUM
dpc-3114	120	38	%	%	NOUN
dpc-3114	120	39	of	of	ADP
dpc-3114	120	40	bio	bio	ADJ
dpc-3114	120	41	-	-	ADJ
dpc-3114	120	42	experienced	experienced	ADJ
dpc-3114	120	43	patients	patient	NOUN
dpc-3114	120	44	[	[	X
dpc-3114	120	45	8	8	NUM
dpc-3114	120	46	]	]	PUNCT
dpc-3114	120	47	.	.	PUNCT
dpc-3114	121	1	an	an	DET
dpc-3114	121	2	italian	italian	ADJ
dpc-3114	121	3	retrospective	retrospective	ADJ
dpc-3114	121	4	study	study	NOUN
dpc-3114	121	5	included	include	VERB
dpc-3114	121	6	237	237	NUM
dpc-3114	121	7	adults	adult	NOUN
dpc-3114	121	8	with	with	ADP
dpc-3114	121	9	moderate	moderate	ADJ
dpc-3114	121	10	-	-	PUNCT
dpc-3114	121	11	to	to	ADP
dpc-3114	121	12	-	-	PUNCT
dpc-3114	121	13	severe	severe	ADJ
dpc-3114	121	14	plaque	plaque	NOUN
dpc-3114	121	15	psoriasis	psoriasis	NOUN
dpc-3114	121	16	,	,	PUNCT
dpc-3114	121	17	enrolled	enrol	VERB
dpc-3114	121	18	in	in	ADP
dpc-3114	121	19	10	10	NUM
dpc-3114	121	20	different	different	ADJ
dpc-3114	121	21	centers	center	NOUN
dpc-3114	121	22	and	and	CCONJ
dpc-3114	121	23	treated	treat	VERB
dpc-3114	121	24	with	with	ADP
dpc-3114	121	25	tildrakizumab	tildrakizumab	NOUN
dpc-3114	121	26	up	up	ADP
dpc-3114	121	27	to	to	ADP
dpc-3114	121	28	week	week	NOUN
dpc-3114	121	29	52	52	NUM
dpc-3114	121	30	.	.	PUNCT
dpc-3114	122	1	at	at	ADP
dpc-3114	122	2	week	week	NOUN
dpc-3114	122	3	52	52	NUM
dpc-3114	122	4	,	,	PUNCT
dpc-3114	122	5	90.91	90.91	NUM
dpc-3114	122	6	%	%	NOUN
dpc-3114	122	7	,	,	PUNCT
dpc-3114	122	8	73.55	73.55	NUM
dpc-3114	122	9	%	%	NOUN
dpc-3114	122	10	and	and	CCONJ
dpc-3114	122	11	58.68	58.68	NUM
dpc-3114	122	12	%	%	NOUN
dpc-3114	122	13	of	of	ADP
dpc-3114	122	14	patients	patient	NOUN
dpc-3114	122	15	achieved	achieve	VERB
dpc-3114	122	16	a	a	DET
dpc-3114	122	17	pasi	pasi	NOUN
dpc-3114	122	18	75	75	NUM
dpc-3114	122	19	,	,	PUNCT
dpc-3114	122	20	pasi	pasi	NOUN
dpc-3114	122	21	90	90	NUM
dpc-3114	122	22	and	and	CCONJ
dpc-3114	122	23	pasi	pasi	NOUN
dpc-3114	122	24	100	100	NUM
dpc-3114	122	25	,	,	PUNCT
dpc-3114	122	26	respectively	respectively	ADV
dpc-3114	122	27	.	.	PUNCT
dpc-3114	123	1	an	an	DET
dpc-3114	123	2	absolute	absolute	ADJ
dpc-3114	123	3	pasi	pasi	NOUN
dpc-3114	123	4	≤	≤	X
dpc-3114	123	5	2	2	NUM
dpc-3114	123	6	was	be	AUX
dpc-3114	123	7	reached	reach	VERB
dpc-3114	123	8	by	by	ADP
dpc-3114	123	9	85.95	85.95	NUM
dpc-3114	123	10	%	%	NOUN
dpc-3114	123	11	at	at	ADP
dpc-3114	123	12	week	week	NOUN
dpc-3114	123	13	52	52	NUM
dpc-3114	124	1	[	[	X
dpc-3114	124	2	14	14	NUM
dpc-3114	124	3	]	]	PUNCT
dpc-3114	124	4	.	.	PUNCT
dpc-3114	125	1	we	we	PRON
dpc-3114	125	2	observed	observe	VERB
dpc-3114	125	3	similar	similar	ADJ
dpc-3114	125	4	rates	rate	NOUN
dpc-3114	125	5	of	of	ADP
dpc-3114	125	6	pasi	pasi	NOUN
dpc-3114	125	7	75/90/100	75/90/100	PROPN
dpc-3114	125	8	responses	response	NOUN
dpc-3114	125	9	in	in	ADP
dpc-3114	125	10	the	the	DET
dpc-3114	125	11	present	present	ADJ
dpc-3114	125	12	study	study	NOUN
dpc-3114	125	13	.	.	PUNCT
dpc-3114	126	1	notably	notably	ADV
dpc-3114	126	2	,	,	PUNCT
dpc-3114	126	3	it	it	PRON
dpc-3114	126	4	has	have	VERB
dpc-3114	126	5	to	to	PART
dpc-3114	126	6	be	be	AUX
dpc-3114	126	7	taken	take	VERB
dpc-3114	126	8	into	into	ADP
dpc-3114	126	9	account	account	NOUN
dpc-3114	126	10	6	6	NUM
dpc-3114	126	11	original	original	ADJ
dpc-3114	126	12	article	article	NOUN
dpc-3114	126	13	|	|	ADV
dpc-3114	126	14	dermatol	dermatol	ADJ
dpc-3114	126	15	pract	pract	NOUN
dpc-3114	126	16	concept	concept	NOUN
dpc-3114	126	17	.	.	PUNCT
dpc-3114	127	1	2023;13(4):e2023215	2023;13(4):e2023215	NUM
dpc-3114	127	2	9	9	NUM
dpc-3114	127	3	.	.	PUNCT
dpc-3114	128	1	simpson	simpson	PROPN
dpc-3114	128	2	k	k	PROPN
dpc-3114	128	3	,	,	PUNCT
dpc-3114	128	4	low	low	PROPN
dpc-3114	128	5	zm	zm	PROPN
dpc-3114	128	6	,	,	PUNCT
dpc-3114	128	7	howard	howard	PROPN
dpc-3114	128	8	a	a	PRON
dpc-3114	128	9	,	,	PUNCT
dpc-3114	128	10	kern	kern	PROPN
dpc-3114	128	11	js	js	PROPN
dpc-3114	128	12	.	.	PUNCT
dpc-3114	129	1	successful	successful	ADJ
dpc-3114	129	2	management	management	NOUN
dpc-3114	129	3	of	of	ADP
dpc-3114	129	4	treatment	treatment	NOUN
dpc-3114	129	5	resistant	resistant	ADJ
dpc-3114	129	6	nail	nail	NOUN
dpc-3114	129	7	psoriasis	psoriasis	NOUN
dpc-3114	129	8	with	with	ADP
dpc-3114	129	9	tildrakizumab	tildrakizumab	NOUN
dpc-3114	129	10	.	.	PUNCT
dpc-3114	130	1	australas	australas	PROPN
dpc-3114	130	2	j	j	PROPN
dpc-3114	130	3	dermatol	dermatol	NOUN
dpc-3114	130	4	2021;62(3):390–393	2021;62(3):390–393	PROPN
dpc-3114	130	5	.	.	PUNCT
dpc-3114	131	1	doi	doi	NOUN
dpc-3114	131	2	:	:	PUNCT
dpc-3114	131	3	10.1111	10.1111	NUM
dpc-3114	131	4	/ajd.13642	/ajd.13642	PROPN
dpc-3114	131	5	.	.	PUNCT
dpc-3114	132	1	pmid	pmid	NOUN
dpc-3114	132	2	:	:	PUNCT
dpc-3114	132	3	34114645	34114645	NUM
dpc-3114	132	4	.	.	PUNCT
dpc-3114	133	1	10	10	NUM
dpc-3114	133	2	.	.	PUNCT
dpc-3114	134	1	galluzzo	galluzzo	NOUN
dpc-3114	134	2	m	m	PROPN
dpc-3114	134	3	,	,	PUNCT
dpc-3114	134	4	talamonti	talamonti	PROPN
dpc-3114	134	5	m	m	PROPN
dpc-3114	134	6	,	,	PUNCT
dpc-3114	134	7	cioni	cioni	ADJ
dpc-3114	134	8	a	a	X
dpc-3114	134	9	,	,	PUNCT
dpc-3114	134	10	et	et	PROPN
dpc-3114	134	11	al	al	PROPN
dpc-3114	134	12	.	.	PROPN
dpc-3114	134	13	efficacy	efficacy	NOUN
dpc-3114	134	14	of	of	ADP
dpc-3114	134	15	tildrakizumab	tildrakizumab	NOUN
dpc-3114	134	16	for	for	ADP
dpc-3114	134	17	the	the	DET
dpc-3114	134	18	treatment	treatment	NOUN
dpc-3114	134	19	of	of	ADP
dpc-3114	134	20	difficult	difficult	ADJ
dpc-3114	134	21	-	-	PUNCT
dpc-3114	134	22	to	to	ADP
dpc-3114	134	23	-	-	PUNCT
dpc-3114	134	24	treat	treat	NOUN
dpc-3114	134	25	areas	area	NOUN
dpc-3114	134	26	:	:	PUNCT
dpc-3114	134	27	scalp	scalp	NOUN
dpc-3114	134	28	,	,	PUNCT
dpc-3114	134	29	nail	nail	NOUN
dpc-3114	134	30	,	,	PUNCT
dpc-3114	134	31	palmoplantar	palmoplantar	NOUN
dpc-3114	134	32	and	and	CCONJ
dpc-3114	134	33	genital	genital	ADJ
dpc-3114	134	34	psoriasis	psoriasis	NOUN
dpc-3114	134	35	.	.	PUNCT
dpc-3114	135	1	j	j	PROPN
dpc-3114	135	2	clin	clin	PROPN
dpc-3114	135	3	med	me	VERB
dpc-3114	135	4	2022;11(9):2631	2022;11(9):2631	NUM
dpc-3114	135	5	.	.	PUNCT
dpc-3114	136	1	doi	doi	NOUN
dpc-3114	136	2	:	:	PUNCT
dpc-3114	136	3	10.3390	10.3390	NUM
dpc-3114	136	4	/	/	SYM
dpc-3114	136	5	jcm11092631	jcm11092631	NOUN
dpc-3114	136	6	.	.	PUNCT
dpc-3114	137	1	pmid	pmid	NOUN
dpc-3114	137	2	:	:	PUNCT
dpc-3114	137	3	35566756	35566756	NUM
dpc-3114	137	4	.	.	PUNCT
dpc-3114	138	1	pmcid	pmcid	NOUN
dpc-3114	138	2	:	:	PUNCT
dpc-3114	138	3	pmc9100809	pmc9100809	NOUN
dpc-3114	138	4	.	.	PUNCT
dpc-3114	139	1	11	11	NUM
dpc-3114	139	2	.	.	PUNCT
dpc-3114	140	1	conti	conti	PROPN
dpc-3114	140	2	a	a	PROPN
dpc-3114	140	3	,	,	PUNCT
dpc-3114	140	4	peccerillo	peccerillo	PROPN
dpc-3114	140	5	f	f	NOUN
dpc-3114	140	6	,	,	PUNCT
dpc-3114	140	7	amerio	amerio	ADP
dpc-3114	140	8	p	p	X
dpc-3114	140	9	,	,	PUNCT
dpc-3114	141	1	et	et	PROPN
dpc-3114	141	2	al	al	PROPN
dpc-3114	141	3	.	.	PROPN
dpc-3114	141	4	efficacy	efficacy	NOUN
dpc-3114	141	5	and	and	CCONJ
dpc-3114	141	6	safety	safety	NOUN
dpc-3114	141	7	of	of	ADP
dpc-3114	141	8	switching	switch	VERB
dpc-3114	141	9	to	to	PART
dpc-3114	141	10	ixekizumab	ixekizumab	NOUN
dpc-3114	141	11	in	in	ADP
dpc-3114	141	12	secukinumab	secukinumab	NOUN
dpc-3114	141	13	nonresponder	nonresponder	NOUN
dpc-3114	141	14	patients	patient	NOUN
dpc-3114	141	15	with	with	ADP
dpc-3114	141	16	psoriasis	psoriasis	NOUN
dpc-3114	141	17	:	:	PUNCT
dpc-3114	141	18	results	result	VERB
dpc-3114	141	19	from	from	ADP
dpc-3114	141	20	a	a	DET
dpc-3114	141	21	multicentre	multicentre	NOUN
dpc-3114	141	22	experience	experience	NOUN
dpc-3114	141	23	.	.	PUNCT
dpc-3114	142	1	br	br	PROPN
dpc-3114	142	2	j	j	PROPN
dpc-3114	142	3	dermatol	dermatol	NOUN
dpc-3114	142	4	.	.	PUNCT
dpc-3114	143	1	2019;180(6):1547	2019;180(6):1547	NUM
dpc-3114	143	2	-	-	SYM
dpc-3114	143	3	1548	1548	NUM
dpc-3114	143	4	.	.	PUNCT
dpc-3114	144	1	doi	doi	NOUN
dpc-3114	144	2	:	:	PUNCT
dpc-3114	144	3	10.1111	10.1111	NUM
dpc-3114	144	4	/	/	SYM
dpc-3114	144	5	bjd.17580	bjd.17580	NOUN
dpc-3114	144	6	.	.	PUNCT
dpc-3114	145	1	pmid	pmid	NOUN
dpc-3114	145	2	:	:	PUNCT
dpc-3114	145	3	30578668	30578668	NUM
dpc-3114	145	4	.	.	PUNCT
dpc-3114	146	1	12	12	NUM
dpc-3114	146	2	.	.	PUNCT
dpc-3114	147	1	torres	torres	PROPN
dpc-3114	147	2	t	t	PROPN
dpc-3114	147	3	,	,	PUNCT
dpc-3114	147	4	puig	puig	PROPN
dpc-3114	147	5	l	l	NOUN
dpc-3114	147	6	,	,	PUNCT
dpc-3114	147	7	vender	vender	NOUN
dpc-3114	147	8	r	r	NOUN
dpc-3114	147	9	,	,	PUNCT
dpc-3114	147	10	et	et	PROPN
dpc-3114	147	11	al	al	PROPN
dpc-3114	147	12	.	.	PROPN
dpc-3114	147	13	drug	drug	PROPN
dpc-3114	147	14	survival	survival	NOUN
dpc-3114	147	15	of	of	ADP
dpc-3114	147	16	interleukin	interleukin	NOUN
dpc-3114	147	17	(	(	PUNCT
dpc-3114	147	18	il)-17	il)-17	PROPN
dpc-3114	147	19	and	and	CCONJ
dpc-3114	147	20	il-23	il-23	VERB
dpc-3114	147	21	inhibitors	inhibitor	NOUN
dpc-3114	147	22	for	for	ADP
dpc-3114	147	23	the	the	DET
dpc-3114	147	24	treatment	treatment	NOUN
dpc-3114	147	25	of	of	ADP
dpc-3114	147	26	psoriasis	psoriasis	NOUN
dpc-3114	147	27	:	:	PUNCT
dpc-3114	147	28	a	a	DET
dpc-3114	147	29	retrospective	retrospective	ADJ
dpc-3114	147	30	multi	multi	ADJ
dpc-3114	147	31	-	-	NOUN
dpc-3114	147	32	country	country	NOUN
dpc-3114	147	33	,	,	PUNCT
dpc-3114	147	34	multicentric	multicentric	ADJ
dpc-3114	147	35	cohort	cohort	NOUN
dpc-3114	147	36	study	study	NOUN
dpc-3114	147	37	.	.	PUNCT
dpc-3114	148	1	am	be	AUX
dpc-3114	148	2	j	j	PROPN
dpc-3114	148	3	clin	clin	PROPN
dpc-3114	148	4	dermatol	dermatol	NOUN
dpc-3114	148	5	.	.	PUNCT
dpc-3114	149	1	2022;23(6):891	2022;23(6):891	PROPN
dpc-3114	149	2	-	-	PUNCT
dpc-3114	149	3	904	904	NUM
dpc-3114	149	4	.	.	PUNCT
dpc-3114	150	1	doi	doi	NOUN
dpc-3114	150	2	:	:	PUNCT
dpc-3114	150	3	10.1007	10.1007	NUM
dpc-3114	150	4	/	/	SYM
dpc-3114	150	5	s40257	s40257	NOUN
dpc-3114	150	6	-022	-022	PROPN
dpc-3114	150	7	-	-	PUNCT
dpc-3114	150	8	00722	00722	NUM
dpc-3114	150	9	-	-	PUNCT
dpc-3114	150	10	y.	y.	NOUN
dpc-3114	150	11	pmid	pmid	PROPN
dpc-3114	150	12	:	:	PUNCT
dpc-3114	150	13	35976568	35976568	NUM
dpc-3114	150	14	.	.	PUNCT
dpc-3114	151	1	13	13	NUM
dpc-3114	151	2	.	.	PUNCT
dpc-3114	152	1	wei	wei	PROPN
dpc-3114	152	2	nw	nw	PROPN
dpc-3114	152	3	,	,	PUNCT
dpc-3114	152	4	chi	chi	PROPN
dpc-3114	152	5	s	s	PROPN
dpc-3114	152	6	,	,	PUNCT
dpc-3114	152	7	lebwohl	lebwohl	VERB
dpc-3114	152	8	mg	mg	PROPN
dpc-3114	152	9	.	.	PUNCT
dpc-3114	153	1	retrospective	retrospective	ADJ
dpc-3114	153	2	analysis	analysis	NOUN
dpc-3114	153	3	in	in	ADP
dpc-3114	153	4	patients	patient	NOUN
dpc-3114	153	5	with	with	ADP
dpc-3114	153	6	moderate	moderate	ADJ
dpc-3114	153	7	to	to	ADP
dpc-3114	153	8	severe	severe	ADJ
dpc-3114	153	9	plaque	plaque	NOUN
dpc-3114	153	10	psoriasis	psoriasis	NOUN
dpc-3114	153	11	treated	treat	VERB
dpc-3114	153	12	with	with	ADP
dpc-3114	153	13	tildrakizumab	tildrakizumab	NOUN
dpc-3114	153	14	:	:	PUNCT
dpc-3114	153	15	real	real	ADJ
dpc-3114	153	16	-	-	PUNCT
dpc-3114	153	17	life	life	NOUN
dpc-3114	153	18	clinical	clinical	ADJ
dpc-3114	153	19	data	datum	NOUN
dpc-3114	153	20	.	.	PUNCT
dpc-3114	154	1	j	j	PROPN
dpc-3114	154	2	psoriasis	psoriasis	NOUN
dpc-3114	154	3	psoriatic	psoriatic	ADJ
dpc-3114	154	4	arthritis	arthritis	NOUN
dpc-3114	154	5	.	.	PUNCT
dpc-3114	155	1	2022;7(2):55–9	2022;7(2):55–9	NOUN
dpc-3114	155	2	.	.	PUNCT
dpc-3114	156	1	doi	doi	NOUN
dpc-3114	156	2	:	:	PUNCT
dpc-3114	156	3	5	5	NUM
dpc-3114	156	4	10.1177/24755303221077211	10.1177/24755303221077211	NUM
dpc-3114	156	5	.	.	PROPN
dpc-3114	157	1	14	14	NUM
dpc-3114	157	2	.	.	PUNCT
dpc-3114	157	3	narcisi	narcisi	PROPN
dpc-3114	157	4	a	a	PROPN
dpc-3114	157	5	,	,	PUNCT
dpc-3114	157	6	valenti	valenti	PROPN
dpc-3114	157	7	m	m	PROPN
dpc-3114	157	8	,	,	PUNCT
dpc-3114	157	9	gargiulo	gargiulo	PROPN
dpc-3114	157	10	l	l	NOUN
dpc-3114	157	11	,	,	PUNCT
dpc-3114	157	12	et	et	PROPN
dpc-3114	157	13	al	al	PROPN
dpc-3114	157	14	.	.	PUNCT
dpc-3114	158	1	real	real	ADJ
dpc-3114	158	2	-	-	PUNCT
dpc-3114	158	3	life	life	NOUN
dpc-3114	158	4	effectiveness	effectiveness	NOUN
dpc-3114	158	5	of	of	ADP
dpc-3114	158	6	tildrakizumab	tildrakizumab	NOUN
dpc-3114	158	7	in	in	ADP
dpc-3114	158	8	chronic	chronic	ADJ
dpc-3114	158	9	plaque	plaque	NOUN
dpc-3114	158	10	psoriasis	psoriasis	NOUN
dpc-3114	158	11	:	:	PUNCT
dpc-3114	158	12	a	a	DET
dpc-3114	158	13	52	52	NUM
dpc-3114	158	14	-	-	PUNCT
dpc-3114	158	15	week	week	NOUN
dpc-3114	158	16	multicentre	multicentre	NOUN
dpc-3114	158	17	retrospective	retrospective	ADJ
dpc-3114	158	18	study	study	NOUN
dpc-3114	158	19	—	—	PUNCT
dpc-3114	158	20	il	il	PROPN
dpc-3114	158	21	pso	pso	NOUN
dpc-3114	158	22	(	(	PUNCT
dpc-3114	158	23	italian	italian	ADJ
dpc-3114	158	24	landscape	landscape	NOUN
dpc-3114	158	25	psoriasis	psoriasis	NOUN
dpc-3114	158	26	)	)	PUNCT
dpc-3114	158	27	.	.	PUNCT
dpc-3114	159	1	j	j	PROPN
dpc-3114	159	2	eur	eur	PROPN
dpc-3114	159	3	acad	acad	PROPN
dpc-3114	159	4	dermatol	dermatol	NOUN
dpc-3114	159	5	venereol	venereol	NOUN
dpc-3114	159	6	.	.	PUNCT
dpc-3114	160	1	2023;37(1):93	2023;37(1):93	NUM
dpc-3114	160	2	-	-	SYM
dpc-3114	160	3	103	103	NUM
dpc-3114	160	4	.	.	PUNCT
dpc-3114	161	1	doi	doi	NOUN
dpc-3114	161	2	:	:	PUNCT
dpc-3114	161	3	10.1111	10.1111	NUM
dpc-3114	161	4	/	/	SYM
dpc-3114	161	5	jdv.18594	jdv.18594	PROPN
dpc-3114	161	6	.	.	PUNCT
dpc-3114	162	1	pmid	pmid	NOUN
dpc-3114	162	2	:	:	PUNCT
dpc-3114	162	3	36156312	36156312	NUM
dpc-3114	162	4	.	.	PUNCT
dpc-3114	163	1	pmcid	pmcid	ADJ
dpc-3114	163	2	:	:	PUNCT
dpc-3114	163	3	pmc10092064	pmc10092064	NOUN
dpc-3114	163	4	.	.	PUNCT
dpc-3114	164	1	15	15	X
dpc-3114	164	2	.	.	PUNCT
dpc-3114	165	1	poulin	poulin	PROPN
dpc-3114	165	2	y	y	PROPN
dpc-3114	165	3	,	,	PUNCT
dpc-3114	165	4	ramon	ramon	PROPN
dpc-3114	165	5	m	m	PROPN
dpc-3114	165	6	,	,	PUNCT
dpc-3114	165	7	rosoph	rosoph	PROPN
dpc-3114	165	8	l	l	PROPN
dpc-3114	165	9	,	,	PUNCT
dpc-3114	165	10	et	et	PROPN
dpc-3114	165	11	al	al	PROPN
dpc-3114	165	12	.	.	PROPN
dpc-3114	165	13	efficacy	efficacy	NOUN
dpc-3114	165	14	of	of	ADP
dpc-3114	165	15	tildrakizumab	tildrakizumab	NOUN
dpc-3114	165	16	by	by	ADP
dpc-3114	165	17	patient	patient	ADJ
dpc-3114	165	18	demographic	demographic	ADJ
dpc-3114	165	19	and	and	CCONJ
dpc-3114	165	20	disease	disease	NOUN
dpc-3114	165	21	characteristics	characteristic	NOUN
dpc-3114	165	22	across	across	ADP
dpc-3114	165	23	a	a	DET
dpc-3114	165	24	phase	phase	NOUN
dpc-3114	165	25	2b	2b	NOUN
dpc-3114	165	26	and	and	CCONJ
dpc-3114	165	27	2	2	NUM
dpc-3114	165	28	phase	phase	NOUN
dpc-3114	165	29	3	3	NUM
dpc-3114	165	30	trials	trial	NOUN
dpc-3114	165	31	in	in	ADP
dpc-3114	165	32	patients	patient	NOUN
dpc-3114	165	33	with	with	ADP
dpc-3114	165	34	moderate	moderate	ADJ
dpc-3114	165	35	-	-	PUNCT
dpc-3114	165	36	to	to	ADP
dpc-3114	165	37	-	-	PUNCT
dpc-3114	165	38	severe	severe	ADJ
dpc-3114	165	39	chronic	chronic	ADJ
dpc-3114	165	40	plaque	plaque	NOUN
dpc-3114	165	41	psoriasis	psoriasis	NOUN
dpc-3114	165	42	.	.	PUNCT
dpc-3114	166	1	j	j	PROPN
dpc-3114	166	2	eur	eur	PROPN
dpc-3114	166	3	acad	acad	PROPN
dpc-3114	166	4	dermatol	dermatol	NOUN
dpc-3114	166	5	venereol	venereol	NOUN
dpc-3114	166	6	.	.	PUNCT
dpc-3114	167	1	2020;34(7	2020;34(7	NUM
dpc-3114	167	2	):	):	PUNCT
dpc-3114	167	3	1500–1509	1500–1509	NUM
dpc-3114	167	4	.	.	PUNCT
dpc-3114	168	1	doi	doi	NOUN
dpc-3114	168	2	:	:	PUNCT
dpc-3114	168	3	10.1111	10.1111	NUM
dpc-3114	168	4	/	/	SYM
dpc-3114	168	5	jdv.16187	jdv.16187	PROPN
dpc-3114	168	6	.	.	PUNCT
dpc-3114	169	1	pmid:31919889	pmid:31919889	NOUN
dpc-3114	169	2	.	.	PROPN
dpc-3114	169	3	16	16	NUM
dpc-3114	169	4	.	.	PUNCT
dpc-3114	170	1	graier1	graier1	PROPN
dpc-3114	170	2	t	t	PROPN
dpc-3114	170	3	,	,	PUNCT
dpc-3114	170	4	weger	weger	NOUN
dpc-3114	170	5	w	w	PROPN
dpc-3114	170	6	,	,	PUNCT
dpc-3114	170	7	jonak	jonak	NOUN
dpc-3114	170	8	c	c	PROPN
dpc-3114	170	9	,	,	PUNCT
dpc-3114	170	10	et	et	PROPN
dpc-3114	170	11	al	al	PROPN
dpc-3114	170	12	.	.	PUNCT
dpc-3114	171	1	real	real	ADJ
dpc-3114	171	2	world	world	NOUN
dpc-3114	171	3	effectiveness	effectiveness	NOUN
dpc-3114	171	4	of	of	ADP
dpc-3114	171	5	anti	anti	ADJ
dpc-3114	171	6	interleukin	interleukin	NOUN
dpc-3114	171	7	23	23	NUM
dpc-3114	171	8	antibodies	antibodie	VERB
dpc-3114	171	9	in	in	ADP
dpc-3114	171	10	chronic	chronic	ADJ
dpc-3114	171	11	plaque	plaque	NOUN
dpc-3114	171	12	type	type	NOUN
dpc-3114	171	13	psoriasis	psoriasis	NOUN
dpc-3114	171	14	of	of	ADP
dpc-3114	171	15	patients	patient	NOUN
dpc-3114	171	16	from	from	ADP
dpc-3114	171	17	the	the	DET
dpc-3114	171	18	austrian	austrian	ADJ
dpc-3114	171	19	psoriasis	psoriasis	NOUN
dpc-3114	171	20	registry	registry	NOUN
dpc-3114	171	21	(	(	PUNCT
dpc-3114	171	22	psora	psora	PROPN
dpc-3114	171	23	)	)	PUNCT
dpc-3114	171	24	.	.	PUNCT
dpc-3114	172	1	sci	sci	PROPN
dpc-3114	172	2	rep	rep	PROPN
dpc-3114	172	3	.	.	PROPN
dpc-3114	172	4	2022;12(1):15078	2022;12(1):15078	NUM
dpc-3114	172	5	.	.	PUNCT
dpc-3114	173	1	doi	doi	NOUN
dpc-3114	173	2	:	:	PUNCT
dpc-3114	173	3	10.1038	10.1038	NUM
dpc-3114	173	4	/	/	SYM
dpc-3114	173	5	s41598	s41598	NOUN
dpc-3114	173	6	-	-	PUNCT
dpc-3114	173	7	022	022	NUM
dpc-3114	173	8	-	-	PUNCT
dpc-3114	173	9	18790	18790	NUM
dpc-3114	173	10	-	-	SYM
dpc-3114	173	11	9	9	NUM
dpc-3114	173	12	.	.	PUNCT
dpc-3114	174	1	pmid	pmid	NOUN
dpc-3114	174	2	:	:	PUNCT
dpc-3114	174	3	36064563	36064563	NUM
dpc-3114	174	4	.	.	PUNCT
dpc-3114	175	1	pmcid	pmcid	NOUN
dpc-3114	175	2	:	:	PUNCT
dpc-3114	175	3	pmc9442573	pmc9442573	NOUN
dpc-3114	175	4	.	.	PUNCT
dpc-3114	176	1	references	reference	NOUN
dpc-3114	176	2	1	1	NUM
dpc-3114	176	3	.	.	PUNCT
dpc-3114	177	1	ghoreschi	ghoreschi	PROPN
dpc-3114	177	2	k	k	NOUN
dpc-3114	177	3	,	,	PUNCT
dpc-3114	177	4	balato	balato	NOUN
dpc-3114	177	5	a	a	PRON
dpc-3114	177	6	,	,	PUNCT
dpc-3114	177	7	enerbäck	enerbäck	ADJ
dpc-3114	177	8	c	c	X
dpc-3114	177	9	,	,	PUNCT
dpc-3114	177	10	sabat	sabat	PROPN
dpc-3114	177	11	r.	r.	PROPN
dpc-3114	177	12	therapeutics	therapeutic	NOUN
dpc-3114	177	13	targeting	target	VERB
dpc-3114	177	14	the	the	DET
dpc-3114	177	15	il-23	il-23	NOUN
dpc-3114	177	16	and	and	CCONJ
dpc-3114	177	17	il-17	il-17	ADV
dpc-3114	177	18	pathway	pathway	NOUN
dpc-3114	177	19	in	in	ADP
dpc-3114	177	20	psoriasis	psoriasis	NOUN
dpc-3114	177	21	.	.	PUNCT
dpc-3114	178	1	lancet	lancet	NOUN
dpc-3114	178	2	.	.	PUNCT
dpc-3114	179	1	2021	2021	NUM
dpc-3114	179	2	;	;	PUNCT
dpc-3114	179	3	397(10275):754	397(10275):754	NUM
dpc-3114	179	4	-	-	SYM
dpc-3114	179	5	766	766	NUM
dpc-3114	179	6	.	.	PUNCT
dpc-3114	180	1	doi	doi	NOUN
dpc-3114	180	2	:	:	PUNCT
dpc-3114	180	3	10.1016	10.1016	NUM
dpc-3114	180	4	/	/	SYM
dpc-3114	180	5	s0140	s0140	PROPN
dpc-3114	180	6	-	-	PUNCT
dpc-3114	180	7	6736(21)00184	6736(21)00184	NOUN
dpc-3114	180	8	-	-	PUNCT
dpc-3114	180	9	7	7	NUM
dpc-3114	180	10	.	.	PUNCT
dpc-3114	181	1	pmid	pmid	NOUN
dpc-3114	181	2	:	:	PUNCT
dpc-3114	181	3	33515492	33515492	NUM
dpc-3114	181	4	.	.	PUNCT
dpc-3114	182	1	2	2	X
dpc-3114	182	2	.	.	X
dpc-3114	182	3	markham	markham	PROPN
dpc-3114	182	4	a.	a.	PROPN
dpc-3114	182	5	tildrakizumab	tildrakizumab	PROPN
dpc-3114	182	6	:	:	PUNCT
dpc-3114	182	7	first	first	ADJ
dpc-3114	182	8	global	global	ADJ
dpc-3114	182	9	approval	approval	NOUN
dpc-3114	182	10	.	.	PUNCT
dpc-3114	183	1	drugs	drug	NOUN
dpc-3114	183	2	.	.	PUNCT
dpc-3114	184	1	2018;78(8):845–849	2018;78(8):845–849	X
dpc-3114	184	2	.	.	X
dpc-3114	184	3	doi	doi	NOUN
dpc-3114	184	4	:	:	PUNCT
dpc-3114	184	5	10.1007	10.1007	NUM
dpc-3114	184	6	/	/	SYM
dpc-3114	184	7	s40265	s40265	NOUN
dpc-3114	184	8	-	-	PUNCT
dpc-3114	184	9	018	018	NUM
dpc-3114	184	10	-	-	PUNCT
dpc-3114	184	11	0917	0917	NUM
dpc-3114	184	12	-	-	SYM
dpc-3114	184	13	3	3	NUM
dpc-3114	184	14	.	.	PUNCT
dpc-3114	185	1	pmid	pmid	NOUN
dpc-3114	185	2	:	:	PUNCT
dpc-3114	185	3	29752706	29752706	NUM
dpc-3114	185	4	.	.	PUNCT
dpc-3114	186	1	3	3	X
dpc-3114	186	2	.	.	X
dpc-3114	186	3	papp	papp	PROPN
dpc-3114	186	4	k	k	PROPN
dpc-3114	186	5	,	,	PUNCT
dpc-3114	186	6	thaçi	thaçi	PROPN
dpc-3114	186	7	d	d	PROPN
dpc-3114	186	8	,	,	PUNCT
dpc-3114	186	9	reich	reich	PROPN
dpc-3114	186	10	k	k	PROPN
dpc-3114	186	11	,	,	PUNCT
dpc-3114	186	12	et	et	PROPN
dpc-3114	186	13	al	al	PROPN
dpc-3114	186	14	.	.	PROPN
dpc-3114	186	15	tildrakizumab	tildrakizumab	NOUN
dpc-3114	186	16	(	(	PUNCT
dpc-3114	186	17	mk-3222	mk-3222	NOUN
dpc-3114	186	18	)	)	PUNCT
dpc-3114	186	19	,	,	PUNCT
dpc-3114	186	20	an	an	DET
dpc-3114	186	21	anti	anti	ADJ
dpc-3114	186	22	-	-	ADJ
dpc-3114	186	23	interleukin-23p19	interleukin-23p19	ADJ
dpc-3114	186	24	monoclonal	monoclonal	NOUN
dpc-3114	186	25	antibody	antibody	NOUN
dpc-3114	186	26	,	,	PUNCT
dpc-3114	186	27	improves	improve	VERB
dpc-3114	186	28	psoriasis	psoriasis	NOUN
dpc-3114	186	29	in	in	ADP
dpc-3114	186	30	a	a	DET
dpc-3114	186	31	phase	phase	NOUN
dpc-3114	186	32	iib	iib	NOUN
dpc-3114	186	33	randomized	randomize	VERB
dpc-3114	186	34	placebo	placebo	NOUN
dpc-3114	186	35	-	-	PUNCT
dpc-3114	186	36	controlled	control	VERB
dpc-3114	186	37	trial	trial	NOUN
dpc-3114	186	38	.	.	PUNCT
dpc-3114	187	1	br	br	PROPN
dpc-3114	187	2	j	j	PROPN
dpc-3114	187	3	dermatol	dermatol	NOUN
dpc-3114	187	4	.	.	PUNCT
dpc-3114	188	1	2015;173(4):930–939	2015;173(4):930–939	NUM
dpc-3114	188	2	.	.	PUNCT
dpc-3114	188	3	doi	doi	NOUN
dpc-3114	188	4	:	:	PUNCT
dpc-3114	188	5	10.1111	10.1111	NUM
dpc-3114	188	6	/	/	SYM
dpc-3114	188	7	bjd.13932	bjd.13932	NUM
dpc-3114	188	8	.	.	PUNCT
dpc-3114	189	1	pmid	pmid	NOUN
dpc-3114	189	2	:	:	PUNCT
dpc-3114	189	3	26042589	26042589	NUM
dpc-3114	189	4	.	.	PUNCT
dpc-3114	190	1	4	4	X
dpc-3114	190	2	.	.	X
dpc-3114	190	3	reich	reich	PROPN
dpc-3114	190	4	k	k	PROPN
dpc-3114	190	5	,	,	PUNCT
dpc-3114	190	6	papp	papp	PROPN
dpc-3114	190	7	ka	ka	PROPN
dpc-3114	190	8	,	,	PUNCT
dpc-3114	190	9	blauvelt	blauvelt	VERB
dpc-3114	190	10	a	a	PRON
dpc-3114	190	11	,	,	PUNCT
dpc-3114	190	12	et	et	PROPN
dpc-3114	190	13	al	al	PROPN
dpc-3114	190	14	.	.	PROPN
dpc-3114	190	15	tildrakizumab	tildrakizumab	NOUN
dpc-3114	190	16	versus	versus	ADP
dpc-3114	190	17	placebo	placebo	NOUN
dpc-3114	190	18	or	or	CCONJ
dpc-3114	190	19	etanercept	etanercept	NOUN
dpc-3114	190	20	for	for	ADP
dpc-3114	190	21	chronic	chronic	ADJ
dpc-3114	190	22	plaque	plaque	NOUN
dpc-3114	190	23	psoriasis	psoriasis	NOUN
dpc-3114	190	24	(	(	PUNCT
dpc-3114	190	25	resurface	resurface	NOUN
dpc-3114	190	26	1	1	NUM
dpc-3114	190	27	and	and	CCONJ
dpc-3114	190	28	resurface	resurface	NOUN
dpc-3114	190	29	2	2	NUM
dpc-3114	190	30	):	):	PUNCT
dpc-3114	190	31	results	result	NOUN
dpc-3114	190	32	from	from	ADP
dpc-3114	190	33	two	two	NUM
dpc-3114	190	34	randomised	randomise	VERB
dpc-3114	190	35	controlled	control	VERB
dpc-3114	190	36	,	,	PUNCT
dpc-3114	190	37	phase	phase	NOUN
dpc-3114	190	38	3	3	NUM
dpc-3114	190	39	trials	trial	NOUN
dpc-3114	190	40	.	.	PUNCT
dpc-3114	191	1	lancet	lancet	NOUN
dpc-3114	191	2	.	.	PUNCT
dpc-3114	192	1	2017;390(10091):276	2017;390(10091):276	NUM
dpc-3114	192	2	-	-	SYM
dpc-3114	192	3	288	288	NUM
dpc-3114	192	4	.	.	PUNCT
dpc-3114	193	1	doi	doi	NOUN
dpc-3114	193	2	:	:	PUNCT
dpc-3114	193	3	10.1016	10.1016	NUM
dpc-3114	193	4	/	/	SYM
dpc-3114	193	5	s0140	s0140	PROPN
dpc-3114	193	6	-	-	PUNCT
dpc-3114	193	7	6736(17)31279	6736(17)31279	NUM
dpc-3114	193	8	-	-	SYM
dpc-3114	193	9	5	5	NUM
dpc-3114	193	10	.	.	PUNCT
dpc-3114	194	1	pmid	pmid	NOUN
dpc-3114	194	2	:	:	PUNCT
dpc-3114	194	3	28596043	28596043	NUM
dpc-3114	194	4	.	.	PUNCT
dpc-3114	195	1	5	5	X
dpc-3114	195	2	.	.	X
dpc-3114	195	3	burlando	burlando	PROPN
dpc-3114	195	4	m	m	PROPN
dpc-3114	195	5	,	,	PUNCT
dpc-3114	195	6	castelli	castelli	PROPN
dpc-3114	195	7	r	r	PROPN
dpc-3114	195	8	,	,	PUNCT
dpc-3114	195	9	cozzani	cozzani	ADJ
dpc-3114	195	10	e	e	NOUN
dpc-3114	195	11	,	,	PUNCT
dpc-3114	195	12	parodi	parodi	PROPN
dpc-3114	195	13	,	,	PUNCT
dpc-3114	195	14	a.	a.	NOUN
dpc-3114	195	15	treatment	treatment	NOUN
dpc-3114	195	16	of	of	ADP
dpc-3114	195	17	moderate	moderate	ADJ
dpc-3114	195	18	-	-	PUNCT
dpc-3114	195	19	to	to	ADP
dpc-3114	195	20	-	-	PUNCT
dpc-3114	195	21	severe	severe	ADJ
dpc-3114	195	22	plaque	plaque	NOUN
dpc-3114	195	23	psoriasis	psoriasis	NOUN
dpc-3114	195	24	with	with	ADP
dpc-3114	195	25	tildrakizumab	tildrakizumab	NOUN
dpc-3114	195	26	in	in	ADP
dpc-3114	195	27	the	the	DET
dpc-3114	195	28	real	real	ADJ
dpc-3114	195	29	-	-	PUNCT
dpc-3114	195	30	life	life	NOUN
dpc-3114	195	31	setting	setting	NOUN
dpc-3114	195	32	.	.	PUNCT
dpc-3114	196	1	drugs	drug	NOUN
dpc-3114	196	2	context	context	VERB
dpc-3114	196	3	.	.	PUNCT
dpc-3114	197	1	2021;10:2021	2021;10:2021	NUM
dpc-3114	197	2	-	-	PUNCT
dpc-3114	197	3	2	2	NUM
dpc-3114	197	4	-	-	SYM
dpc-3114	197	5	6	6	NUM
dpc-3114	197	6	.	.	PUNCT
dpc-3114	197	7	doi	doi	NOUN
dpc-3114	197	8	:	:	PUNCT
dpc-3114	197	9	10.7573	10.7573	NUM
dpc-3114	197	10	/	/	SYM
dpc-3114	197	11	dic.2021	dic.2021	NUM
dpc-3114	197	12	-	-	PUNCT
dpc-3114	197	13	2	2	NUM
dpc-3114	197	14	-	-	SYM
dpc-3114	197	15	6	6	NUM
dpc-3114	197	16	.	.	PUNCT
dpc-3114	198	1	pmid	pmid	NOUN
dpc-3114	198	2	:	:	PUNCT
dpc-3114	198	3	34104197	34104197	NUM
dpc-3114	198	4	.	.	PUNCT
dpc-3114	199	1	pmcid	pmcid	NOUN
dpc-3114	199	2	:	:	PUNCT
dpc-3114	199	3	pmc8152773	pmc8152773	NOUN
dpc-3114	199	4	.	.	PUNCT
dpc-3114	200	1	6	6	X
dpc-3114	200	2	.	.	X
dpc-3114	200	3	galán	galán	NOUN
dpc-3114	200	4	-	-	PUNCT
dpc-3114	200	5	gutierrez	gutierrez	PROPN
dpc-3114	200	6	m	m	PROPN
dpc-3114	200	7	,	,	PUNCT
dpc-3114	200	8	rodriguez	rodriguez	NOUN
dpc-3114	200	9	-	-	PUNCT
dpc-3114	200	10	fernandez	fernandez	PROPN
dpc-3114	200	11	freire	freire	PROPN
dpc-3114	200	12	l	l	PROPN
dpc-3114	200	13	,	,	PUNCT
dpc-3114	200	14	ruiz	ruiz	NOUN
dpc-3114	200	15	-	-	PUNCT
dpc-3114	200	16	villaverde	villaverde	NOUN
dpc-3114	200	17	r.	r.	PROPN
dpc-3114	200	18	tildrakizumab	tildrakizumab	PROPN
dpc-3114	200	19	:	:	PUNCT
dpc-3114	200	20	short	short	ADJ
dpc-3114	200	21	-	-	PUNCT
dpc-3114	200	22	term	term	NOUN
dpc-3114	200	23	efficacy	efficacy	NOUN
dpc-3114	200	24	and	and	CCONJ
dpc-3114	200	25	safety	safety	NOUN
dpc-3114	200	26	in	in	ADP
dpc-3114	200	27	real	real	ADJ
dpc-3114	200	28	clinical	clinical	ADJ
dpc-3114	200	29	practice	practice	NOUN
dpc-3114	200	30	.	.	PUNCT
dpc-3114	201	1	int	int	NOUN
dpc-3114	201	2	j	j	PROPN
dpc-3114	201	3	dermatol	dermatol	NOUN
dpc-3114	201	4	.	.	PUNCT
dpc-3114	202	1	2022;61(9):e355	2022;61(9):e355	PROPN
dpc-3114	202	2	-	-	PUNCT
dpc-3114	202	3	e357	e357	PROPN
dpc-3114	202	4	.	.	PUNCT
dpc-3114	202	5	doi	doi	NOUN
dpc-3114	202	6	:	:	PUNCT
dpc-3114	202	7	10.1111	10.1111	NUM
dpc-3114	202	8	/	/	SYM
dpc-3114	202	9	ijd.15840	ijd.15840	NUM
dpc-3114	202	10	.	.	PUNCT
dpc-3114	203	1	pmid	pmid	NOUN
dpc-3114	203	2	:	:	PUNCT
dpc-3114	203	3	34632570	34632570	NUM
dpc-3114	203	4	.	.	PUNCT
dpc-3114	204	1	7	7	X
dpc-3114	204	2	.	.	X
dpc-3114	204	3	drerup	drerup	PROPN
dpc-3114	204	4	ka	ka	PROPN
dpc-3114	204	5	,	,	PUNCT
dpc-3114	204	6	seemann	seemann	VERB
dpc-3114	204	7	c	c	NOUN
dpc-3114	204	8	,	,	PUNCT
dpc-3114	204	9	gerdes	gerdes	PROPN
dpc-3114	204	10	s	s	PROPN
dpc-3114	204	11	,	,	PUNCT
dpc-3114	204	12	mrowietz	mrowietz	PROPN
dpc-3114	204	13	u.	u.	PROPN
dpc-3114	204	14	effective	effective	ADJ
dpc-3114	204	15	and	and	CCONJ
dpc-3114	204	16	safe	safe	ADJ
dpc-3114	204	17	treatment	treatment	NOUN
dpc-3114	204	18	of	of	ADP
dpc-3114	204	19	psoriatic	psoriatic	ADJ
dpc-3114	204	20	disease	disease	NOUN
dpc-3114	204	21	with	with	ADP
dpc-3114	204	22	the	the	DET
dpc-3114	204	23	anti	anti	ADJ
dpc-3114	204	24	-	-	ADJ
dpc-3114	204	25	il-23p19	il-23p19	ADJ
dpc-3114	204	26	biologic	biologic	NOUN
dpc-3114	204	27	tildrakizumab	tildrakizumab	NOUN
dpc-3114	204	28	:	:	PUNCT
dpc-3114	204	29	results	result	NOUN
dpc-3114	204	30	of	of	ADP
dpc-3114	204	31	a	a	DET
dpc-3114	204	32	real	real	ADJ
dpc-3114	204	33	-	-	PUNCT
dpc-3114	204	34	world	world	NOUN
dpc-3114	204	35	prospective	prospective	ADJ
dpc-3114	204	36	cohort	cohort	NOUN
dpc-3114	204	37	study	study	NOUN
dpc-3114	204	38	in	in	ADP
dpc-3114	204	39	nonselected	nonselected	ADJ
dpc-3114	204	40	patients	patient	NOUN
dpc-3114	204	41	.	.	PUNCT
dpc-3114	205	1	dermatology	dermatology	NOUN
dpc-3114	205	2	.	.	PUNCT
dpc-3114	206	1	2022;238(4):615	2022;238(4):615	NUM
dpc-3114	206	2	-	-	SYM
dpc-3114	206	3	619	619	NUM
dpc-3114	206	4	.	.	PUNCT
dpc-3114	207	1	doi	doi	NOUN
dpc-3114	207	2	:	:	PUNCT
dpc-3114	207	3	10.1159/000519924	10.1159/000519924	NUM
dpc-3114	207	4	.	.	PUNCT
dpc-3114	208	1	pmid	pmid	NOUN
dpc-3114	208	2	:	:	PUNCT
dpc-3114	208	3	34775387	34775387	NUM
dpc-3114	208	4	.	.	PUNCT
dpc-3114	209	1	pmcid	pmcid	NOUN
dpc-3114	209	2	:	:	PUNCT
dpc-3114	209	3	pmc9393809	pmc9393809	NOUN
dpc-3114	209	4	.	.	PUNCT
dpc-3114	210	1	8	8	X
dpc-3114	210	2	.	.	X
dpc-3114	210	3	caldarola	caldarola	PROPN
dpc-3114	210	4	g	g	PROPN
dpc-3114	210	5	,	,	PUNCT
dpc-3114	210	6	galluzzo	galluzzo	PROPN
dpc-3114	210	7	m	m	PROPN
dpc-3114	210	8	,	,	PUNCT
dpc-3114	210	9	bernardini	bernardini	PROPN
dpc-3114	210	10	n	n	CCONJ
dpc-3114	210	11	,	,	PUNCT
dpc-3114	210	12	et	et	PROPN
dpc-3114	210	13	al	al	PROPN
dpc-3114	210	14	.	.	PROPN
dpc-3114	210	15	tildrakizumab	tildrakizumab	NOUN
dpc-3114	210	16	in	in	ADP
dpc-3114	210	17	moderate	moderate	ADJ
dpc-3114	210	18	-	-	PUNCT
dpc-3114	210	19	to	to	ADP
dpc-3114	210	20	-	-	PUNCT
dpc-3114	210	21	severe	severe	ADJ
dpc-3114	210	22	plaque	plaque	NOUN
dpc-3114	210	23	psoriasis	psoriasis	NOUN
dpc-3114	210	24	:	:	PUNCT
dpc-3114	210	25	a	a	DET
dpc-3114	210	26	multicenter	multicenter	NOUN
dpc-3114	210	27	,	,	PUNCT
dpc-3114	210	28	retrospective	retrospective	ADJ
dpc-3114	210	29	,	,	PUNCT
dpc-3114	210	30	real	real	ADJ
dpc-3114	210	31	-	-	PUNCT
dpc-3114	210	32	life	life	NOUN
dpc-3114	210	33	study	study	NOUN
dpc-3114	210	34	.	.	PUNCT
dpc-3114	211	1	dermatol	dermatol	NOUN
dpc-3114	211	2	ther	ther	ADV
dpc-3114	211	3	.	.	PUNCT
dpc-3114	212	1	2022;35(6):e15488	2022;35(6):e15488	X
dpc-3114	212	2	.	.	PUNCT
dpc-3114	212	3	doi	doi	NOUN
dpc-3114	212	4	:	:	PUNCT
dpc-3114	212	5	10.1111	10.1111	NUM
dpc-3114	212	6	/	/	SYM
dpc-3114	212	7	dth.15488	dth.15488	NOUN
dpc-3114	212	8	.	.	PUNCT
dpc-3114	213	1	pmid:35384168.pmcid	pmid:35384168.pmcid	NOUN
dpc-3114	213	2	:	:	PUNCT
dpc-3114	213	3	pmc9287013	pmc9287013	NOUN
dpc-3114	213	4	.	.	PUNCT